

Curriculum Vitae

Sandra L. Kane-Gill, Pharm. D., M.Sc., FCCM, FCCP

Office Address: University of Pittsburgh Home Address: 1804 Thornewood Ct.
School of Pharmacy Pittsburgh, PA 15237
6462 Salk Hall Phone: (412) 318-3333
3501 Terrace St.
Pittsburgh, PA 15261
Phone: (412) 624-5150
E-mail: SLK54@pitt.edu or Kane-Gill@pitt.edu

EDUCATION

| | | |
|-----------|--|---|
| 2018-2019 | University of California, San Francisco Dept. of Epidemiology and Biostatistics CTSI Online Training Program | Certificate in Implementation Science |
| 1998-2001 | The Ohio State University Columbus, OH | Critical Care Fellowship Mentor: Joseph F. Dasta, MSc, FCCM |
| 1999-2001 | The Ohio State University Columbus, OH | Master of Science, Pharmacy Administration Emphasis: Pharmacoeconomics and Health Outcomes Advisor: Dev S. Pathak, DBA |
| 1996-1998 | University of Toledo Toledo, OH | Doctor of Pharmacy |
| 1995-1996 | West Virginia University Hospital Morgantown, WV | ASHP-Accredited Pharmacy Practice Residency |
| 1989-1994 | Wayne State University Detroit, MI | Bachelor of Science, Pharmacy |

LICENSURE/CERTIFICATION/ID NUMBERS

| | |
|------|--|
| 2021 | Pennsylvania Authorization to Administer Injectables for Pharmacists # RPI014903 |
| 2003 | Pennsylvania #RP438392 |
| 1995 | Ontario #203428 |
| 1994 | Michigan #5302029730 |
| 2011 | NPI- 1750659553 ORCID- 0000-0001-7523-4846 |

APPOINTMENTS AND POSITIONS

ACADEMIC

| | |
|---------------|---|
| 2022- present | Interim Chair, Department of Pharmacy and Therapeutics School of Pharmacy, University of Pittsburgh, Pittsburgh, PA |
| 2022-2023 | Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN Temporary Faculty Privileges |
| 2019- present | University of Pittsburgh, Pittsburgh, PA Graduate Faculty |
| 2018- present | University of Pittsburgh, Pittsburgh, PA Professor (with tenure), School of Pharmacy |
| 2019-present | University of Pittsburgh, Pittsburgh, PA Faculty, The Program for Critical Care Nephrology (C3N), Department of Critical Care Medicine, University of Pittsburgh School of Medicine https://ccm.pitt.edu/content/critical-care-nephrology |
| 2013-2019 | University of Pittsburgh, Pittsburgh, PA Faculty, The Center for Critical Care Nephrology (C3N), Department of Critical Care Medicine, University of Pittsburgh School of Medicine https://pre.ccm.pitt.edu/content/center-critical-care-nephrology |
| 2013-2019 | University of Pittsburgh, Pittsburgh, PA Faculty, Center for Pharmaceutical Policy and Prescribing (CP3), Health Policy Institute |
| 2012- present | University of Pittsburgh, Pittsburgh, PA Professor, School of Medicine, Department of Biomedical Informatics (secondary appointment) https://www.dbmi.pitt.edu/people/affiliated?page=2 |
| 2019-2024 | Department of Biomedical Informatics, Training Program Core Faculty https://www.dbmi.pitt.edu/training-programs |
| 2012- present | University of Pittsburgh, Pittsburgh, PA Professor, School of Medicine, Department of Critical Care Medicine (secondary appointment) Kane-Gill, Sandra Department of Critical Care Medicine (pitt.edu) |
| 2011-2018 | University of Pittsburgh, Pittsburgh, PA Faculty, University of Pittsburgh Geriatric Pharmaceutical Outcomes and Gero-Informatics Research and Training Program, Division of Geriatric Medicine and Gerontology, and the Department of Biomedical Informatics, School of Medicine |
| 2009- present | University of Pittsburgh, Pittsburgh, PA |

Professor, Clinical Translational Science Institute (secondary appointment)

- 2009- present Director, Residency Research Series
Department of Pharmacy, University of Pittsburgh Medical Center and University of Pittsburgh, School of Pharmacy, Pittsburgh, PA
https://youtu.be/Kj3HRn_5dac
- 2008- 2018 University of Pittsburgh, Pittsburgh, PA
Associate Professor, School of Pharmacy
- 2001-2007 University of Pittsburgh, Pittsburgh, PA
Assistant Professor, School of Pharmacy
Critical Care Specialist, Center for Pharmacoinformatics and Outcomes
- 1998-2001 The Ohio State University, Columbus, OH
Teaching Assistant
- 1996-1997 University of Toledo, Toledo, OH
Teaching Assistant

PHARMACY PRACTICE

- 2012-2015 Director, Medication Use Safety Residency
Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA
- 2007-present Critical Care Medication Safety Pharmacist
Department of Pharmacy, UPMC, Pittsburgh, PA
- 1995-1997 Staff Pharmacist
Detroit Riverview Hospital, Detroit, MI

HONORS AND AWARDS

- 2024 Faculty Honoree, University of Pittsburgh Honors Convocation
- 2023 **American College of Clinical Pharmacists (ACCP) Therapeutic Frontiers Lecture Award**- honors an outstanding, internationally recognized scientist whose research is actively advancing the frontiers of pharmacotherapy.
- 2023 **American Associate of Colleges of Pharmacy (AACP) Paul R. Dawson Award for Excellence in Patient Care Research** – Recognizes an active scientist within the ranks of pharmacy education as a leader in the broad range of research related to health services delivery directly affecting patient outcomes, including basic, clinical, translational and health services research. Notably, Dr. Kane-Gill is the second non-PhD researcher to receive this award since its inception in 2008.
- 2022 **Expertscape: Expert in Acute Kidney Injury**
Recognized as top 1% of scholars in the world writing about acute kidney injury over the past 10 years <https://expertscape.com/au/acute+kidney+injury/Kane-Gill%2C+Sandra>
- 2023 Faculty Honoree, University of Pittsburgh Honors Convocation

- 2021 **American Society of Health System Pharmacists (ASHP) Literature Award for Sustained Contributions** given to someone who exemplifies excellence in research through original, significant contributions to biomedical literature that impacts pharmacy practice and patient care. The pharmacist is recognized for having at least a 20-year record of publishing high quality and impactful peer-reviewed biomedical literature. [ASHP Foundation 2021 Pharmacy Residency Excellence Awards - YouTube](#)
- Faculty Honoree, University of Pittsburgh Honors Convocation
- 2021 **Expertscape: Expert in Medication Errors**
Recognized as top 1% of scholars in the world writing about Medication Errors over the past 10 years and acknowledge on World Patient Safety Day
<https://expertscape.com/ex/medication+errors>
https://twitter.com/Daily_Experts/status/1438853281791553540
- 2021 **Sternfel Prize for Drug Safety Discoveries:** Acknowledged as one of Top 30 Grant Proposals
- 2020 **UPMC Quality and Safety Fair- Safety award** (second place) recognizes a project that provides safe and effective care to our patients through error reduction. Project: Medication optimization upon transition of care from the medication intensive care unit.
- 2019 **Pennsylvania Pharmacists Association Excellence in Innovation Award** recognizes a pharmacist who is involved in an innovative pharmacy practice resulting in improved patient care. <https://www.papharmacists.com/page/Awards>
- 2019 **West Virginia University Hospitals, Commitment to Pharmacy Excellence Award,** Inaugural Award. The Commitment to Pharmacy Excellence Award is to be given every two years to an alumnus of the WVU Hospitals Pharmacy Residency Program who have distinguished themselves by significantly advancing or contributing to pharmacy practice throughout their careers.
- 2016 **American Society of Health-System Pharmacist (ASHP) Residency Excellence Award- Preceptor.** This award recognizes a pharmacy residency preceptor who has excelled in the training of residents. Recognition of this preceptor enables them to serve as role model for other residency preceptors. ASHP Midyear Meeting, Las Vegas, NV. A testament of her trainees and colleagues is provided at <http://ow.ly/S7O1306PMoO>
- 2016 **ASHP Award for Innovation in Pharmacy Practice** for an outstanding contribution to the biomedical literature as a co-author on “Impact of a Clinical Pharmacist Acid Suppression Therapy Management Program on Inappropriate Use in Intensive Care Unit and General Ward Patients” conducted at Banner Good Samaritan Medical Center in Phoenix, Az and published in *Am J Med* 2015;128:905-913. ASHP Midyear Meeting, Las Vegas, NV.
- 2016 **Best Reviewer** Acknowledgement Pharmacoepidemiology and Drug Safety
- 2015 **Patient and Family Support Specialty Award** for the top-scoring poster at SCCM Congress in Phoenix, Az.
- 2015 Society of Critical Care Medicine (SCCM), Clinical Pharmacy and Pharmacology Section **Patient Safety Technology Award*** for using an automated trigger alert system to identify ADEs in 4 institutions in the Banner Good Samaritan Medical Center, Phoenix, AZ.
- 2015 SCCM, Clinical Pharmacy and Pharmacology Section **Medication Safety Award*** for evaluating off-label drug use as a risk for ADEs in the ICU.
- 2014 **ASHP Best Practice Award** for assistance with the project “Impact of a Clinical Pharmacist Acid Suppression Therapy Management Program on Inappropriate Use in Intensive Care Unit and General Ward Patients” at Banner Good Samaritan Medical Center in Phoenix, Az.

- 2014 **ACCP- Mentored the Best Student Poster Award** Characterization of delirium in a medical ICU that emphasizes frequent delirium screening at a tertiary, academic medical center, Austin, Texas
- 2014 **Pitt Innovation Challenge (PiNCH) Finalist** for “MyKidney” App and Peoples Choice Award for Video <http://www.pinch.pitt.edu/PeoplesChoice/Create>
<http://www.youtube.com/watch?v=7v59NfZRbG4>
- 2013 **ACCP Critical Care PRN Achievement Award**
• Faculty Honoree, University of Pittsburgh Honors Convocation
- 2013 SCCM, Clinical Pharmacy and Pharmacology Section **Medication Safety Award*** for evaluating the impact of transfer summaries as part of an active surveillance system for the detection of ADEs in the ICU
• Faculty Honoree, University of Pittsburgh Honors Convocation
- 2012 **Finalist for the “Simmy Award”, Simulation Journal Club** at the International Meeting for Simulation in Healthcare
- 2012 SCCM, Clinical Pharmacy and Pharmacology Section **Patient Safety Technology Award*** for using simulation-based learning to reduce medication errors in critically ill patients.
- 2012 SCCM, Clinical Pharmacy and Pharmacology Section **Medication Safety Award*** for evaluating the impact of pharmacist-conducted admission medication reconciliation program on unintended medication discrepancies
- 2011 **ACCP Critical Care PRN Research Award**
- 2011 **SCCM Research Citation Award** for “Evaluating the occurrence of QT prolongation resulting from drug-drug interactions”
- 2010 University of Pittsburgh, Rho Chi Society, **Innovation in Teaching Award**
- 2010 American Association of Colleges of Pharmacy, **Innovations in Teaching**, Honorable Mention
- 2009 Fellow, American College of Clinical Pharmacy
• Faculty Honoree, University of Pittsburgh Honors Convocation
- 2008 Fellow, American College of Critical Care Medicine
• Faculty Honoree, University of Pittsburgh Honors Convocation
- 2008 University of Pittsburgh, Rho Chi Society, **Outstanding Scholarly Contribution Award**
- 2003-2013 **SCCM Presidential Citation** (as a Council member I am no longer eligible)
- 2003 SCCM Clinical Pharmacy and Pharmacology **Research Abstract Award** for “Diltiazem versus amiodarone for new onset atrial arrhythmias in non-cardiac post surgical patients: a cohort study”
- 1998 Rho Chi Honor Society

* The Pharmacy Section of the Society of Critical Care Medicine offered their inaugural medication safety award in 2012 for medication safety quality and research initiatives and the technology award for effectively incorporating technology in clinical practice. I have been fortunate to be a recipient/co-recipient of one of these awards for medication safety work at UPMC or collaborative work with other institutions in multiple years 2012, 2013, 2015.

SCHOLARLY ACTIVITY

PEER REVIEWED ARTICLES

Students/residents* under my direction are indicated by an asterisk following their name.
Scholarship of education articles are indicated by ** following the publication citation.

1. Gray MP, Kellum JA, Kirisci L, Boyce RD, Kane-Gill SL. Long-Term Outcomes Associated With β -Lactam Allergies. *JAMA Netw Open*. 2024 May 1;7(5):e2412313. doi: 10.1001/jamanetworkopen.2024.12313. PMID: 38758551.
2. Nadim MK, Kellum JA, Forni L, Francoz C, Asrani SK, Ostermann M, Allegretti AS, Neyra JA, Olson JC, Piano S, VanWagner LB, Verna EC, Akcan-Arikan A, Angeli P, Belcher JM, Biggins SW, Deep A, Garcia-Tsao G, Genyk YS, Gines P, Kamath PS, Kane-Gill SL, Kaushik M, Lumlertgul N, Macedo E, Maiwall R, Marciano S, Pichler RH, Ronco C, Tandon P, Velez JQ, Mehta RL, Durand F. Acute kidney injury in patients with Cirrhosis: Acute disease quality Initiative (ADQI) and international Club of ascites (ICA) joint multidisciplinary consensus meeting. *J Hepatol*. 2024 Mar 23:S0168-8278(24)00214-9. doi: 10.1016/j.jhep.2024.03.031. Epub ahead of print. PMID: 38527522.
3. Manis MM, Skelley JW, Read JB, Maxson R, O'Hagan E, Wallace JL, Siew ED, Barreto EF, Silver SA, Kane-Gill SL, Neyra JA. Role of a Pharmacist in Postdischarge Care for Patients with Kidney Disease: A Scoping Review. *Ann Pharmacother*. 2024; Epub ahead of print. PMID: 38563565.
4. Li X*, Chenyu and Kravchenko, Olga and Chou, Eric and Handler, Steven M. and Hume, Nicole E. and Romagnoli, Katrina and Karp, Jordan F. and Landsittel, Douglas P. and Kane-Gill, Sandra L. and Gray, Matthew P. and Albert, Steven and Castle, Nicholas G. and Reynolds III, Charles F. and Boyce, Richard D., Identifying Clinician-Reported Medication "Failure Modes" in the Nursing Home Setting that are Amenable to Active Monitoring. Available at SSRN: <https://ssrn.com/abstract=4745057> or <http://dx.doi.org/10.2139/ssrn.4745057> (pre-print)
5. Hume N*, Zerfas I*, Wong A, Fedyshin M, Buckley MS, Smithburger PL, Devlin J, Kane-Gill SL. Implementation strategies used for the uptake of the PAD and PADIS guidelines in clinical practice. *Crit Care Med* 2024; online ahead of print. PMID: 38193764.
6. Peasah SK, Swart ECS, Huang Y, Kane-Gill SL, Seybert AL, Patel U, Manolis, C Good CB. Disease modifying medications inpatients with rheumatoid arthritis in the USA: Trends from 2016 to 2021. *Drugs Real World Outcomes* 2024; online ahead of print.
7. Newman TV, Yang J, Suh K, Jonassaint CR, Kane-Gill SL, Novelli EM. Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease. *JAMA Netw Open*. 2023;6:e2344546. PMID: 37991760.
8. Karimzadeh I, Barreto EF, Kellum JA, Awdishu L, Murray PT, Ostermann M, Bihorac A, Mehta RL, Goldstein SL, Kashani KB, Kane-Gill SL. Moving toward a contemporary classification of drug-induced kidney disease. *Crit Care*. 2023;27:435. PMID: 37946280.
9. Wong A, Berenbrok LA, Snader L, Soh YH, Kumar VK, Javed MA, Bates DW, Sorce LR, Kane-Gill SL. Facilitators and Barriers to Interacting with clinical decision support in the ICU: A Mixed-Methods Approach. *Crit Care Explor* 2023 Aug 25;5:e0967. PMID: 37644969

10. Karimzadeh I, Strader M, Kane-Gill SL, Murray PT. Prevention and management of antibiotic associated acute kidney injury in critically ill patients: new insights. *Curr Opin Crit Care*. 2023 Dec 1;29:595-606. PMID: 37861206.
11. Kashani KB, Awdishu L, Bagshaw SM, Barreto EF, Claire-Del Granado R, Evans BJ, Forni LG, Ghosh E, Goldstein SL, Kane-Gill SL, Koola J, Koyner JL, Liu M, Murugan R, Nadkarni GN, Neyra JA, Ninan J, Ostermann M, Pannu N, Rashidi P, Ronco C, Rosner MH, Selby NM, Shickel B, Singh K, Soranno DE, Sutherland SM, Bihorac A, Mehta RL. Digital health and acute kidney injury: consensus report of the 27th Acute Disease Quality Initiative workgroup. *Nat Rev Nephrol* 2023; 19:8087-18. PMID: 37580570.
12. Gray MP*, Dhavalikar N*, Boyce RD, Kane-Gill SL. Qualitative analysis of healthcare provider perspectives to evaluating the legitimacy of beta-lactam drug allergies. *J Hosp Infect* 2023;141:198:208. PMID: 37574018
13. Amatullah N*, Stottlemeyer B*, Zerfas I*, Stevens C*, Ozrazgat-Baslanti T, Bihorac A, Kane-Gill SL. Challenges in Pharmacovigilance: Variability in the Criteria for Determining Drug Associated Acute Kidney Injury in Retrospective, Observational Studies. *Nephron* 2023;147:725-32.
14. Zarbock A, Nadim MK, Pickkers P, Gomez H, Bell S, Joannidis M, Kashani K, Koyner JL, Pannu N, Meersch M, Reis T, Rimmelé T, Bagshaw SM, Bellomo R, Cantaluppi V, Deep A, De Rosa S, Perez-Fernandez X, Husain-Syed F, Kane-Gill SL, Kelly Y, Mehta RL, Murray PT, Ostermann M, Prowle J, Ricci Z, See EJ, Schneider A, Soranno DE, Tolwani A, Villa G, Ronco C, Forni LG. Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup. *Nat Rev Nephrol*. 2023; 19:401-417. PMID: 36823168.
15. Zarbock A, Koyner JL, Gomez H, Pickkers P, Forni L; ADQI group. Sepsis-associated acute kidney injury - treatment standard. *Nephrol Dial Transplant*. 2023;39:26-35. PMID: 37401137.
16. Adiyee E, Ren Y, Tupper MM, Shickel B, Kane-Gill SL, Murugan R, Rashidi P, Bihorac A, Ozrazgat-Baslanti T. A deep learning based dynamic model for predicting inpatient acute kidney injury risk severity. *Surgery* 2023; 174:709-718. PMID: 37316372
17. Yoo YJ, Wilkins KJ, Alakwaa F, Liu F, Torre-Healy LA, Krichevsky S, Hong SS, Sakhuja A, Potu CK, Saltz JH, Saran R, Zhu RL, Setoguchi S, Kane-Gill SL, Mallipattu SK, He Y, Ellison DH, Byrd JB, Parikh CR, Moffitt RA, Korashy FM; N3C and RECOVER Consortia. Geographic and Temporal Trends in COVID-Associated Acute Kidney Injury in the National COVID Cohort Collaborative. *Clin J Am Soc Nephrol* 2023;18:1006-1018. PMID: 37131278.
18. Morin C, Padki A, Wong A, Miano T, Kane-Gill SL, Cozzi G, Deveau R. Comparison of COVID-19 preprint and peer-reviewed versions of studies on therapies for critically ill patients. *J Intensive Care Med* 2023;38:1060-1067. PMID: 37337731.
19. Stottlemeyer BA*, McDermott M*, Minogue M*, Gray MP*, Boyce RD, Kane-Gill SL. Assessing adverse drug reaction reports for antidiabetic medications approved by the Food and Drug Administration between 2012-2017: A pharmacovigilance study. *Ther Adv Drug Saf* 2023; 14:20420986231181334; PMID: 37332887
20. Stottlemeyer BA*, Abebe KZ, Palevsky PM, Fried L, Schulman IH, Parikh CR, Poggio E, Siew ED, Gutierrez OM, Horwitz E, Weir MR, Wilson FP, Kane-Gill SL. Expert Consensus on the Nephrotoxic

Potential of 195 Medications in the Non-intensive Care Setting: A Modified Delphi Method. *Drug Saf* 2023; 46(7):677-687. PMID: 37223847.

21. Taneja SB, Callahan TJ, Paine MF, Kane-Gill SL, Kilicoglu H, Joachimiak MP, Boyce RD. Developing a knowledge graph for pharmacokinetic natural product-drug interactions. arXiv. 2022. [10.48550/arXiv.2209.11950](https://arxiv.org/abs/2022.10.48550). *J Biomed Inform* 2023 2023;140:104341. DOI: doi.org/10.1016/j.jbi.2023.104341.
22. Buckley MS, Roberts R, Yerondopoulos FM, Bushway A, Korkames G, Kane-Gill SL. Impact of Critical Care Pharmacist-Led Interventions on Pain, Agitation, and Delirium in Mechanically Ventilated Adults: A Systematic Review. *J Am Coll Clin Pharm* 2023; 1-12. <https://accpjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.1778>
23. Li X*, Ndungu P*, Taneja S*, Chapin M, Egbert S, Akenapalli K*, Paine M, Kane-Gill SL, Boyce R. An evaluation of outcomes and adverse drug reactions attributed to Kratom in the US Food and Drug Administration Adverse Event Reporting System. *Clin Transl Sci* 2023;16(6):1002-1011. PMID: 36861661
24. Williams VL*, Groetzing L, Smithburger PL, Imhoff A, Culley CM, Murugan R, Kellum JA, Kane-Gill SL. Case presentations of medication management for patients at high-risk for drug associated acute kidney injury identified with CDSS and a novel biomarker. *Am J Health Syst Pharm* 2023 Mar 21;80:423-429. PMID: 36308452.
25. Komerdelj IA, Buckley MS, D'Alessio PA, Ziadat DS, Kobic E, Rangan P, Agarwal SK, Tinta NC, Yerondopoulos MJ, Kane-Gill SL. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in general ward patients: a multicenter propensity score-matched study. *J Pharm Pract* 2023;67:134-140. PMID: 36075000.
26. Williams VL*, Smithburger PL, Imhoff A, Groetzing L, Culley CM, Burke C, Murugan R, Mahmud M, Benedict NJ, Kellum JA, Kane-Gill SL. Barriers and solutions to the implementation of a program that uses a stress biomarker test to identify patients at risk for drug associated acute kidney injury. *Ann Pharmacother* 2023 Apr;57(4):408-415.
27. Masthead, Yoo YJ, Wilkins KJ, Alakwaa F, Liu F, Torre-Healy LA, Krichevsky S, Hong SS, Sakhuja A, Potu CK, Saltz JH, Saran R, Zhu RL, Setoguchi S, Kane-Gill SL, Mallipattu SK, He Y, Ellison DH, Byrd JB, Parikh CR, Moffitt RA, Korashy FM. COVID-19-associated AKI in hospitalized US patients: incidence, temporal trends, geographical distribution, risk factors and mortality. medRxiv [Preprint]. 2022 PMID: 36093355
28. Cardone KE, Maxson R, Cho KH, Davis JM, El Nikidy WS, Kane-Gill SL, McNamara A, Wazny L, Wong L, Battistella M. Pharmacy practice standards for outpatient nephrology settings. *Kidney Med* 2022; 26;4(8):100509.
29. Desai R*, Kazarov C*, Wong A, Kane-Gill SL. A systematic review of kidney damage biomarkers for early identification of drug associated kidney injury. *Drug Saf* 2022; 45(8):839-852
30. Boyce RD, Kravchenko OV, Perera S, Karp J, Kane-Gill SL, Reynolds CF, Albert SM, Handler SM. Falls prediction using the nursing home minimum dataset. *J Am Med Inform Assoc* 2022; 29:1497-1507

31. Gray MP, Barreto EF, Schreier DJ, Kellum JA, Suh K, Kahani KB, Rule AD, Kane-Gill SL. Consensus obtained for the nephrotoxic potential of 167 drugs in adult critically ill patients using a modified-Delphi method. *Pharm Epi Drug Saf* 2022;45:389-98.
*Published in April 2022 and ranked as top 5 downloads from Jan to June 2022 for *Drug Saf*
32. Schreier DJ, Rule AC, Kashani KB, Mara KC, Kane-Gill SL, Lieske JC, Chamberlain A, Barreto EF. Nephrotoxin Exposure in the 3 Years Following Hospital Discharge Predicts Development or Worsening of Chronic Kidney Disease Among Acute Kidney Injury Survivors. *Am J Nephrol* 2022;53:273-81.
33. Patel JJ, Volino L, Cosler LE, Wang X, Kane-Gill SL, Toscani M, Barone J. Opioid abuse risk among student pharmacists. *J Opioid Management* 2022;18:161-66
34. Meissen H, Gong M, Wong A, Zimmerman JJ, Nadkarni N, Kane-Gill SL, Amador-Castaneda J, Bailey H, Brown SM, DePriest AD, Eche IM, Narayan M, Provenio JJ, Sederstrom NO, Servancky J, Tremper J, Aslakson RA. The future of critical care: Optimizing technologies for a more humanistic approach to clinical care. *Crit Care Explor* 2022
35. Gray M*, Priyanka P, Kane-Gill SL, Wang L, Kellum JA. Kidney and morality outcomes associated with ondansetron in critically ill patients. *J Intens Care Med* 2022; 37:1403-1410
36. Switzer G, Puttarajappa C, Kane-Gill S, Fried LF, Abebe K, Kellum JA, Jhamb M, Bruce J, Kuniyil V, Conway P, Knight R, Murphy J, Palevsky P. Patient-reported experiences after acute kidney injury across multiple health-related quality-of-life domains. *Kidney360* 2021;3:426-34.
37. Taneja SB, Callahan TJ, Brochhausen M, Paine MF, Kane-Gill SL, Boyce RD. Designing potential extensions from G-SRS to ChEBI to identify natural product-drug interactions. Intelligent Systems for Molecular Biology/European Conference on Computational Biology (ISMB/ECCB), 2021. <https://doi.org/10.5281/zenodo.5736386>
38. Buckley MS, Komerdelj I, D'Alessio P, Rangan P, Agarwal SK, Tinta NC, Martinez, Ziadat, Yerondopoulos MJ, Kobic E, Kane-Gill SL. Vancomycin and concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study. *J Intens Care Med* 2021;67:134-40.
39. Barreto EF, Schreier DJ, May HP, Mara KC, Chamberlain AM, Kashani KB, Piche SL, Wi CI, Kane-Gill SL, Smith VT, Rule AD; ACT Study Group. Incidence of Serum Creatinine Monitoring and Outpatient Visit Follow-Up among Acute Kidney Injury Survivors after Discharge: A Population-Based Cohort Study. *Am J Nephrol*. 2021;52(10-11):817-826.
40. Callaway Kim K, Tadrous M, Kane-Gill SL, Barbash IJ, Rothenberger S, Suda KJ. Changes in purchases for intensive care medicines during the COVID-19 pandemic: A global time series study. *Chest* 2021; Dec;160(6):2123-2134
41. Pruskowski JA, Kane-Gill SL, Kavalieratos D, Wilson B, Arnold R, Nace D, Handler SM. Feasibility of an academic detailing intervention to support deprescribing in the nursing home. *J Am Dir Assoc* 2021; 22:2398-2400.
42. Pfeiffer CM*, Kim H*, Stottlemeyer BA*, Gray MP*, Boyce RD, Kane-Gill SL. Assessing adverse drug reactions reported in the Food and Drug Administration Adverse Drug Event Reporting Database for newly approved respiratory medications: A pharmacovigilance study. *Resp Care* 2021;66:1739-45.

43. Kane-Gill, Barreto EF, Bihorac A, Kellum JA. Developing a theory-informed behavior change intervention to reduce inappropriate prescribing of nephrotoxins and renally eliminated drugs. *Ann Pharmacother* 2021;55:1474-1485.
44. Suh K, Kellum JA, Kane-Gill SL. A systematic review of cost-effectiveness analyses across the acute kidney injury landscape. *Expert Rev Pharmacoeconomics Outcomes Res* 2021; 21:571-78.
45. Patel NM*, Stottlemeyer BA*, Gray MP*, Boyce RD, Kane-Gill SL. A pharmacovigilance study of adverse drug reactions reported for new cardiovascular disease medications in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. *Cardiovascular Drugs Ther* 2022;36:309-22.
46. Badowski ME, Bente J, Davis E, Isaacs D, Lewis L, Martello J, Pitlick M, Silva Almodovar A, Stadler S, Sutton E, Belk M, Tovey A, Kane-Gill SL. Telehealth and technology applications in patient-centered care: Implications for students, post-graduate trainees and clinical pharmacists. *J Am Coll Clin Pharm* 2021;4:1044-55.
47. Moreland-Head L*, Coons J, Seybert AL, Gray MP*, Kane-Gill SL. Use of disproportionality analysis to identify previously unknown drug-associated cardiac arrhythmias using the Food and Drug Administration adverse event reporting system (FAERS) database: Known and Unknown Causes. *J Cardiovasc Pharmacol Ther* 2021;26:341-8.
48. Kane-Gill SL, Wong A, Culley CM, Perera S, Reynolds MD, Handler SM, Kellum JA, Aspinall M, Pellett M, Long K, Nace D, Boyce RD. Transforming the medication regimen review process of high-risk drugs using a patient-centered telemedicine-based approach to prevent adverse drug events in the nursing home. *J Am Geriatric Soc* 2021;69: 530-538.
The current consultant pharmacist process was transformed by altering how medication regimen reviews and medication reviews are conducted with a clinical decision support stimulus and telemedicine delivery during transitional care and throughout the resident's nursing home stay. This combination increased pharmacist's interventions and reduced the incidence of post-admission, alert-specific adverse drug vents compared to usual care. The findings were highlighted by the AHRQ Patient Safety Network
<https://psnet.ahrq.gov/issue/transforming-medication-regimen-review-process-using-telemedicine-prevent-adverse-events>
49. Ostermann M, Zarbock A, Goldstein S, Kianoush K, Macedo E, Murugan R, Bell M, Forni L, Guzzi L, Joannidis M, Kane-Gill SL, Legrand M, Mehta R, Murray P, Pickkers P, Plebani M, Prowle J, Rixxi Z, Rimmele T, Rosner M, Shaw A, Kellum J, Ronco C. Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: A consensus statement. *JAMA Network Open* 2020;3:e2019209.
Guidance is needed regarding how best to incorporate injury biomarkers into clinical practice. A panel of 23 international experts developed 11 consensus statements for biomarker use and 14 research recommendations. The key suggestions were that a combination of damage and functional biomarkers, along with clinical information, be used to identify high-risk patient groups, improve the diagnostic accuracy of AKI, improve processes of care, and assist the management of AKI. Importantly, new criteria for AKI assessment are proposed that includes consideration of damage biomarkers with or without a change in functional biomarkers (serum creatinine and urine output), thus rethinking the current KDIGO criteria.

50. Levito M*, Coons JC, Verrico MM, Szymkowiak A, Dueweke E, Legler B, Kane-Gill SL. A systemwide approach for navigating interference with unfractionated heparin anti-Xa concentrations in the setting of oral factor Xa inhibitor use. *Ann Pharmacother* 2021;55:618-23.
51. Ammar MA, Sacha GL, Welch S, Bass S, Kane-Gill SL, Ammar AA. Sedation, analgesia and paralysis in COVID-19 in the setting of drug shortages. *J Intensive Care Med* 2021;36:157-74.
52. Buckley MS, Smithburger PL, Wong A, Fraser G, Reade MS, Fedyshin MK, Ardiles T, Kane-Gill SL. Dexmedetomidine for facilitating mechanical ventilation extubation in difficult-to-wean ICU patients: Systematic review and meta-analysis of clinical trials. *J Intensive Care Med* 2021;36:925-36.
53. Prakasam D*, Wong A, Smithburger PL, Buckley MS, Kane-Gill SL. Benefits of engaging patients and family members in reporting ADRs in the hospital setting. *J Patient Saf* 2021;17: e765-71
54. Rice M*, Lear A*, Kane-Gill SL, Seybert AL, Smithburger PL. Pharmacy personnel's involvement in transitions of care of intensive care unit patients: A systematic review. *J Pharm Pract* 2021; 34:117-26.
55. Andreaggi C*, Novak E*, Mirabile M*, Sampathkumar S*, Gray MP*, He W, Kane-Gill SL. Safety Concerns Reported by Consumers, Manufacturers and Healthcare Professionals: A Detailed Evaluation of Opioid Related Adverse Drug Events in the FDA Database over 15 years. *Pharmacoepidemiol Drug Saf* 2020; 29:1627-1635.
56. Camacho J, Zanoletti Mannello M, Landis-Lewis Z, Kane-Gill SL, Boyce R. A conceptual framework to study the implementation of clinical decision support systems (BEAR): Literature review and concept mapping. *J Med Internet Res* 2020 22:e18388.

We have developed an integrated framework (BEAR – BEhavior and Acceptance fRamework) that bridges the gap between behavioral change and technology acceptance aspects of the implementation of CDS, widening the view established by current models. The BEAR framework was developed using an iterative process to map constructs from four contributing frameworks (TDF - Theoretical Domains Framework, CFIR - Consolidated Framework for Implementation Research, HOT-fit - Human, Organization and Technology-fit, and UTAUT - Unified Theory of Acceptance and Use of Technology).
57. Ostermann M, Bellomo R, Burdmann EA, Doi K, Endre ZH, Goldstein SL, Kane-Gill SL, Liu K, Prowle JR, Shaw AD, Srisawat N, Cheung M, Jadoul M, Winkelmayere WC, Kellum JA for the conference participants. Controversies in acute kidney injury: conclusions from a kidney disease improving global outcomes (KDIGO) conference. *Kidney Int* 2020;98:294-309.
58. Kleinpell R, Ferraro DM, Maves RC, Kane-Gill SL, Branson R, Greenberg S, Doersam JK, Raman R, Kaplan LJ. COVID-19 Pandemic measures: Reports from a national survey of 9,120 ICU clinicians. *Crit Care Med* 2020;48:e846-e855.
59. Babichenko E, Healy P, Gomez M, Kane-Gill S, Littleton E, Brusilovsky P, Cohen P, Patel R. The use of agent-based models as non-player characters in serious games. *IEEE xplore – SeGAH conference paper* 8th International Conference on Serious Games and Applications for Health 2020: article number 9201889
60. Wunderink RG, Svrinivasan A, Barie P, Chastre J, Dela Cruz C, Douglas I, Ecklund M, Evans S, Gerlach A, Hicks L, Howell, M, Hutchinson M, Hyzy R, Kane-Gill SL, Lease E, Metersky M, Munro N, Niederman M, Restrepo, Sessler C, Simpson S, Swoboda S, Vazquez Guillament C, Waterer GW, Weiss C. Antibiotic stewardship in the intensive care unit. An Official American Thoracic Society Workshop Report

in Collaboration with ASCN, CHEST, CDC, SCCM. *Ann Am Thorac Soc* 2020;17:531-40. PMID: 32356696

61. Kane-Gill SL, Peerapornratana W, Wong, A Groetzinger LM, Kim C, Smithburger PL, Then J, Murugan R, Kellum JA. Use of TIMP2-IGFBP7 as an AKI risk screening tool to manage patients in the real-world setting. *J Crit Care* 2020;57:97-101
62. Buckley MS, Agarwal SK, MacLaren R, Kane-Gill SL. Adverse hemodynamic events associated with concomitant dexmedetomidine and propofol for sedation in mechanically ventilated ICU patients. *J Intensiv Care Med* 2020; 35:1536-45.
63. Chen HX*, Coons JC, Iasella CJ, Empey PI, Stevenson JM, Kane-Gill SL. Triple antithrombotic therapy with direct oral anticoagulants versus warfarin after percutaneous coronary intervention with genotyping. *J Heart and Vascular Diseases* 2019;1:1000002 <https://www.onjourn.org/open-access-pdf/triple-antithrombotic-therapy-with-direct-oral-anticoagulants-versus-warfarin-after-percutaneous-coronary-intervention-with-genoty-100002.pdf>
64. Malinowski A, Benedict N, Ho M, Kirisci L, Kane-Gill SL. Patient reported outcomes associated with sedation and agitation intensity in the critically ill. *Am J Crit Care* 2020;29: 29;140-44.
65. Choi SH*, Li A, Smithburger PL, Gray MP*, Wong A, Kane-Gill SL. Drug-associated delirium identified in the food and drug administration adverse events reporting system. *Psychological Disorders and Research* 2019;2:2-7 https://www.sciencepository.org/drug-associated-delirium-identified-in-the-food-and-drug-administration-adverse-events-reporting-system_PDR-2019-3-101
66. Joyce EL, Kane-Gill SL, Priyanka P, Fuhman DY, Kellum JA. Piperacillin/tazobactam and antibiotic associated acute kidney injury in critically ill children. *J Am Soc Nephrol* 2019; 30:2243-2251.
67. Kane-Gill SL, Ostermann M, Shi J, Joyce EL, Kellum JA. Evaluating renal stress using pharmacokinetic urinary biomarker data in critically ill patients receiving vancomycin and/or piperacillin-tazobactam: A secondary analysis of the multicenter sapphire study. *Drug Saf* 2019; 42:1149-55.
68. Reardon C*, Kane-Gill SL, Smithburger PL, Dasta JF. Sufentanil sublingual tablet: a new option for acute pain management. *Ann Pharmacother* 2019; 53:1220-1226.
69. Seybert AL, Smithburger PL, Benedict NJ, Kobulinsky L, Kane-Gill SL, Coons JC. Evidence for simulation in pharmacy education. *J Am Coll Clin Pharm* 2019;2:686-692. <https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.1167>
70. Fitzmaurice MG, Wong A, Akerberg H, Avramovska S, Smithburger PL, Buckley MS, Kane-Gill SL. Evaluation of potential drug-drug interactions in adults in the intensive care unit: a systematic review and meta-analysis. *Drug Saf* 2019;42:1035-44.

This is a comprehensive summary of the data evaluating drug interactions in the intensive care unit. We noted that two-thirds (63%) of patients are exposed to at least one potential drug interaction during their ICU admission. One-sixth of patients were exposed to a clinically relevant event, a drug interaction resulting in negative consequences (ADE).
71. Dasta JF, Kane-Gill SL. Current assessment of the costs associated with acute kidney injury. *J Pharm Prac* 2019;32:292-302.

72. Kashani K, Rosner MH, Haase M, Lewington APL, O'Donoghue, DJ, Wilson FP, Nadim MK, Silver SA, Zarbock A, Ostermann M, Mehta RL, Kane-Gill SL, Ding X, Pickkers P, Bihorac A, Siew ED, Barreto EF, Macedo M, Kellum JA, Palevsky PM, Tolwani J, Ronco C, Juncos LA, Rews OG, Bagshaw SM, Mottes TM, Koyner JL, Liu KD, Forni LG, Heung M Wu V. Quality improvement goals for acute kidney injury. *Clin J Am Soc Nephrol* 2019; 14:941-53.
73. Altawalbeh SM, Abu-Su'ud R, Alefan Q, Momany S, Kane-Gill SL. Evaluating intensive care unit medication charges in a teaching hospital in Jordan. *Expert Rev Pharmacoecon Outcomes Res* 2019;28:1-7.
74. Barreto EF, Rule AD, Kieske JC, Kashani KB, Hassan Murad M, Erwin P, Kane-Gill SL. Prediction of renal elimination of drugs with cystatin C versus creatinine: a systematic review. *Mayo Clinic Pro* 2019;94:500-14.
75. Buckley MS, Barletta JF, Smithburger PL, Radosevich JJ, Kane-Gill SL. Catecholamine vasopressor support sparing strategies in vasodilatory shock. *Pharmacotherapy* 2019; 39:382-98.
76. Gray MP*, Dziuba G*, Quach K*, Wong A, Smithburger PL, Seybert AL, Kane-Gill SL. Assessing adverse drug reactions from psychotropic medications reported to the FDA in older adults. *Am J Geriatr Psychiatry* 2018;27:181-185.
77. Korenoski A, Li A, Kane-Gill SL, Seybert AL, Smithburger PL. Pharmacologic treatment of delirium in the ICU: A review of the literature. *J Intensive Care Med* 2020;35:107-117.
78. Benedict NJ, Wong A, Cassidy EA, Lohr BR, Pizon TF, Smithburger PL, Falcione B, Kirsci L, Kane-Gill SL. Predictors of resistant alcohol withdrawal. *Drug Alcohol Depend* 2018;192:303-8.
- A retrospective cohort of adults with severe alcohol withdrawal were screened. 736 patients (515 nRAW, 221 RAW) were analyzed. These data demonstrate the predictive ability of a history of psychiatric illness, thrombocytopenia, gender, race, baseline severity of illness and comorbidity scores for developing RAW. This is the first study assessing risk factors for benzodiazepine resistant alcohol withdrawal syndrome.*
79. Strnad K, Shoulders BR, Smithburger PL, Kane-Gill SL. A systematic review of non-ICU and ICU pharmacy services using telepharmacy. *Ann Pharmacother* 2018; 52:1250-58.
80. Ong CL, Kane-Gill SL, Kobulinsky LR, Hon JS, Kong MC, Seybert AL. Evaluation of pharmacist satisfaction with simulation-based learning in Singapore. *Curr Pharm Teach Learn* 2018; 10:1414-18.**
81. Barreto EF, Voils SA, Rule AD, Kane-Gill SL. Innovative use of novel biomarkers to improve the safety of renally-eliminated and nephrotoxic medications. *Pharmacotherapy* 2018; 38:794-803.
- Unique approaches that we have employed to use structural and functional biomarkers to improve medication safety are described in manuscript. My approach is the nephrotoxic stewardship for critically ill adult patients receiving 3 or more nephrotoxins and an evaluation of risk for AKI progression using TIMP2-IGFBP7.*
82. Welch H, Kellum JA, Kane-Gill SL. Drug-associated acute kidney injury identified in the food and drug administration adverse events reporting system. *Pharmacotherapy* 2018; 38:785-93.

83. Pizon AF, Lynch AJ, Benedict NJ, Yanta JH, Frisch A, Menke NB, Swartzentruber GS, King AM, Abesamis MG, Kane-Gill SL. Adjunct ketamine use in the management of severe ethanol withdrawal. *Crit Care Med* 2018; 46:e768-771.
84. Altawalbeh SM*, Thrope CT, Zgibor JC, Kane-Gill SL, Kany Y, Thorpe JM. Economic burden associated with receiving inhaled corticosteroids with leukotriene receptor antagonists or long-acting beta agonists as combination therapy in older adults. *J Manag Care Spec Pharm* 2018;24:478-86.
85. Fuhrman D, Goldstein SL, Kane-Gill SL, Kellum JA. Acute kidney injury epidemiology, risk factors and outcomes in critically ill young adults. *Ann Intens Care Med* 2018;8:26. <http://rdcu.be/G1uv>
86. Buckley MS, Rasmussen JR, Bikin DS, Richards EC, Berry AJ, Culver MA, Rivosecchi RM, Kane-Gill SL. Trigger alerts associated with laboratory abnormalities on identifying potentially preventable adverse drug events in the intensive care unit and general ward. *Ther Adv Drug Saf* 2018; 9:207-17.
87. Turco NJ, Kane-Gill SL, Hernandez I, Oleksiuk LM, D'Amico F, Pickering AJ. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections. *Expert Opin Pharmacother* 2018;19:319-325.
88. Ostermann M, Chawla LS, Forni L, Kane-Gill SL, Kellum JA, Koyner J, Murray P, Goldstein SL. Drug dosing in acute kidney disease- report of the ADQI XVI meeting. *Br J Pharmacol* 2018;84:396-403.
89. Winters BD, Cvach MM, Pelter MM, Bonafide CP, Hu X, Konkani A, O'Connor M, Rothschild JM, Selby NM, McLean B, Kane-Gill SL. Technological distractions in the ICU (Part 2): Recommendations for managing alarm fatigue. *Crit Care Med* 2018;46:130-37.
90. Niznik J*, He H*, Kane-Gill SL. Impact of clinical pharmacist services delivered via telemedicine in the outpatient or ambulatory care setting: A systematic review. *Res Soc Admin Pharm* 2017; pii: S1551-7411(17)30236-X.
91. Altawalbeh SM*, Saul MI, Seybert AL, Thorpe JM, Kane-Gill SL. Intensive care unit drug costs in the context of total hospital drug expenditures with suggestions for targeted cost containment efforts. *J Crit Care* 2017;44:77-81.
92. Smithburger PL, Korenoski AS*, Alexander SA, Kane-Gill SL. Perceptions of families of intensive care unit patients regarding involvement in delirium-prevention activities: a qualitative study. *Crit Care Nurse* 2017;37:e1-e9.
93. Boyce RD, Miller T, Jao J, Kane-Gill SL. Automated screening of emergency department notes for drug-associated bleed events occurring in older adults. *Appl Clin Inform* 2017;8:1022-30.
94. Hammond DA, Rowe JM, Wong A, Wiley TL, Lee C, Kane-Gill SL. Patient outcomes associated with phenobarbital use with or without benzodiazepines for alcohol withdrawal syndrome: systematic review. *Hosp Pharm* 2017;52:607-16.
95. Smithburger PL, Korenoski AS*, Kane-Gill SL, Alexander SA. Perceptions of family members, nurses, and physicians on involving the patients' families in delirium prevention. *Crit Care Nurse* 2017;37:48-57.

96. Kane-Gill SL, Dasta JF, Buckley MS, Devabhakthuni S, Lui M, Cohen H, George EL, Pohlman AS, Agarwal S, Henneman EA, Bejian SM, Berneholtz S, Pepin JL, Scanlon MC, Smith BS. Clinical Practice Guideline: Safe Medication Use in the ICU. *Crit Care Med* 2017;45(9):e877-e915

The manuscript referenced above represents the first guideline published on the topic of safe medication use in the ICU. The guideline review was completed with a thorough GRADE process.

97. Kane-Gill SL, Dasta JF, Buckley MS, Devabhakthuni S, Lui M, Cohen H, George EL, Pohlman AS, Agarwal S, Henneman EA, Bejian SM, Berneholtz S, Pepin JL, Scanlon MC, Smith BS. Executive summary: Clinical Practice Guideline: Safe Medication Use in the ICU. *Crit Care Med* 2017; 45(9):1546-51.
98. Kane-Gill SL, Smithburger PL, Kashani K, Kellum JA, Frazee E. Clinical relevance and predictive value of damage biomarkers of drug-induced kidney injury. *Drug Saf* 2017;40:1049-74. Leading Article
99. Shoulders BR, Smithburger PL, Tchen S, Buckley MS, Lat I, Kane-Gill SL. Characterization of guideline evidence for off-label medication use in the intensive care unit (ICU). *Ann Pharmacother* 2017;51:529-42.
100. Kane-Gill SL, O'Connor M, Rothschild JM, Selby NM, McLean B, Bonafide CP, Cvach MM, Hu X, Konkani A, Pelter MM, Winters BD. Technologic distractions in the ICU (Part 1): Summary of approaches to manage alert quantity with intent to reduce alert fatigue and suggestions for alert fatigue metrics. *Crit Care Med* 2017; 45(9):1481-1488.
101. Kramer A, Dasta JF, Kane-Gill SL. A multifactorial study of the effect of patient case mix, mortality, length of stay, and mechanical ventilation on ICU charges. *Crit Care Med* 2017; 45(9):1457-83.
102. Weaver CB, Kane-Gill SL, Gunn SR, Kirsci L, Smithburger PL. A retrospective analysis of the effectiveness of antipsychotics in the treatment of ICU delirium. *J Crit Care* 2017; 41:234-239.
103. Verlinden NJ, Coons JC, Iasella C, Saul MI, Kane-Gill SL. Triple antithrombotic therapy with aspirin, P2Y12 inhibitor, and warfarin after percutaneous coronary intervention: an evaluation of prasugrel or ticagrelor versus clopidogrel. *J Cardiovasc Pharmacol Ther* 2017; 22:546-551.
104. Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew E, Bagshaw S, Bittleman D, Cruz D, Endre Z, Fitzgerald RL, Forni L, Kane-Gill SL, Hoste E, Koyner J, Liu K, Macedo E, Mehta R, Murray P, Nadim M, Ostermann M, Palevsky P, Pannu N, Rosner M, Wald R, Zarbock A, Ronco C, Kellum JA. Acute Kidney Disease and Renal Recovery: Consensus Report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. *Nat Review Nephrol* 2017;13;241-47.

ADQI is an international, interdisciplinary organization with over 150 members from leading universities around the world. Founded in 2000, the membership includes adult and pediatric nephrologists, intensivists, cardiologists, surgeons, hepatologists, pharmacists and radiologists. I have the pleasure of being one of 3 pharmacists to join this group of experts. The above referenced article fills a major gap in clinical practice and the literature by:

- *Providing a description of acute kidney disease. After an episode of acute kidney injury, which is an abrupt decline in kidney function within 7 days or less, there is a period of up to 90 days for medical management and monitoring that could prevent patients from progressing to chronic kidney disease. This period between acute kidney injury and chronic kidney disease is known as acute kidney disease as named in this article.*

105. Rivosecchi RM*, Kane-Gill SL, Garavaglia J, MacLasco A, Johnson HJ. The effectiveness of intravenous vitamin K in cirrhotic patients with coagulopathy in the intensive care unit. *Int J Pharm Pract* 2017;25:463-65.
106. Leblanc JM, Cameron K, Symes J, Kane-Gill SL, Duplisea K, Mowatt J. Implementation and assessment of a pharmacy educational intervention on laboratory monitoring for medications. *Can J Hosp Pharm* 2017; 70:19-26.**
107. Kane-Gill SL, Niznik J, Kellum JA, Culley CM, Boyce RD, Marcum Z, He H, Perera S, Handler SM. Use of telemedicine to enhance pharmacist services in the nursing home. *Consult Pharm* 2017;32(2):93-98.
108. Witcher R Dzierba AL, Kim C, Smithburger PL, Kane-Gill SL. Adverse drug reactions in therapeutic hypothermia after cardiac arrest. *Ther Adv Drug Saf* 2017;8:101-11.
109. Hammond DA, Oyler DR, Devlin JW, Painter JT, Bolesta S, Swanson JM, Bailey BJ, Branan T, Barletta J, Dunn B, Haney J, Juang P, Kane-Gill SL, Kiser TH, Shafeeq H, Skaar D, Smithburger PL, Taylor J for the Preparing Our Learners for Success (POLS) Network. Perceived motivating factors and barriers for the completion of postgraduate training among American pharmacy students prior to beginning advanced pharmacy practice experiences. *Am J Pharm Ed* 2017;81:90.**
- I am a contributing member to development of a research network with a group of 15 academicians across the country that evaluates teaching and learning activities. The Preparing Our Learners for Success (POLS) Network began in 2014 and as a group allowed for 1000's of student participants contributing to the external validity of our findings. This study reference above evaluated the motivating factors and barriers for completing postgraduate training. Our network has several more projects aligned for future productivity.*
110. Joyce E, Kane-Gill SL, Fuhrman D, Kellum JA. Drug associated AKI: Who's at risk? *Pediatr Nephrol* 2017;32:59-69.
111. Kane-Gill SL, Hanlon JT, Fine MJ, Perera S, Culley CM, Studenski SA, Nace DA, Boyce RD, Castle NG, Handler SM. Physician perceptions of the importance and performance of consultant pharmacist services associated with a new care delivery model for the detection and management of adverse drug events in the nursing home. *Consult Pharm* 2016;31(12):711-23.
112. Kane-Gill SL, Achanta A, Kellum JA, Handler SM. Clinical decision support for drug related events: Moving towards better prevention. *World J Crit Care Med* 2016;5:204-211.
113. Groetzinger LM, Rivosecchi RM, Kane-Gill SL, Donahoe MP. An evaluation of the association between train of four values and gas exchanged indices in severe acute respiratory distress syndrome. *Ann Pharmacother* 2016;50:1009-15
114. Kane-Gill SL, MacLasco A*, Saul MI, Politz Smith T*, Kloet M*, Kim C, Anthes A, Smithburger PL, Seybert AL. Use of text searching for triggers words in medical records to identify adverse drug reactions within an ICU discharge summary. *Appl Clin Inform* 2016;7:660-71.
115. Rivosecchi RM*, Kellum JA, Dasta JF, Armahizer MA, Bolesta S, Buckley MS, Dzierba A, Frazee E, Johnson H, Kim C, Murugan R, Smithburger PL, Wong A, Kane-Gil SL. Drug class combination-associated with acute kidney injury: A review of the literature. *Ann Pharmacother* 2016; 50:953-72.

116. Altawalbeh SM*, Thrope CT, Zgibor JC, Kane-Gill SL, Kany Y, Thorpe JM. Antileukotriene agents versus long-acting beta -agonist in older adults with persistent asthma: A comparison of add-on therapies. *J Am Geriatr Soc* 2016;64:1592-600.
117. Sutherland SM, Chawla LS, Kane-Gill SL, Hsu RK, Kramer AA, Goldstein SL, Kellum JA, Ronco C, Bagshaw SM for the 15th ADQI Consensus Group. Utilizing the electronic health record to predict acute kidney injury risk and outcomes: Workgroup statements from the 15th ADQI consensus conference. *Can J Kidney Health Dis* 2016;3:11.
118. Liput S*, Kane-Gill SL, Seybert AL, Smithburger PL. Attitudes and perceptions of healthcare providers and family members towards family involvement in active patient care in the intensive care unit. *Crit Care Med* 2016;44:1191-7.
119. Ridenour TA, Wittenborn AK, Raiff BR, Benedict N, Kane-Gill S. Illustrating idiographic methods for translation research: moderation effects, natural clinical experiments, and complex treatment-by-subgroup interactions. *Transl Behav Med* 2016;6:125-34.
120. Rivosecchi RM*, Kane-Gill SL, Svec S, Campbell S, Smithburger PL. Giving your patients M.O.R.E.: The implementation of a non-pharmacologic protocol to prevent intensive care delirium. *J Crit Care* 2015; 31:206-11.

The study referenced above demonstrates:

- *Implementation of an evidence-based nonpharmacologic protocol reduced time spent delirious by 50% in the medical ICU.*
- *Use of the protocol decreased incidence of delirium from 15.7% to 9.6% (<0.001) and the odds of developing delirium by 57%*
- *Work is 1/14 citations in the delirium section of the 2020 final report by the National Academy of Medicine on strategies to improve patient safety and reduce medical errors to Congress by the U.S. Department of Health and Human Services in consultation with AHRQ. Document title "Making Healthcare Safer III: A Critical Analysis of Existing and Emerging Patient Safety Practices"*

121. Farina NM*, Smithburger PL, Kane-Gill SL. Screening and management of delirium in critically ill patients. *Hosp Pharm* 2015;50:667-71.
122. Riley CL, Sarani B, Sullivan JA, Upperman JS, Kane-Gill SL, Bailey H. Critical violent injury in the United States: A review and call to action. *Crit Care Med* 2015;43:2460-7.
123. Kane-Gill SL and Kellum JA. Advancing the use of clinical decision support to prevent drug-associated acute kidney injury. *Nephron* 2015;131:259-61.
124. Wong A*, Smithburger PL, Kane-Gill SL. Review of adjunctive dexmedetomidine for the management of severe alcohol withdrawal syndrome. *Am J Drug Alcohol Abuse* 2015;41:382-91.
125. Culley C, Perera S, Marcum ZA, Kane-Gill SL, Handler SM. Using a clinical surveillance system to detect drug-associated hypoglycemia in nursing home residents. *J Am Geriatr Soc* 2015;31:675-84.

The article referenced above is the first published report addressing the magnitude of the problem of drug-induced hypoglycemia in nursing home residents.

126. Wong A*, Benedict NJ, Lohr B, Pizon A, Kane-Gill SL. Management of benzodiazepine-resistant alcohol withdrawal across a health system: benzodiazepine dose escalation with or without propofol. *Drug Alcohol Depend* 2015;154:296-9.
127. Lyons P*, Nery *J, Rivosecchi R*, Smithburger PL, Kane-Gill SL. Fentanyl induced hyperalgesia in acute pain management. *J Pain Palliat Care Pharmacother* 2015;29:153-60.
128. Buckley MS, Park AS, Anderson CS, Barletta JF, Gerkin R, O'Malley, Wicks LM, Kane-Gill SL. Impact of a clinical pharmacist stress ulcer prophylaxis management program on inappropriate use in hospitalized patients. *Am J Med* 2015;128:905-913.
129. Smithburger PL, Buckley MS, Lat I, Culver MA, Handler SM, Sokol S, Kane-Gill SL. A multicenter evaluation of off-label use and associated adverse drug reactions in adult medical intensive care units. *Crit Care Med* 2015; 43:1612-1621.

The study cited above is the first to evaluate the impact of off-label drug use on patient safety in the ICU.

130. DiPoto JP, Buckley MS, Kane-Gill SL. Evaluation of an automated surveillance system using trigger alerts to prevent adverse drug events in the intensive care unit and general ward. *Drug Saf* 2015; 83:311-7.
131. Kane-Gill SL, Smithburger PL, Williams EA*, Felton MA*, Wang N*, Seybert AL. Published cases of adverse drug reactions: Has the quality of reporting improved over time? *Ther Adv Drug Saf* 2015;6:38-44.
132. Hale GM*, Kane-Gill SL, Groetzinger L, Smithburger PL. An evaluation of adverse drug reactions associated with antipsychotic use for the treatment of delirium in a medical intensive care unit. *J Pharm Practice* 2016;29:355-60.
133. Rivosecchi RM, Smithburger PL, Svec SM, Campbell S, Kane-Gill SL. The effect of non-pharmacologic interventions to prevent the development of delirium: An evidence based systematic review. *Crit Care Nurse* 2015;35:39-49.
134. Rivosecchi RM*, Garavaglia J, Kane-Gill SL. An evaluation of intravenous vitamin K for warfarin reversal: Are guideline recommendations being followed? *Hosp Pharm* 2015;50:18-14
135. Sileanu F, Murugan R, Lucko N, Clermont G, Kane-Gill SL, Handler SM, Kellum JA. Acute kidney injury in “low-risk” patients in intensive care. *Clin J Am Soc Nephrol* 2015;10:187-196.
136. Kane-Gill SL, Sileanu F, Murugan R, Trietley G*, Handler SM, Kellum JA. Risk factors for acute kidney injury in older adults with critical illness: A retrospective cohort study. *Am J Kidney Dis* 2015; 85:860-9.

The study referenced above demonstrates:

- *The likelihood of developing Acute kidney injury (AKI) increases with age*
- *Risk factors for developing AKI in the elderly include nephrotoxins, history of hypertension, and sepsis.*
- *Risk factors for developing AKI vary by age*

137. Wong A*, Benedict NJ, Kane-Gill SL. Multicenter evaluation of pharmacologic management and related outcomes associated with severe resistant alcohol withdrawal. *J Crit Care* 2015;20:405-9.

138. Wong A*, Benedict NJ, Armahizer MJ, Kane-Gill SL. Evaluation of adjunctive ketamine to benzodiazepines for the management alcohol withdrawal syndrome. *Ann Pharmacother* 2015;49:14-9.
139. Kauffman YS*, Connor SE, Jonkman LJ, Himisi T, Kane-Gill SL, Gillespie EM, Douglas G. Retrospective evaluation of adverse drug reactions in a central hospital in Malawi. *Pharmacovigil Drug Saf* 2014;1:004. <http://www.enlivenarchive.org/pharmacovigilance-drug-safety-004.html>
140. Benedict N, Felbinger M, Anthes A, Altawalbeh S*, Ridenour TA, Kane-Gill S. Correlation of patient reported outcomes of sedation and sedation assessment scores in critically ill patients. *J Crit Care* 2014; 29:1132.e5-9.
141. Kane-Gill SL, Rubin E*, Smithburger PL, Buckley MS, Dasta JF. The cost of opioid related adverse drug events. *J Pain Palliat Care Pharmacother* 2014; 28:282-93.
142. Kane-Gill SL, Leblanc JL, Dasta JF, Devabhakthuni S* for the Critical Care Pharmacotherapy Trials Network (CCPTN). A multicenter study of the point prevalence of drug-induced hypotension in the ICU. *Crit Care Med* 2014;42:2197-2203.

The above referenced study demonstrates:

- *Approximately 25% of hypotensive episodes in the ICU are unintentional and drug related, and one-fourth of these episodes are due to medication errors. This is the first study to evaluate drug induced hypotension in the ICU.*

143. Rivosecchi RM*, Rice MJ, Smithburger PL, Buckley MS, Coons JC, Kane-Gill SL. An evidenced based systematic review of remifentanyl-induced hyperalgesia. *Expert Opin Drug Saf* 2014;13:587-603.
144. Kloet MA*, Lohr BR*, Smithburger PL, Seybert AL, Kane-Gill SL. Assessment of inpatient boxed warning adherence. *J Patient Saf* 2017; 13:25-30.

This is the first study to evaluate the impact of using drugs with boxed warnings on patient safety in the ICU and non-ICU.

145. Sales I*, Meyer S, Kane-Gill SL, Schiff D. Teaching emphasis within pharmacy residency programs. *Currents in Pharmacy Teaching and Learning* 2014; 6:455-459.**
146. Smithburger PL, Smith RB, Kane-Gill SL, Empey PE. Variability of dexmedetomidine use and effectiveness in a medical intensive care unit. *Am J Crit Care* 2014; 23:160-5.
147. Holliday SF*, Kane-Gill SL, Empey PE, Buckley MS, Smithburger PL. Interpatient variability in dexmedetomidine response: a survey of the literature. *ScientificWorldJournal* 2014; article ID 805013. <http://www.hindawi.com/journals/tswj/2014/805013/>
148. Buckley MS, Harinstein LM, Smithburger PL, Devabhakthuni S, Alexander E, Clark KB, Wesley CA, Butch D, Kane-Gill SL. Impact of a clinical pharmacy admission medication reconciliation program on medication discrepancies. *Ann Pharmacother* 2013;47:1599-610.

The study referenced above indicates:

- *More than 25% of patients had at least 1 error associated with a medication ordered on hospital admission.*
- *Most common type of medication error resolved was medication omission (79.6%).*

- 46% of medication errors were considered significant or serious.
 - This clinical pharmacy program was estimated to carry a net present value in savings of \$5.7 million over 5 years.
149. Kane-Gill SL, Wytiaz N*, Thompson L, Buckley MS, Muzykovsky K, Cohen H, Seybert AL. A real-world, multicenter assessment of drugs requiring weight-based calculations in adult critically ill patients. *ScientificWorldJournal* 2013, article ID 909135. <http://dx.doi.org/10.1155/2013/909135>
 150. Kane-Gill SL, Williams EA*, Smithburger PL, Seybert AL. Tips for developing an integrated online and simulation course based on 6-years of experience. *Pharmacy* 2013;1:34-42. doi:10.3390/pharmacy1010034. <http://www.mdpi.com/2226-4787/1/1/34/htm> **
 151. Buckley MA, MacLaren RM, Frazee EN, Smithburger PL, Personett HA, Kane-Gill SL. Surveying residents on postgraduate year 2 critical care pharmacy residencies about their level of preparedness to practice. *Currents in Pharmacy Teaching and Learning* 2014;6:76-84 <http://www.sciencedirect.com/science/article/pii/S1877129713001627> **
 152. Buckley MS, Dzierba AL, Smithburger PL, McAllen KJ, Jordan CJ, Kane-Gill SL. Chlorhexidine for the prevention of ventilator-associated pneumonia. *J Infect Prev* 2013;14:162-169. <http://bjj.sagepub.com/content/early/2013/06/14/1757177413490814.abstract>
 153. Smithburger PL, Kane-Gill SL, Lohr BR, Kloet MA, Seybert AL. Advancing interprofessional education through the use of high fidelity human patient simulators. *Pharm Pract* 2013;11:61-65 <http://www.pharmacypractice.org/journal/index.php/pp/article/view/336> **
 154. Buckley MS, Kane-Gill SL, Patel SA. Clinical and economic evaluation of an evidence-based institutional epoetin-utilization management program. *Clin Ther* 2013;35:294-302.
 155. Anthes, AM*, Harinstein LM*, Smithburger PL, Seybert AL, Kane-Gill SL. Improving adverse drug event detection in critically ill patients through screening intensive care unit transfer summaries. *Pharmacoepidemiol Drug Saf* 2013; 22:510-16.
 156. Smithburger PL, Campbell SC, Kane-Gill SL. Alteplase treatment of acute pulmonary emboli in the intensive care unit. *Crit Care Nurse* 2013;33:17-27.
 157. Havrda DE, Engle JP, Ray SM, Haines SL, Kane-Gill SL, Ballard SL, Crannage AJ, Rochester CD, Parman MG. Guidelines for residency teaching experiences. *Pharmacotherapy* 2013; 33:e147-61. **
 158. Armahizer MJ*, Seybert AL, Smithburger PL, Kane-Gill SL. Drug-drug interactions contributing to QT prolongation in the ICU. *J Crit Care* 2013; 28:243-9.
 159. Sales I, * Dzeirba A, Smithburger PL, Rowe D*, Kane-Gill SL. Use of acetylcysteine treatment for non-acetaminophen acute liver failure. *Ann Hepatol* 2013; 12:6-10.
 160. Armahizer MJ*, Kane-Gill SL, Smithburger PL, Anthes AM, Seybert AL. Comparing DDI severity for clinician opinion to proprietary databases. *ISRN Critical Care* volume 2013, article ID 347346, <http://www.hindawi.com/isrn/cc/aip/347346/>
 161. Smithburger PL, Kane-Gill SL, Seybert AL. Drug-drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved. *Int J Pharm Pract* 2012;20:402-8.

162. Kane-Gill SL, Post JP*, Smithburger PL, Seybert AL. “Bump”: Using a mobile app to enhance human patient simulation learning. *Simul Healthc* 2012;326-327. **
163. LeBlanc J, Kane-Gill S, Pohlman A, Herr D. Multiprofessional survey of protocol use in the intensive care unit. *J Crit Care* 2012;27:738.e9-738.e17
164. Abel EE*, Kane-Gill SL, Seybert AL, Kellum JA. direct thrombin inhibitors (DTIs) for management of heparin-induced thrombocytopenia (HIT) in patients receiving renal replacement therapy: comparison of clinical outcomes. *Am J Health-Syst Pharm* 2012; 69:1559-67.
165. Kane-Gill SL, Forsberg EA*, Verrico MM, Handler SM. Comparison of three pharmacovigilance algorithms in the ICU setting: a retrospective and prospective evaluation of ADRs. *Drug Saf* 2012;35:645-53.

The above referenced study indicates:

- *All adverse drug reaction causality instruments are not created equal.*
- *The reliability as measured with the kappa statistic indicates reliability is better when adverse drug reactions are evaluated subsequent to a patients’ discharge compared to an ongoing adverse drug reaction during a patients’ hospitalization*

166. Seybert AL, Smithburger PL, Kobulinsky LR, Kane-Gill SL. Simulation based learning versus problem-based learning in an acute care course. *Simul Healthc* 2012;7:162-165. **
167. Harinstein LM*, Kane-Gill SL, Smithburger PL, Culley CM, Reddy VK, Seybert AL. Use of a laboratory-drug combination alert to detect drug-induced thrombocytopenia in critically ill patients. *J Crit Care* 2012;27:242-249.

Work is cited in the clinical decision support section of the 2020 final report by the National Academy of Medicine on strategies to improve patient safety and reduce medical errors to Congress by the U.S. Department of Health and Human Services in consultation with AHRQ. Document title “Making Healthcare Safer III: A Critical Analysis of Existing and Emerging Patient Safety Practices”

168. Devabhakthuni S*, Armahizer M*, Dasta JF, Kane-Gill SL. Analgo-sedation: A paradigm shift in ICU sedation practice. *Ann Pharmacother* 2012;46:530-540.
169. Smithburger PL, Kane-Gill SL, Ruby C, Seybert AL. Comparing the effectiveness of three learning strategies: simulation-based learning, standardized patient interviews and problem-based learning. *Simul Healthc* 2012;7:141-146.**
170. Kane-Gill SL, Kirisci L, Verrico MM, Rothschild JM. Identification of risk factors for adverse drug events in critically ill patients. *Crit Care Med* 2012;40:823-828.

The above referenced article is the first to evaluate risk factors for adverse drug events in the ICU. An extensive number (n=34) of risk factors were considered making this a thorough analysis and an advancement in the patient safety literature. This study demonstrates that:

- *Patients with kidney injury, thrombocytopenia, and those admitted emergently were 16 times, 3-times, and 2-times more likely to have an adverse drug event, respectively.*

- *Patients who were administered intravenous medications had a 3% higher risk of having an adverse drug event for each drug dispensed.*
 - *Overall, the case group received more drugs per intensive care unit day and more drugs per intensive care unit stay.*
171. Gokhman R*, Seybert AL, Phrampus P, Darby J, Kane-Gill SL. Medication errors during medical emergencies in a large, tertiary care, academic medical center. *Resuscitation* 2012;83:482-487.
172. Kane-Gill SL, Visweswaran S, Saul MI, Wong I, Penrod L, Handler SM. Computerized detection of adverse drug reactions in the medical ICU. *Int J Med Inform* 2011; 80:570-578.
173. Smithburger PL, Buckley MS, Bejian S, Burenheide K, Kane-Gill SL. A critical evaluation of clinical decision support used for the detection of drug-drug interactions. *Expert Opin Drug Saf* 2011;10:871-82
174. Seybert AL, Kane-Gill SL. Elective course in acute care using online learning and patient simulation. *Am J Pharm Ed* 2011;75:article 54. **
175. Gesin G, Kane-Gill SL, Dasta JF, Birrer KL, Kolnik L, Cheatham M. Diazepam as a component of goal-directed sedation in critically ill trauma patients. *J Crit Care* 2011;122-126.
176. Smithburger PL*, Kane-Gill SL, Benedict N, Falcione BA, Seybert AL. Grading the severity of drug-drug interactions in the intensive care unit: A comparison between clinical opinion and database severity ratings. *Ann Pharmacother* 2010; 44:1718-1724.
177. Gokhman R*, Smithburger PL*, Kane-Gill SL, Seybert AL. Pharmacologic and pharmacokinetic rationale for combination therapy of pulmonary arterial hypertension. *J Cardiovasc Pharmacol* 2010;56:686-695.
178. Smithburger PL*, Kane-Gill SL, Nestor BL, Seybert AL. Recent advancements and opinions in the treatment of hypertensive emergencies. *Crit Care Nurse* 2010;30(5):24-30. (Cover article)
179. Smithburger PL*, Kane-Gill SL, Seybert AL. Drug-drug interactions in cardiac and cardiathoracic intensive care units: an analysis of patients in an academic medical centre in the US. *Drug Saf* 2010;33:879-888.
180. Kane-Gill SL, Van Den Bos J, Handler SM. A comparison of adverse drug reactions in ambulatory care and hospital settings using a large database. *Ann Pharmacother* 2010; 44:1054-1060.

The study referenced above demonstrates:

- *The prevalence and distribution of suspected ADEs by demographics and drug class for ambulatory and hospitalized patients in 20 million medicare and commercially insured patients.*

181. Ford DG*, Seybert AL, Smithburger PL*, Kobulinsky L, Samosky J, Kane-Gill SL. Impact of simulation-based learning on medication error rates in critically ill patients. *Intens Care Med* 2010;36:1526-1531. **

The study reference above demonstrates:

- *A 25% reduction in medication errors in the ICU with the use of high-fidelity simulation to educate nurses in medication administration techniques.*
- *This is one of the first studies to demonstrate that clinical benefit of high-fidelity simulation education.*

182. Smithburger PL, Seybert AL, Armahizer MJ*, Kane-Gill SL. QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions. *Expert Opin Drug Saf* 2010;9(5):600-712.
183. Kane-Gill SL, Kowiatek JG, Weber RJ. A comparison of voluntarily reported medication errors in intensive care and general care units. *Qual Saf Health Care*. 2010; 19:55-59.
184. Dasta JF, Kane-Gill SL, Pencina M, Shehabi, Y, Bokesch P, Riker R. A cost-minimization analysis of dexmedetomidine compared to midazolam for long-term sedation in the intensive care unit. *Crit Care Med*, 2010;38(2): 497-503.

Dexmedetomidine has a substantial acquisition cost, but the importance of economic evaluation techniques is to evaluate the total cost of care and look beyond acquisition costs. This study demonstrates:

- *The first cost minimization analysis assuming equal efficacy between drugs then comparing costs is the emphasis.*
- *Dexmedetomidine offers the advantage of reducing ICU length of stay so this outcome has demonstrated a decrease in hospital costs for the patient, as seen in our analysis.*

185. Kane-Gill SL, Bellamy CJ*, Verrico MM, Saul MI, Handler SM, Weber RJ. Evaluating the positive predictive values of antidote signals to detect potential adverse drug reactions (ADRs) in the medical intensive care unit (ICU). *Pharmacoepidemiol Drug Saf* 2009; 18:1185-1191.
186. Bellamy CJ*, Kane-Gill SL, Falcione BA, Seybert AL. Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. *J Trauma*, 2009;66:954-958.
187. Havrilla PL*, Kane-Gill SL, Seybert AL, Verrico MM, Reis SE. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. *Ann Pharmacother*, 2009;43:532-536.
188. Gerlach AT, Kane-Gill SL, Steinberg S, Dasta JF, Martin LC, Cook CH. Diltiazem versus amiodarone for new onset atrial arrhythmias in non-cardiac post surgical patients: a cohort study. *Crit Care & Shock* 2008;11:94-106.
189. Dasta JF, Kane-Gill SL, Durtschi AJ, Pathak DS, Kellum J. Costs and outcomes of acute kidney injury (AKI) following cardiac surgery. *Nephrol Dial Transplant*, 2008;0:1-5.

This study reference above indicates:

- *Even small changes in serum creatinine result in greater costs and mortality*
- *As changes in serum creatinine become more substantial as measured by the RIFLE criteria that costs and mortality become more substantial.*

190. Kane-Gill SL, Castelli EE, Kirisci L, Rice TL, Fink MP. Effectiveness study of rHuEPO in the ICU. *Crit Care & Shock* 2007;10:53-62.
191. Watson K*, Seybert AL, Saul MI, Lee JS, Kane-Gill SL. Comparison of patient outcomes of bivalirudin versus unfractionated heparin in percutaneous coronary intervention. *Pharmacotherapy* 2007;27:647-656.

192. Kane-Gill SL, Olsen KM, Rebeck JA, Rea RS, Smythe MA, Boatwright DW, Walker TR, Lager SL, Hodgman T and the Aspiration Evaluation Group of the SCCM Clinical Pharmacy and Pharmacology Section. Multicenter evaluation of the treatment and outcomes of aspiration syndromes in adult critically ill patients. *Ann Pharmacother* 2007; 41:549-555.
193. Rea RS, Donihi Calabrese A, Bobek MB, Herout P, McKaveney TP, Kane-Gill SL, Kortykowski M. Implementing an intravenous insulin infusion protocol in the intensive care unit. *Am J Health Syst Pharm* 2007;64:385-395.
194. Kane-Gill SL, Seybert AL, Lazar J, Shatzer M, Saul MI, Kirisci L, Murali S. Resource use in decompensated heart failure by disease progression category. *Congest Heart Fail* 2007;13:22-28.
195. Kane-Gill SL, Rea RS*, Verrico P, Weber RJ. ADE rates for high cost and frequently used drugs in the ICU: Redirecting pharmacist's time toward ADE prevention efforts. *Am J Health Syst Pharm* 2006;63:1876-1881.
196. Kane-Gill SL, Devlin JW. Adverse drug event reporting in the intensive care unit: a survey of current practices. *Ann Pharmacother* 2006;40:1267-1273.
197. Feng Y, Green B, Duffull SB, Kane-Gill SL, Bobek MB, Bies RR. Development of an appropriate dosing strategy in patients receiving enoxaparin by continuous intravenous with modeling and simulation. *Br J Clin Pharmacol* 2006;62:165-176.
198. Rea RS*, Kane-Gill SL, Rudis MI, Seybert AL, Oyen LJ, Ou NN, Stauss JL, Kirisci L, Idrees U*, Henderson SO. Intravenous amiodarone for the treatment of in-hospital cardiac arrest due to pulseless ventricular tachycardia/ventricular fibrillation. *Crit Care Med* 2006;34:1617-1623.
199. Leblanc JM, Dasta JF, Kane-Gill SL. The role of bispectral index monitoring in the ICU. *Ann Pharmacother* 2006;40:490-500.
200. Curtis JR, Cook DJ, Wall RW, Angus D, Bion J, Kacmerack R, Kane-Gill SL, Kirchhoff K, Levy M, Mitchell P, Moreno R, Pronovost P, Puntillo K. ICU Quality Improvement: A "how-to" guide for the interdisciplinary team. *Crit Care Med* 2006;234:211-216. **
201. Kane-Gill SL, Dasta JF, Schneider PJ, Cook CH. Monitoring abnormal laboratory values as antecedents to drug induced injury. *J Trauma* 2005; 59:1457-1462.
- In this article, I coined the term "drug-related hazardous condition" (DRHC). A DRHC is defined as the step before an adverse drug event (ADE), being injury to the patient. A DRHC is the temporal gap before drug-induced injury allowing the opportunity for clinicians to intervene. This is the foundation for incorporating technology into my research for the identification of DRHCs and prevention of ADEs. The use of DRHCs in clinical decision support shifts the concept of detection to prevention.*
202. Kane-Gill SL, Kirisci L, Pathak DS. Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit? *Ann Pharmacother* 2005; 39: 1823-1827.
203. Coons JC*, Seybert AL, Saul MI, Kirisci L, Kane-Gill SL. Clinical outcomes and costs of abciximab and eptifibatid for percutaneous coronary intervention. *Ann Pharmacother* 2005;39:1621-1626.

204. Kane-Gill SL, Feng Y*, Bobek MB, Bies RR, Pruchnicki MC, Dasta JF. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety. *J Clin Pharm Ther* 2005; 30:207-213.
205. Watson B*, Kane-Gill SL. Sedation assessment in critically ill adults 2001-2004 update. *Ann Pharmacother* 2004; 38: 1898-1906.
206. Lewis KS, Kane-Gill SL, Bobek MB, Dasta JF. Intensive insulin therapy for critically ill patients. *Ann Pharmacother*, 2004;38: 1243-1251.
207. Dasta, JF, Kane-Gill SL, Durtschi, AJ and the Dex Registry Study Group. Comparing dexmedetomidine prescribing patterns and safety in the naturalistic setting versus published data. *Ann Pharmacother* 2004;38: 1130-1135.
208. Kane SL, Weber RJ, Dasta JF. The impact of critical care pharmacists on enhancing outcomes. *Intensive Care Med* 2003;29:691-698.
209. Kane SL, Dasta JF. Clinical outcomes of critical illness polyneuropathy. *Pharmacotherapy* 2002;3:373-379.
210. Kane SL, Dasta JF, Cook CH. Successful treatment of Hansenula anomola pneumonia. *Ann Pharmacother* 2002;36 (1):59-62.
211. Calabrese AD, Erstad BL, Brandl K, Barletta J, Kane SL, Sherman D. Medication administration errors in adult patients in the intensive care unit. *Intensive Care Med* 2001;27:1592-1598.
212. Kane SL, Constantiner M, Staubus AE, Meinecke CD, Sedor JR. High-flux hemodialysis without hemoperfusion is effective management of acute valproic acid overdose. *Ann Pharmacother* 2000; 34(10): 1146-1151.

INVITED MANUSCRIPTS

1. Kane-Gill SL. New perspectives of drug related kidney diseases and disorders. *Curr Opin Crit Care* 2024 (submitted)
2. Mannis M, Wallace J, Kane-Gill SL. Pharmacist and nurse navigator roles in post-discharge AKI care. *Adv Chronic Kid Dis* 2024 (submitted)
3. Karimzadeh I, Strader M, Kane-Gill SL, Murray PT. Prevention and management of antibiotic associated acute kidney injury in critically ill patients: New insights. *Curr Opin Crit Care* 2023;29:595-606
4. Jacobi J, Kane-Gill SL, Boucher B. Critical care pharmacists have a rich history and evolving roles. *JACCP* 2023; <https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.1840>.
5. Kane-Gill SL. Society of Critical Care Medicine Presidential Address, 51st Annual Congress, April 2022. *Crit Care Med* 2022
6. Miller MJ, Kane-Gill SL. Pandemic stimulates a variety of telepharmacy applications: Considerations for implementation, sustainability, and future directions. *Am J Health-Syst Pharm* 2022;79(11):918-920.

7. Kane-Gill SL. Health system perspectives in AKI: commitment to kidney health and planning implementation interventions. *Curr Opin Crit Care* 2021;27:593-603.
<https://www.youtube.com/watch?v=qGcz8KVUsPU>
8. Acquisto NM, Beavers C, Bolesta S, Buckley M, Dobbins K, Finch C, Hayes S, Holdren D, Johnson S, Kane-Gill SL, Lat I. ACCP White Paper: Development and application of quality measures of clinical pharmacist services provided in inpatient/acute care settings. *J Am Coll Clin Pharm* 2021. doi: 10.1002/jac5.1559.
9. Kane-Gill SL, Meersch M, Bell M. Biomarker-guided management of acute kidney injury. *Curr Opin Crit Care* 2020;26:556-62.
10. Kane-Gill SL. Nephrotoxin stewardship. *Crit Care Clin* 2021;37:303-320. PMID:33752857
This article contributes to the literature with the first definition of nephrotoxin stewardship and nephrotoxin burden. A detailed description of a comprehensive nephrotoxin stewardship program is provided.
11. Kane-Gill SL, Rincon F. Expansion of telemedicine services: telepharmacy, telestroke, teledialysis, tele-emergency medicine. *Crit Care Clin* 2019; 35:519-33.
12. Deal EN, Stranges PM, Maxwell WD, Bacci J, Ashjian EJ, BeRemer DL, Kane-Gill SL, Norgard NB, Dombrowski L, Parker RB, American College of Clinical Pharmacy. The importance of research and scholarly activity in pharmacy training. *Pharmacotherapy* 2016;36Le200-e205. **
13. Kane-Gill SL, Goldstein SL. Drug-induced AKI: A focus on risk assessment for prevention. *Crit Care Clin* 2015;31:675-84.
14. Kane-Gill SL and Smithburger PL. Transitioning knowledge gained from simulation to pharmacy practice. *Am J Pharm Educ* 2011;75:210. **
15. Dasta JF, Kane-Gill SL. Pharmacoeconomics of sedation in the ICU. *Anesthesiol Clin* 2011;29:707-720.
16. Dager W, Bolesta S, Brophy G, Dell K, Gerlach, A, Kristeller J, Micek S, Hess M, Bentley M, Juang P, MacLaren R, Kane-Gill S, Haase K, Mann H, Miller C, Pepe D, Southwood R, Weant K, Rebeck J, Wood C. (ACCP Critical Care PRN Opinion Paper Committee). An opinion paper outlining recommendations for training, credentialing, and documenting and justifying critical care pharmacy services. Endorsed by SCCM, the American Society of Health-Systems Pharmacists, and the ACCP Critical Care Practice and Research Network. *Pharmacotherapy* 2011;31:829 and 2011;31:135e-175e. Copy available at: http://www.accp.com/docs/positions/opinionPapers/Pharm3108e_MacLaren_PRN_Credentials.pdf **
17. Kane-Gill SL, Jacobi J, Rothschild JR. Adverse drug events in the ICU: risk factors, impact and role of team care. *Crit Care Med* 2010;38 (6suppl):s83-89
18. Stockwell D and Kane-Gill SL. Developing a patient safety surveillance system to prevent adverse drug events in the ICU. *Crit Care Med* 2010;38 (6 suppl):s117-25.
19. Patel G, Kane-Gill SL. Medication error analysis: A systematic approach. *Curr Drug Saf* 2010;5:2-5.

20. Goodwin SD, Kane-Gill SL, Ng T, Melroy JT, Hess M, Tallian K, Trujillo T, Vermeulen LC. (ACCP Clinical Affairs Committee). ACCP White Paper: Rewards and advancements for clinical pharmacists. *Pharmacotherapy* 2010;30:114. Copy available at: <http://www.accp.com/docs/positions/whitePapers/RewardsAdvancements.pdf>
21. Dasta JF, Kane-Gill SL. Pharmacoeconomics of sedation in the ICU. *Crit Care Clin* 2009;25:571-583.
22. Kane-Gill SL, Reddy P, Gupta S, Bakst A, the ACCP Publication Committee and the ISPOR Fellowship Taskforce. ACCP/ISPOR guidelines for pharmacoeconomic and outcomes fellowship training programs. *Pharmacotherapy* 2008;28:1552. Copy available at: http://www.pharmacotherapy.org/pdf/free/Pharm2810_ACCP-Gill-ResFel.pdf **
23. Kane-Gill SL, Weber RJ. Principles and practices of medication errors in the ICU. *Crit Care Clin* 2006;22:273-290.
24. Weber RJ, Kane SL, Oriolo VA, Saul MI, Skledar SJ, Dasta JF. The impact of ICU drug use on hospital costs: A descriptive analysis with recommendations for optimizing ICU pharmacotherapy. *Crit Care Med* 2003;31:s17-s24.

BOOK CHAPTERS

1. Karimzadeh I, Kane-Gill SL. Prescribing and dosing in acute kidney injury.
2. Kane-Gill SL and Buckley MS. Medication Safety and Active Surveillance. In: Erstad BL (ed). *Critical Care Pharmacotherapy Second Edition*. Lenexa, KS: American College of Clinical Pharmacy 2023; 1073-84
3. Keating J, Kane-Gill SL, Kaplan LJ. Interaction of opioids with sedative practices in the ICU. In: Pascual JL and Gaulton TG (eds) *Opioid Use in Critical Care: A Practical Guide*. Switzerland: Springer, Cham 2021:147-64.
4. Wong A, Kane-Gill SL. *Pharmacotherapy: A pathophysiologic approach*. Introduction to critical care. McGraw Hill Education, U.S, 2020; chapter e25; p73.
5. Wong A, Kane-Gill SL. In: Hatton-Kolpek J et al, eds. In: *American College of Clinical Pharmacy Critical Care Self-Assessment Program (CCSAP), Neurocritical Care/Technology in the ICU. Technology and Medication Safety in the ICU*. Lenexa, KS: American College of Clinical Pharmacy, 2017:71-85.
6. Kane-Gill SL, Cohen H. Pharmacy administration and development: Pharmacoeconomics and Safe Medication Use. *Critical Care Preparatory Review and Recertification Course*. Lenexa, KS: American College of Clinical Pharmacy, 2017:461-492.

7. Kane-Gill SL, Dasta JF. Severe drug reactions. In: Kellum JA, Fortenberry JD, Fuchs BD, Shaw A (editors). Clinical decision support: Critical care medicine 2016 www.decisionsupportinmedicine.com
8. Wong A*, Kane-Gill SL. Antibiotic prescribing in the ICU and AKI. In: Ronco C, Bellomo R, Kellum J, Ricci Z. Critical Care Nephrology (third edition). Saunders Elsevier, Philadelphia, PA. 2017:539-42 (chapter 92)
9. Kane-Gill SL and Buckley MS. Medication Safety and Active Surveillance. In: Erstad BL (ed). Critical Care Pharmacotherapy. Lenexa, KS: American College of Clinical Pharmacy 2016:971-982.
10. Wong A, Kane-Gill SL, Kellum JA. Drug dosing in continuous renal replacement therapy. In: Kellum JA, Bellomo R, Ronco C. Continuous renal replacement therapy (second edition). Chapter 20.
11. Kane-Gill SL, Cagle WE, Stockwell D. Active patient safety surveillance systems used to prevent ADEs in the ICU. In: Papadopoulos J, Cooper B, Kane-Gill SL, Mallow-Corbett S, Barletta J.(editors) Drug induced complications in critically ill patients: a guide for recognition and treatment. 2012:347-358.
12. Harinstein L, Kane-Gill SL. A practical approach to assessing ADRs in the ICU using a reliable and valid pharmacovigilance algorithm. In: Papadopoulos J, Cooper B, Kane-Gill SL, Mallow-Corbett S, Barletta J.(editors) Drug induced complications in critically ill patients: a guide for recognition and treatment. 2012;413-421.
13. Kane-Gill SL, Dasta JF. Severe drug reactions. In: Kellum JA, Fortenberry JD, Fuchs BD, Shaw A (editors). Clinical decision support: Critical care medicine 2013 www.decisionsupportinmedicine.com
14. Smithburger PL and Kane-Gill SL. Adenergetic antagonists and Prostanoids. In: Kane-Gill SL, Dasta JF (editors) High-risk IV medications in special patient populations. 2011:221-250.
15. Dasta JF, Kane-Gill SL. Pharmacoeconomics In: Vincent JL, Abraham E, Moore FA, Kochanek PM, Fink MP (editors) Textbook of Critical Care, 6th Edition, 2011;1387-1392.
16. Kane-Gill SL and Buckley MS. In: Richardson M, Chant C, Cheng JWM, Chessman KH, Hemstreet Hume AL, BA et al, eds. Pharmacotherapy Self-Assessment Program (PSAP), 7th ed. Safe Drug Use in the Critically Ill Patients. Lenexa, KS: American College of Clinical Pharmacy, 2010:145-159.
17. Dasta JF, Kane-Gill SL. Economic impact of acute kidney failure, In Management of Acute Kidney Problems. Jorres A, Ronco C, Kellum J, eds., Springer Publications, 2009:75-80.
18. Kane-Gill SL. Health policies that influence cost, quality and safety in critical care. In: Chant C (Editor) Pharmacotherapy Self-Assessment Program (PSAP): Pulmonary/Critical Care, 6th Edition, 2008:73-89.
19. Goodwin D, Hess M, Kane-Gill SL, Ng T, Tallian K, Trujillo T, Vermeulen L, West K, Kehoe W. Business practice model for clinical pharmacy services in the inpatient setting. In: Schumock G, Stuggings J. How to develop a business plan for pharmacy services. Lenexa KS: American College of Clinical Pharmacy, 2007:109-136.
20. Dasta JF, Durtschi AJ, Kane-Gill SL. Pharmacoeconomics in critical care. In: Grenvik A (Editor) Textbook of Critical Care, 5th Edition, 2005:1732-1739.

LETTERS AND EDITORIALS

1. Nunnally ME, Dager WE, Patel H, Al-Hazzani W, Nadkarni VM, Kane-Gill SL. Revising the Process and Structure of the Society of Critical Care Medicine Guidelines Toward a Living Guideline Model. *Crit Care Med*. 2023 Oct 1;51(10):1281-1284
2. Cote JM, Kane-Gill SL, Murray P. “Editorial- Association of Vancomycin Plus Piperacillin-Tazobactam with Early Changes in Creatinine versus Cystatin C in Critically Ill Adults: A Prospective Cohort Study” Title: A Ray of Hope in the Discord; Is adding Piperacillin-tazobactam to Vancomycin truly more Nephrotoxic? *Intensive Care Med* 2022; 48(9):1208-1210
3. Kane-Gill SL, Winkle J, Kaplan LJ, Nadkarni V, Sorce LR, Harmon L, Martin GS. SCCM/ACCM Guideline and Toolkit Development Pathways. *Crit Care Med*. 2021;49(11):1851-1854. PMID: 34643577.
4. Martin GS, Kane-Gill SL, Nadkarni V, Sorce LR, Kaplan LJ, Cecconi M, Azoulay E, Teboul JL, Forni L, Kesecioglu J. The Evolution of Toolkits and Bundles to Improve the Care of Sepsis Patients. *Crit Care Med*. 2021;49(11):1849-1850. PMID: 34643576.
5. Kellum JA, Kane-Gill SL, Landsittel DP, Bihorac A, Sakhujia A. RE: Electronic health record alerts for acute kidney injury: multicenter randomized clinical trial. *BMJ* 2021;372:m4786
<https://www.bmj.com/content/372/bmj.m4786/rr-1>
6. Kane-Gill SL, Kaplan LJ. Key roles for pharmacists in family-centered care to advance patient safety. *Crit Care Med* 2021;49:e454-55. PMID: 33731616
7. Wong A, Fitzmaurice MG, Smithburger PL, Buckley MS, Kane-Gill SL. Author’s reply: Evaluation of potential drug-drug interactions in adults in the intensive care unit: a systematic review and meta-analysis. *Drug Saf* 2020;43:195-96
8. Reardon CE, Kane-Gill SL, Smithburger PL, Dasta JF. Reply: Sufentail sublingual tablet: a new option for acute pain management. *Ann Pharmacother* 2020;54:619.
9. Dzierba A, Kane-Gill SL. Contemporary topics in critical care with evolving medication management considerations. *J Pharm Pract (editorial)* 2019;32:254-55.
10. Kane-Gill SL. Innovations in medication safety: Services and technologies to enhance the understanding, and prevention of adverse drug reactions. *Pharmacotherapy* 2018;38:782-4.
11. Barreto EF, Mueller BA, Kane-Gill SL, Rule AD, Gajic O, Seckelberg JM. Beta Lactams: The competing priorities of nephrotoxicity, neurotoxicity and stewardship. *Ann Pharmacother* 2018;52:1167.
12. Kane-Gill SL and Bauer SR. AKD: the time between AKI and CKD. What is the role for the pharmacist? *Hosp Pharm* 2017; 52:663-665.
13. Bauer SR, Kane-Gill SL. Outcome assessment of critical care pharmacist services. *Hosp Pharm* 2016;51:507-13.
14. Kellum JA, Kane-Gill SL, Handler SM. Can decision support systems work for acute kidney injury? *Nephrol Dial Transplant* 2015; 30:1786-9.

15. Wong A*, Benedict NJ, Armahizer MJ, [Kane-Gill SL](#). Reply: evaluation of adjunctive ketamine to benzodiazepines for the management of alcohol withdrawal syndrome. *Ann Pharmacother* 2015;49:371-2.
16. Handler SM, [Kane-Gill SL](#), Kellum JA. Optimal and early detection of acute kidney injury requires effective clinical decision support. *Nephrol Dial Transplant*. 2014;29:1803-1803.
17. Armahizer MJ*, Seybert AL, Smithburger PL, [Kane-Gill SL](#). Corrected QT interval for possible drug-drug interactions in the intensive care unit. *J Crit Care* 2013; 28:1107.
18. [Kane-Gill SL](#). Institutional and National MEDMARX data have differences in causes and types of medication errors but agree on the higher propensity for harm in the ICU (letter). *Crit Care Med* 2013;41:e234-5
19. Daley M, Lat I, [Kane-Gill SL](#). Applicability of guideline recommendations challenged in the setting of drug shortages. (letter) *Crit Care Med* 2013;41:e143-4.
20. [Kane-Gill SL](#). Comment: Prevalence and nature of medication administration errors in health care settings: a systematic review of direct observation. *Ann Pharmacother* 2013;47:760-761.
21. [Kane-Gill SL](#), Chapman T*, Dasta JF. Drug related hazardous conditions to prevent injury and defining injury is also important (editorial). *Pharmacoepidemiol Drug Saf* 2012; 21:1247-8.
22. [Kane-Gill SL](#), Kosmisky DE*, Dasta JF. Critically evaluating ADEs retrospectively for research: Is there a standard? (Alternative viewpoint) *Pharmacotherapy* 2013;33:e143-144
23. [Kane-Gill SL](#), McCartney LN*. The elusive quest to maximize voluntary reporting and optimize pharmacovigilance: A matter of the reporting mechanisms or more? (editorial) *Adv Pharmacoepidemiol Drug Safety* 2012;1:e108. doi: 10.4172/2167-1052.1000e108
24. Dasta JF, [Kane-Gill SL](#). Additional economic and pharmacokinetic considerations of acetaminophen in acutely ill patients. (Alternative viewpoint) *Pharmacotherapy* 2013;33:e83-84.
25. Leblanc JM, [Kane-Gill SL](#), Cook CH, Dasta JF. Bispectral index does not correlate with stress response in critical care (letter) *Anesth Analg* 2007;104:616.
26. Dasta JF, [Kane SL](#), Gerlach AT, Cook CH. Bispectral index in the intensive care setting (letter). *Crit Care Med* 2003;31:998.

NON-REFEREED PUBLICATIONS

1. [Kane-Gill SL](#). Doing the right thing: President's reflection. *Critical Connections* February 2023
2. [Kane-Gill SL](#). Clinical Subphenotypes of AKI Using a Biomarker Driven Approach for Predictive and Prognostic Enrichment *Critical Connections* Fall 2022
3. [Kane-Gill SL](#). Society of Critical Care Medicine Presidential Address-51st Annual Congress, April 2022. *Crit Care Med*. 2022 Jul 1;50(7):1035-1039. PMID: 35726977.
4. [Kane-Gill SL](#). Innovation meets implementation. *Critical Connections* Summer 2022

5. Kane-Gill SL. Team dynamic affects more than performance measures: Collective mental health and burnout *Critical Connections* Spring 2022
6. Kane-Gill SL. Advancing research for effective alert development to avoid alert fatigue. *Critical Connections* June 2018 [Advancing Research for Effective Alerts to Avoid Alert Fatigue | SCCM](#)
7. Kane-Gill SL. Critical Care: New guidance for medication safety in the ICU. Wolters Kluwer Blog. December 2017. <http://www.wolterskluwercli.com/blog/critical-care-new-guidance-medication-safety-icu/>
8. Chapman T, Fanikos J, Kane-Gill SL. Safe IV Medication use in critically ill patients. *Pharmacy Purchasing and Products Magazine*. 2013;10(3):6
9. Kane-Gill SL. Commentary on ICU Sedation. *Pharmacy Practice News* 2011
10. Kane-Gill SL. Book Review. Drug-induced diseases: prevention, detection, and management, 2nd edition. Tisdale JE and Miller DA (editors) *Ann Pharmacother* 2010. (online) <http://www.theannals.com/cgi/reprint/aph.1P158v1>
11. Kane-Gill SL. Review of Plenary Discussion at the 37th SCCM Critical Care Congress, Oahu, HI: Drug Costs in the ICU – More than What Meets the Eye. *Critical Connections* 2008;7(3):28.
12. Kane-Gill SL. Individualizing hemoglobin targets and treatment in critically ill patients. In: Dasta JF (Editor) *Clinical Issues in Critical Care: Focus on Anemia* 2007, pp 43-54.
13. Kane-Gill SL, Olsen K. “How- to” write an abstract suitable for publication. *Hosp Pharm* 2004;39:92-95.
**
14. Kane SL, Manduru M. Continuing Education: continuous beta-lactam infusion. *Pharmacy Connection* 1997; 4(4): 29-33.

SUBMITTED ARTICLES

Students/residents* under my direction are indicated by an asterisk.

1. St. Peter W, Bzowycky A, Anderson-Haag T, Awdishu L, Blackman M, Bland A, Chan E, Chmielewski C, Eyler R, Goster C, Hudson J, Kane-Gill SL, Kliethermes M, Le T, Madabushi R, Marin B, Miller WG, Philbrick AM, Robers G, Schandorf B, Webb AJ, Wu D, Nolin T. on behalf of the National Kidney Foundation Pharmacy Engagement Workgroup. Moving forward from Cockcroft-gault: Aligning kidney function assessment across healthcare setting for medication decision making in adults. *Am J Health Sys Pharm*
2. Gray MP*, Zervas I*, Kane-Gill SL. Reserve antibiotic usage and clinical outcomes associated with antimicrobial allergies. *J Allergy Clin Immunol*
3. Stottlemeyer BA*, Tran T, Suh K, Kane-Gill SL. A systematic review of the costs of drug associated acute kidney injury and potential cost savings with prevention strategies. *Clin Pharmacol Ther*

ARTICLES IN PREPARATION

Students/residents* under my direction are indicated by an asterisk.

1. Karimzadeh I, Gou X*, Barreto EF, Suh K, Buckley MS, Smithburger PL, Kane-Gill SL. Drug induced acute kidney injury: epidemiology and mechanisms of injury for nephrotoxins in critically ill patients.
2. Kane-Gill SL, Barreto EF, Miano T, Flannery A, Murugan R, Ozrazgat-Baslanti T, Bihorac A, Kellum JA. Taxonomy of kidney disease and disorders related to nephrotoxic drug exposure.
3. Amatuallah N, Barreto EF, Zervas I*, Flannery A, Miano T, Suh K, Ruppert M, Ozrazgat-Baslanti T, Shickel B, Murugan R, Rashidi P, Bihorac A, Kellum JA, Kane-Gill SL. Systematic approach to detecting drug related kidney diseases and disorders in database research.
4. Ray L*, Yagnala N*, Le T*, Culley CM, Beisel CR*, Kellum JA, L'Altrelli AA, Kane-Gill SL. Performance characteristics of a clinical decision support alert for drug associated AKI.
5. Albert SM, Li X*, Kane-Gill SL, Lombardi J*, Boyce R. Incidence of Potentially Inappropriate Prescribing among Older Adults: A Large-Scale, Longitudinal Investigation of Outpatient Prescriptions.
6. Multi-hospital Electronic Decision Support for Drug-associated AKI (MEND-AKI): study protocol for a randomized interventional controlled trial.
7. Severe AKI risk prediction among patients in ward: A multicenter study.

FUNDED RESEARCH GRANTS

1. Jewish Healthcare Foundation (4/15/23-4/15/24)
Medication Error Avoidance at Region Scale (MEARS)
Co-Investigator: Boyce (PI)
\$500,000 salary support 2.0%

Pitt faculty— working with Carnegie Mellon University's Initiative for Patient Safety Research—to develop, test, and implement the MEARS project, a medication monitoring intervention for skilled nursing facility patients transitioning between hospitals and long-term care. The goal of the MEARS project is to use data to reduce preventable adverse drug events, identify patients who have experienced medication-related kidney injury and other adverse effects from medications; and employ strategies for communicating potential medication errors and risks to avoid issues with alert fatigue. The study will design and rigorously evaluate a clinical decision support system that can act as an adverse drug event prevention intervention by developing and pilot testing a system able to identify medication errors occurring during patient care transitions from hospitals to a skilled nursing facility and pilot a medication monitoring intervention. The study will also result in validated and sharable decision support rules using data from multiple care settings.
2. National Institute of Diabetes and Digestive and Kidney Diseases (5/1/23-4/30/26)
A Randomized Clinical Trial of the Safety and Feasibility of Metformin as a Treatment for Sepsis Induced AKI (LiMiT AKI)
Co-Investigator: Gomez (PI), R01DK133142-01
\$954,000 salary support 2.5%

This study aims to conduct a randomized, placebo-controlled, feasibility study to establish the safety and feasibility of the use of oral metformin to prevent the development of sepsis-induced acute kidney injury and inform a future full-scale efficacy trial. Our overarching hypothesis is that in treatment of patients with sepsis, metformin is safe and effective in reducing sepsis-induced elevations in AKI biomarkers. Investigators will determine the safety of the use of metformin to treat adult patients with sepsis and will determine the pharmacokinetic profile of oral metformin (Aim 1), the feasibility of implementing this therapy (Aim 2) and estimate the heterogeneity of the effect of metformin on markers of kidney injury/stress and on circulating platelet mitochondrial function (Aim 3). This study is the first critical step to inform the design of a future, full-scale efficacy RCT.

3. National Institute of Diabetes and Digestive and Kidney Diseases (7/1/2021-7/1/2026)
The Pittsburgh Scientific and Data Research Center for the **Caring for Outpatients after Acute Kidney Injury (COPE-AKI) Consortium – Pitt-SDRC**
 - Intervention group writing committee
 - Adjudication/Safety committee
 - QA/QC committee
 - Publication/ancillary study committee

Principal Investigator: Abebe/ Fried/Kane-Gill/ Palevesky (MPI), U01DK130010

\$3,663,174 (total) salary support 15%

Clinicaltrials.gov NCT05805709

<https://crhcdc.pitt.edu/our-work/project-9> ; <https://cope-akistudy.pitt.edu>

The Caring for OutPatients after Acute Kidney Injury (COPE-AKI) Consortium will address these important gaps in knowledge to determine optimal management of patients surviving an episode of moderate (stage 2) or severe (stage 3) AKI. The goal of the COPE-AKI Consortium will be to develop and test interventions to enhance processes of care and identify key pharmacologic and non-pharmacologic interventions to reduce morbidity among these high-risk patients. To ensure scientific integrity, comprehensiveness, and robustness of the research design, biostatistics, and implementation, the Center for Clinical Trials & Data Coordination (CCDC) at the University of Pittsburgh will serve as the Scientific and Data Research Center (SDRC) for the COPE-AKI Consortium.

4. National Institute of Diabetes and Digestive and Kidney Diseases (7/1/2021-4/1/2026)
Multicenter Implementation of an Electronic Decision Support System for Drug-Associated AKI (MEN-D-AKI)
Principal Investigator: (salary support 20%); Kane-Gill (contact)/Bihorac (MPI), R01DK121730
\$2,972,994 (total) salary support 25%
Administrative supplement \$278,880 (08/01/22)

Our study tests whether a unique clinical decision support system built with machine learning knowledge designed to identify patients at high-risk for D-AKI coupled with an advanced pharmacist service directed to the primary physician can address D-AKI management and drug dosing to improve patient care. Thus, our central goal is to examine the effect of a pharmacist-led intervention on the early detection and management of AKI, progression of and short-term recovery from AKI, and on various AKI-related outcomes.

5. National Center for Complementary and Integrative Health (9/1/2020-9/1/2025)
Center of Excellence for Natural Product Drug Interaction Research

Natural Product-Drug Interaction (NaPDI): The Roadmap to Best Practices
Co-Investigator; (salary support 5%); Boyce (PI Informatics Core), U54AT008909
[About - NaPDI \(napdicenter.org\)](http://napdicenter.org)
\$1,744,169 (University of Pittsburgh Subcontract) \$10, 866,877 total for all Cores

6. Beckwith Institute (7/1/2019-7/1/2020)
Development, Feasibility and Acceptability of an Academic Detailing Intervention to Support Pharmacist-Led Deprescribing within UPMC Senior Communities
Co-Investigator; Pruskowski (PI)
\$20,000
7. Agency for Healthcare Research and Quality (9/01/15-6/30/18)
Transforming the Medication Regimen Review Process of High-Risk Drugs Using a Patient-Centered Telemedicine-Based Approach to Prevent Adverse Drug Events in the Nursing Home
Principal Investigator; Kane-Gill (PI), R18HS02420
\$1,466,293 (salary support 40%/35%/33%)
8. Clinical & Translational Science Institute at the University of Pittsburgh
“MyKidney” app development. (4/1/15-5/1/16)
Co-Investigator; Kellum (PI)
\$50,000 (salary support 2.5%)
9. Clinical & Translational Science Institute at the University of Pittsburgh (3/1/14-6/30/14)
Improving the identification of actionable adverse drug events associated with acute kidney injury in nursing homes.
Co-Investigator; Handler (PI)
\$100,000 (salary support 10%)
10. The Beckwith Institute (6/1/13-6/1/14)
Transforming the role of the hospital pharmacists to improve patients’ access, adherence and self-management of medications after discharge.
Co-Principal Investigator
\$25,000
11. Hospira, Inc. (9/1/12-8/31/13)
Clinical quality improvement of benzodiazepine-resistant alcohol withdrawal syndrome.
Co-Principal Investigator (salary support 6%).
\$30,000
12. ASHP Foundation 2012 New Investigator Research Grant. (4/1/12-03/31/13)
A multicenter evaluation of off-label medication use and adverse drug events in adult intensive care unit patients.
Senior Principal Investigator (salary support 4%).
\$19,924
13. National Library of Medicine (09/30/11- 09/29/14)
Interactive search and review of clinical records with multilayer semantic annotation.
Co-Investigator (salary support 5%), Chapman (PI), Subcontract UCSD RO1 LM010964
\$591,195

14. Agency for Healthcare Research and Quality (05/01/10-02/28/14)
Enhancing the detection and management of adverse drug events in the nursing home.
Co-Investigator (salary support 16%), Handler (PI) RO1 HS018721
\$1,975,795
15. SCCM, Clinical Pharmacy and Pharmacology Section, 2009.
Visiting Clinical Professorship Program Grant provided to consult with an expert in a clinical/research area of interest for the recipient. Jeff Rothschild, MD, critical care patient safety expert was invited as the visiting professor.
\$1,000
16. University of Pittsburgh Innovation in Education Awards, 2008.
Simulation based learning to enhance problem-solving skills in acute care pharmacotherapy.
Co-Investigator.
\$21,097
17. Ortho McNeil, Inc., 2008. (Investigator initiated)
A case-case control study of carbapenem-resistant *Pseudomonas aeruginosa* infections: risk factors and outcomes.
Principal Investigator.
\$94,375
18. ASHP Fostering Young Investigators: Pharmacy Resident Practice-Based Grant Program, 2007.
A clinical outcome comparison of patients receiving hemodialysis and a non-heparin anticoagulant for the management of heparin-induced thrombocytopenia (HIT) in the real-world setting.
Co- Principal Investigator.
\$5,000
19. University of Pittsburgh Medical Center Electronic Health Record Clinical Informatics, Quality and Safety (CLIQS) Grant, 2007.
Using a clinical event monitor to detect adverse drug events in the ICU.
Co-Principal Investigator.
\$30,000
20. Society of Critical Care Medicine/TAP/Joseph F. Dasta Outcomes Research Grant, 2006.
An analysis of risk factors for adverse drug events in critically ill patients.
Principal Investigator.
\$30,000
21. Clinical Research Feasibility Funds (CReFF) Grant, 2006.
Optimizing aminoglycoside Cmax/MIC to improve clinical outcomes in ICU patients with gram- negative infections.
Co-Investigator.
\$20,000
22. Kos Pharmaceuticals, Inc., 2005. (Investigator initiated)
Frequency of suboptimal HDL-C levels in statin treated patients with unstable angina.
Co-Investigator.
\$30,890

23. Abbott Laboratories, 2004. (Investigator initiated)
Resource utilization of an acute episode of congestive heart failure.
Principal Investigator.
\$200,000
24. University of Pittsburgh Pharmacy Associates, 2004.
Adverse drug event reporting in the intensive care unit: A survey of current practices.
Principal Investigator.
\$4,500
25. Abbott Laboratories, 2002. (Investigator initiated)
Acute renal failure: Cost-effectiveness analysis and expert probability predictions of prevention and treatment strategies.
Co-Principal Investigator.
\$45,000
26. Roche Laboratories Inc., 2002. (Investigator initiated)
Evaluating the treatment of aspiration pneumonia and aspiration pneumonitis.
Principal Investigator.
\$14,500
27. American College of Clinical Pharmacy Research Institute, 2002.
Clinical and economic outcomes of epoetin alfa in critically ill patients.
Principal Investigator.
\$10,000
28. Abbott Laboratories, 2001. (Investigator initiated)
Post-marketing surveillance of dexmedetomidine use in the intensive care setting.
Co-Principal Investigator.
\$91,875

MENTORED RESEARCH GRANTS

1. National Institute of Diabetes and Digestive and Kidney Diseases (9/1/2023-9/1/2025)
Nephrotoxic burden among patients in the non-intensive care setting: The clinical and economic costs of drug-associated acute kidney injury
Mentor to Graduate Student: Britney Stottlemeyer, PharmD, PhD Candidate
\$100,000
2. Personalized vasopressor therapy in patients with septic shock
Co-Mentor to 2022-2026 K08 scholar, Seth Bauer, PharmD 1K08GM147806-01
3. American Foundation for Pharmaceutical Education Gateway Research Award
Students receiving this award gain an understanding of the importance of research by enabling them to apply that knowledge to improve their clinical skills.
Differences in reporting characteristics adverse drug events for prescription versus natural products
Mentor to Student: Christina Kazarov (P3 student)
\$5,000
4. American Association of the Colleges of Pharmacy, New Investigator Award (3/1/2022-2/28/2023)

American Foundation for Pharmaceutical Foundation Gateway Research Award

Mentor to Junior Faculty: Kango Suh, PharmD, PhD

\$8,000

[Current and Past New Investigator Award Recipients | AACP](#)

5. ASHP Foundation Pharmacy Leadership Scholars. (7/1/2021-6/30/2022)
Identifying barriers and facilitators to the use of disease modifying treatments in sickle cell disease: analysis of provider and patient surveys and interviews.
Mentor to Junior Faculty: Terri Newman, PharmD, MS
\$10,000
[PowerPoint Presentation \(ashpfoundation.org\)](#)
6. National Institute of Allergy and Infectious Diseases (NIAID) Loan Repayment Program (9/1/2020-9/1/2022)
Long-term Outcomes Associated with Penicillin Allergies and Economic Evaluation of Literature-Supported Interventions for Removing Erroneous Allergies
Mentor to Graduate Student: Matthew Gray, PharmD, PhD Candidate
\$95,000
7. Student College of Clinical Pharmacy Research Fellowship (9/1/17-8-31/18)
Nursing home resident's willingness to use telemedicine for communication of medication management.
Mentor to Student: Hanna Akerberg (P2)
\$1,000
8. PQA-CVS Health Foundation Scholars Grant (9/1/17-8-31/18)
Understanding Medication-related Fall Risk Pathways Involving Antidepressant, Psychotropic and CNS Exposure
Mentor to Student: Gabrielle Dziuba (P4)
Gabrielle Dziuba received Best Scholar Award at National PQA meeting for her work on this project.
\$1,250
9. Cumberland Pharmaceuticals Resident Grant (11/1/11-06/30/12)
Evaluating the impact of a dose range-checking alert for opioids in elderly patients requiring acute pain management
Mentor to Resident: Stephanie Seaton, PharmD
\$2,500
10. Institute for Clinical Research Education (ICRE), University of Pittsburgh, Short Term Access to Research Training at the University of Pittsburgh (START UP) Program, CTSI, 2009.
An evaluation of weight-based anticoagulant dosing in the intensive care unit.
Mentor to Student: Nick Wytiaz
\$4,250
11. ASHP Pharmacy Resident Medication Safety Grant, 2002.
ADEs in the ICU: redirecting pharmacist efforts to improve patient safety.
Mentor to Resident: Rhonda Rea, PharmD
\$1,600

PROFESSIONAL TEACHING EXPERIENCE

UNIVERSITY OF PITTSBURGH, 2002-present

Courses and Lecture Series

PharmD Curriculum

- 2021-2022
- PharmD Student 5-week APPE Health Outcomes Research Rotation
 - Pharm 5401: Jeanine Flannigan (P4)
 - Pharm 5406: Isabelle Zerfas (P4)
 - PharmD Special Topic Independent Study Rotations
 - Pharm 5852 (8/31/21-11/30/21): Jacob Murawski, (P3), 3 credits
 - Pharm 5851 (8/31/21-11/30/21): Cole Stevens, (P1), 2 credits
 - Pharm 5851 (1/7/22-4-28-22): Angelina Bella (P3), 3 credits
 - Pharm 5851 (1/7/22-4-28-22): Sofiya Tkachuk (P1), 2 credits
 - Pharm 5852 (1/7/22-4-28-22): Matthew Grubic (P3), 1 credit
 - Pharm 5852 (1/7/22-4-28-22): Cole Stevens, (P1), 2 credits
 - Pharm 5853 (1/7/22-4-28-22): Jacob Murawski, (P3), 3 credits
- 2020-2021
- PharmD Student 5-week APPE Health Outcomes Research Rotation
 - Pharm 5401: Nicole Hume (P4)
 - Pharm 5401: Niti Patel (P4)
 - Pharm 5401: Michael McDermott (P4)
 - Pharm 5401: Britney Stottlemeyer (P4)
 - PharmD Special Topic Independent Study Rotations
 - Pharm 5855 (6/5/20-8/18/20): Isabelle Zerfas, (P3), 1 credit
 - Pharm 5853 (8/25/20-12/5/20): Grace Rong (P3), 2 credits
 - Pharm 5851 (8/25/20-12/5/20): Jasmine Chang (P3), 2 credits
 - Pharm 5856 (8/25/20-12/5/20): Isabelle Zerfas, (P3), 1 credit
 - Pharm 5852 (8/25/20-12/5/20): Thomas Rust, (P3), 1 credit
 - Pharm 5852 (8/25/20-12/5/20): Lauren Snader, (P3), 1 credit
 - Pharm 5853 (8/25/20-12/5/20): Noah Delapaz, (P3), 1 credit
 - Pharm 5851 (8/25/20-12/5/20): Nicholas Hammond (P3), 3 credits
 - Pharm 5852 (8/25/20-12/5/20): Chad Beisel, (P2), 1 credit
 - Pharm 5851 (8/25/20-12/5/20): Luke Kulak (P3), 2 credits
 - Pharm 5853 (1/5/21-4/30/21): Lauren Snader, (P3), 2 credits
 - Pharm 5851 (1/5/21-4/30/21): Jacob Murawski, (P2), 2 credits
 - Pharm 5853 (1/5/21-4/30/21): Jasmine Chang, (P3), 2 credits
 - Pharm 5854 (1/5/21-4/30/21): Grace Rong, (P3), 2 credits
 - Pharm 5857 (1/5/21-4/30/21): Isabelle Zerfas, (P3), 1 credit
 - Pharm 5853 (1/5/21-4/30/21): Luke Kulak, (P3), 1 credit
- 2020-2023
- Pharm 5321: Critical Care and Nephrology (P2)
Acute Kidney Injury and Drug Dosing Considerations for Patients with Critical Illness and Kidney Disease

2019-2020

PharmD Student 5-week APPE Health Outcomes Research Rotation
Pharm 5401: Christian Andreaggi (P4)
Pharm 5409: Vivian Tsai, PharmD Candidate (P4)
PharmD Special Topic Independent Study Rotations
Summer Research Experience: Thomas Le, (P1)
Summer Research Experience: Isabelle Zerfas, (P2)
Summer Research Experience: Jessica Hu (P4)
Pharm 5855 (5/7/19-8/10/19): Niti Patel (P2), 2 credits
Pharm 5851 (5/7/19-8/10/19): Britney Stottlemeyer (P2), 3 credits
Pharm 5852 (9/5/19-12/1/19) Michael McDermott (P2), 2 credits
Pharm 5854 (9/5/19-12/1/19) Brittney Stottlemeyer (P2), 2 credits
Pharm 5852 (9/5/19-12/1/19) Colin Pfeiffer (P2), 1 credit
Pharm 5856 (9/5/19-12/1/19) Niti Patel (P2), 1 credit
Pharm 5856 (9/5/19-12/1/19) Mackenzie Minogue (P2), 1 credit
Pharm 5852 (9/5/19-12/1/19) Nicole Hume (P3), 1 credit
Pharm 5852 (9/5/19-12/1/19) Isabelle Zerfas (P2), 1 credit
Pharm 5854 (9/5/19-12/1/19) Nikitha Yagnala (P3), 1 credit
Pharm 5851 (9/5/19-12/1/19) Grace Rong (P3), 1 credit
Pharm 5853 (9/5/19-12/1/19) Sandy Kline (P2), 1 credit
Pharm 5851 (1/3/20-4/20/20) Hyunwoo Kim (P2), 3 credits
Pharm 5851 (1/3/20-4/20/20) Thomas Rust (P2), 2 credits
Pharm 5857 (1/3/20-4/20/20) Mackenzie Minogue (P2), 2 credits
Pharm 5855 (1/3/20-4/20/20) Nikitha Yagnala (P3), 1 credit
Pharm 5853 (1/3/20-4/20/20) Michael McDermott (P2), 2 credits
Pharm 5854 (1/3/20-4/20/20) Colin Pfeiffer (P2), 2 credits
Pharm 5852 (1/3/20-4/20/20) Nicole Hume (P3), 1 credit
Pharm 5853 (1/3/20-4/20/20) Isabelle Zerfas (P2), 1 credit
Pharm 5854 (1/3/20-4/20/20) Sandy Kline (P2), 1 credit
Pharm 5851 (1/3/20-4/20/20) Grace Rong (P3), 2 credits
Pharm 5855 (1/3/20-4/20/20) Brittney Stottlemeyer (P2), 3 credits
Pharm 5851 (1/3/20-4/20/20) Thomas Le (P2), 2 credits
Pharm 5851 (1/3/20-4/20/20) Josephine Kim (P2), 2 credits
Spring Research Experience Nicholas Hammond (P2)

2018-2019

PharmD Student 5-week APPE Health Outcomes Research Rotation
Pharm 5401: Wenqi Chen, PharmD Candidate (P4)
PharmD Special Topic Independent Study Rotations
Pharm 5851 (1/4/19-4/30/19) Sneha Gaitonde (P2), 1 credit
Pharm 5851 (1/4/19-4/30/19) Sandra Kline (P2), 1 credit
Pharm 5852 (1/4/19-4/30/19) Gerald Taylor (P3), 1 credit
Pharm 5852 (1/4/19-4/30/19) Christian Andreaggi (P3), 1 credit
Pharm 5852 (1/4/19-4/30/19) Mitchell Mirabile (P3), 1 credit
Pharm 5853 (1/4/19-4/30/19) Dhanuvarshini Prakasam (P3), 2 credits
Pharm 5854 (1/4/18-4/30/19) Shivani Sampathkumar (P3), 1 credit
Pharm 5852 (1/4/19-4/30/19) Emily Novak (P3), 1 credit
Pharm 5852 (9/5/18-12/1/18) Dhanuvarshini Prakasam (P3), 2 credits
Pharm 5853 (9/5/18-12/1/18) Shivani Sampathkumar (P3), 1 credit
Pharm 5851 (9/5/18-12/1/18) Christian Andreaggi (P3), 1 credit
Pharm 5851 (9/5/18-12/1/18) Mitchell Mirabile (P3), 1 credit

Pharm 5851 (9/5/18-12/1/18) Emily Novak (P3), 1 credit
Pharm 5856 (5/7/18-8/10/18): Hannah Akerberg (P2), 3 credits
Summer Research Experience: Xuanqing (Edith) Wang (P1)
Summer Research Experience: Dhanuvarshini Prakasam (P2)
Summer Research Credit (5/7/18-8/10/18) Emily Novak (P2)

2017-2018

PharmD Student 5-week APPE Health Outcomes Research Rotation
Pharm 5401: Gabrielle Dzuiba, PharmD Candidate (P4)
Pharm 5401: Mary Grace Fitzmaurice, PharmD Candidate (P4)
Pharm 5404: Matthew Gray, PharmD Candidate (P4)
Pharm 5407: Megan Thronberg, PharmD Candidate (P4)
Pharm 5409: Hangil Seo, PharmD Candidate (P4)
PharmD Special Topic Independent Study Rotations
Pharm 5852 (5/8/17-8/12/17): Hannah Akerberg (P2), 2 credits
Pharm 5853 (9/1/17-12/20/17): Hannah Akerberg (P2), 2 credits
Pharm 5851 (1/4/18-5/30/18): Xuanqing (Edith) Wang (P1), 3 credits
Pharm 5851 (1/4/18-5/30/18): Liam Callejas (P3), 1 credit
Pharm 5851 (1/4/18-5/30/18): Rose Zhang (P3), 1 credit
Research Experience: Dhanuvarshini Prakasam (P2)
PharmD Business ARCO Project Mentor
Robert (Bobby) Pardini (P4) – Medication related potentially avoidable hospitalizations
Longitudinal Research Experience: Archita Achanta (P4)
Longitudinal Research Experience: Paul Wherry (P3)
Longitudinal Research Experience: Alexandra Sharer (P3)
Longitudinal Research Experience: Kathryn (Hui Yuan) Ching (P4)
Longitudinal Research Experience: Karen Quach (P4)

2016-2017

PharmD Student 5-week APPE Health Outcomes Research Rotation
Pharm 5401: Stephanie Tchen, PharmD Candidate (P4)
Pharm 5401: Patrick Squires, PharmD Candidate (P4)
Pharm 5401: Harvey He, PharmD Candidate (P4)
PharmD Special Topic Independent Study Rotations
Pharm 5852 (9/1/16-12/23/16): Archita Achanta (P3), 3 credits
Pharm 5852 (9/1/16-12/23/16): Gabrielle Dzuiba (P3), 2 credits
Pharm 5851 (1/4/17-5/5/17): Hannah Akerberg (P1), 2 credits
Pharm 5853 (1/4/17-5/5/17): Archita Achanta (P3), 2 credits
Pharm 5853 (1/4/17-5/5/17): Gabrielle Dzuiba (P3), 3 credits
Pharm 5851 (1/4/17-5/5/17): Karen Quach (P3), 3 credits
Pharm 5851 (1/4/17-5/5/17): Domenick Francis (P1), 1 credits
Longitudinal Research Experience: Max Prokopovich (P2)

2015-2016

PharmD Student 5-week APPE Health Outcomes Research Rotation
Pharm 5401: Alex Cockerham, PharmD Candidate (P4)
PharmD Special Topic Independent Study Rotations
Pharm 5853 (8/24/15-12/11/15): Patrick Squires (P3), 3 credits
Pharm 5853 (8/24/15-12/11/15): Jing (Daisy) Zhu (P3), 2 credits
Pharm 5854 (1/6/16-4/23/16): Patrick Squires (P3), 3 credits
Pharm 5854 (1/6/16-4/23/16): Jing (Daisy) Zhu (P3), 3 credits
Pharm 5851 (1/6/16-4/23/16): Archita Achanta (P2), 3 credits

Pharm 5854 (1/6/16-4/23/16): Stephanie Tchen (P3), 1 credit
Pharm 5851 (1/6/16-4/23/16): Gabrielle Dzuiba (P2), 1 credit

- 2014-2015 PharmD Student 5-week APPE Health Outcomes Research Rotation
Pharm 5401: Maria Felton, PharmD Candidate (P4)
Pharm 5401: Nan Wang, PharmD Candidate (P4)
Pharm 5407: Nick Farina, PharmD Candidate (P4)
Longitudinal Experience: Lindsey Rihtarchik, PharmD Candidate (P4)
Longitudinal Experience: Erin Resetar, PharmD Candidate (P4)
PharmD Special Topic Independent Study Rotations
Pharm 5851 (8/25/14-12/12/14): Patrick Squires (P2), 3 credits
Pharm 5852 (1/5/15-4/25/15): Patrick Squires (P2), 1 credit
Longitudinal Research Experience: Kathryn Bress (P2)
- 2013-2014 PharmD Student 5-week APPE Health Outcomes Research Rotation
Pharm 5408: Pam Lyons, PharmD Candidate (P4)
Pharm 5408: Jose Nery, PharmD Candidate (P4)
Pharm 5407: Jonathan Lucas, PharmD Candidate (P4)
Pharm 5405: Britta Anderson, PharmD Candidate (P4)
Pharm 5403: Brahim Shettima, PharmD Candidate (P4)
Pharm 5402: Emily Graham, PharmD Candidate (P4)
Pharm 5402: Shmuel Isenberg, PharmD Candidate (P4)
Pharm 5402: Gregory Trietley, PharmD Candidate (P4)
Pharm 5401: Ellen Rubin, PharmD Candidate (P4)
Pharm 5401: Evan Williams, PharmD Candidate (P4)
- 2013 Pharm 5800 (8/26/13-12/14/13): Independent Study, Nick Farina (P3), 3 credits
Pharm 5803 (1/6/14-14-4/26-14) Independent Study: Nick Farina (P3), 1 credit
- 2012 PharmD Student 5-week APPE Health Outcomes Research Rotation
Pharm 5405: Tien Van, PharmD Candidate (P4)
Pharm 5404: Ryan Rivosecchi, PharmD Candidate (P4)
Pharm 5401: Desiree Kosmisky, PharmD Candidate (P4)
Pharm 5401: Lindsay McCartney, PharmD Candidate (P4)
- 2011 PharmD Student 5-week APPE Health Outcomes Research Rotation
Pharm 5401: Cortlyn Latsha, PharmD Candidate (P4)
- 2010 PharmD Student 5-week APPE Health Outcomes Research Rotation
Pharm 5405: Jeremy Post, PharmD Candidate (P4)
Pharm 5404: Vanita Sundararaman, PharmD Candidate (P4)
- 2010 Pharm 5800- Independent Study: Tom Wolfel (P3), Laboratory and drug interactions (2 credits)
Pharm 5800- Independent Study: Nicholas Wytiaz (P3), Weight-based dosing of high-risk medications (2 credits)
- 2010 Pharm 5812: Implementing Healthcare Innovations (P3)
Evidence Based Clinical Models: Describing models for surveillance of medication related events and opportunity for change

| | |
|--------------|--|
| 2008-2021 | Pharm 5813: Acute Care Pharmacotherapy Simulation Elective Course Coordinator (P3) Lecturer: Critical Care Pharmacist, PK/PD, Adverse Drug Events, Sedation/Analgesia Simulation Cases (3-hours) all (n=15) course topics |
| 2008 | PharmD Student 5-week Health Outcomes Research Rotation Pharm 5401: Elizabeth Forsberg, PharmD Candidate (P4) |
| 2003-2005 | Pharm 5221: Introduction to Critical Care (P3) Sedation/Pain Management Lecture Critical Care Cases |
| 2002 | Pharm 5401: One-month Pharm. D. Student Critical Care Rotation |
| 2002-present | Pharm 5311: Profession of Pharmacy Course (P3) Health Care Outcomes and Pharmacoeconomics Course Coordinator Lecturer: CMA, CBA, CUA, CBA, HRQoL, PE Literature Evaluation, Medication Safety, ADE Prevention |

Graduate Programs

| | |
|-----------|---|
| 2022- | Pharm 3303 JC for Secondary Databases (course coordinator) |
| 2022- | Pharm 3301: Secondary Database Applications (course coordinator) |
| 2021- | Pharm 3052: JC Pharmaceutical Policy and Outcomes Research |
| 2021- | Pharm 3304: Research Methods |
| 2019- | Pharm 3039: Foundations in Pharmaceutical Sciences ADE Detection and Reporting, Introduction to Phase IV Studies and Outcomes Research; Causal Inference and Study Design Principles, Data Sources and Data Collection, POPR Real World Applications |
| 2012-2021 | Pharm 3067 : Clinical Pharmacy Environments (PhD Program) Determining Quality Improvement vs. Research |
| 2010-2020 | Epidem 2850: Pharmacoepidemiology Course, School of Public Health Inpatient Adverse Drug Event/Medication Error Surveillance |
| 2004 | Pharm 3039: Essentials of Competitive Grant Writing (PhD Students) Grant Reviewer |
| 2002- | Pharm 2003: Introduction to Pharmacoepidemiology Course Pharmaceconomics Lecture |

Lecture Series, Preceptorship and Area of Concentration (ARCO)

Area of concentration program provides an opportunity for students to pursue in depth an area of personal interest during their four years of medical school. This is accomplished with a series of longitudinal elective experiences that supplement the required core curriculum.

| | |
|----------------|--|
| 2018 - present | Lead, Area of Concentration (ARCO) PharmacoAnalytics |
| | 2024-2026 Sora Hashimoto Carson Mello Saranya Muthumula |
| | 2023-2025 Kolbe Bien Rachel Kim Cole Stevens |
| | 2022-2024 Neha Dhavalikar Peter Grandell YeHyeon Soh |
| | 2021-2023 Matthew Grubic* Christina Kazarov Feiran Liang Jacob Murawski* Anthony Poliski* Yuehan Zhou |
| | 2020-2022 Jasmine Chang Noah Delapaz* Hyunwoo Kim* Josephine Kim Luke Kulak Grace Rong Lauren Snader Dominic Yu Isabelle Zerfas |
| | 2019-2021 Michael McDermott Mackenzie Minogue Niti Patel Colin Pfeiffer Brittney Stottlemyer |
| | 2018-2020 Christian Andreaggi Mitchell Mirabile Emily Novak Shivani Sampathkumar |
| | 2018-2019 Anish Patel |
| 2013, 2017 | Human Patient Simulation in Pharmacy Education Intensive Preceptorship Co-Director |
| 2012-2014 | PK/PD Considerations in Critically Ill Patients and Patient Safety in the ICU Presented to the Critical Care Medicine Fellows at UPMC for the Educational Lecture Series |
| 2009-2011 | Common Drug Errors |

Presented to the Internal Medicine Acute Management Series, House staff Monthly Conference at Presbyterian, VA and Shadyside Hospitals, Department of Medicine, University of Pittsburgh, Pittsburgh, PA.

2009-2022 Resident Research Lecture Series, Coordinator
Lecturer: Think about the Study Endpoint: Measurables and Outcomes; Turning Clinical Observations into QI projects; Authorship

Students and Residents

Major Advisor Doctoral Candidate

2021- School of Pharmacy, Pharmaceutical and Therapeutics, Xiaotong Li
2021- School of Pharmacy, Pharmaceutical and Therapeutics, Wafa Alatawi
2021- School of Pharmacy, Pharmaceutical and Therapeutics, Britney Stottlemeyer, PharmD
NIDDK Loan repayment grant recipient
2021- School of Pharmacy, Pharmaceutical and Therapeutics, Xiaojiang Guo
2018-2023 School of Pharmacy, Pharmaceutical and Therapeutics, Matthew Gray, PharmD
[2022 Pitt 3MT Contestants | Graduate Studies](#) (second place in competition)
NIAID loan repayment grant recipient
<http://d-scholarship.pitt.edu/45273/>
Premier Inc. Clinical decision support specialist
2012-2015 School of Pharmacy, Pharmaceutical and Therapeutics, Shoroq Altawalbeh
Associate Professor, Jordan University of Science and Technology

Doctoral Candidate Dissertation Committee

2021- School of Medicine, School of Computing and Information, Intelligent Systems Program, Sanya Taneja (preliminary project committee)
2021- PhD Thesis Advisory Committee, Mayo Clinic Graduate School of Biomedical Sciences, Erin Barreto, PharmD
2021- School of Medicine, Division of Geriatric Medicine, Jennifer Pruskowski, PharmD
2021-2024 School of Pharmacy, Pharmaceutical and Therapeutics, Lanting Yang
2018- 2021(unfinished) School of Medicine, Department of Biomedical Informatics, Jhon Camacho- *started his own business and decided to not complete PhD work in his senior year*

Non-Thesis Master's Degree Candidates

2020-2021 Major Advisor, School of Pharmacy, Pharmaceutical Outcomes and Policy Research, - Ravi Desai, PharmD
2012-2013 Major Advisor, School of Pharmacy, Pharmaceutical Sciences, - Xinyi Gao

Thesis/Essay Master's Degree Candidates

2020-2022 Co-Advisor, (Thesis), School of Pharmacy, Pharmaceutical Outcomes and Policy Research, Nai-Chia (Sammi) Chen
2020-2022 Co-Advisor, (Thesis), School of Pharmacy, Clinical Pharmaceutical Sciences, Xinyun Chen
2020-2021 Defense Committee for Thesis, Pharmaceutical Outcomes and Policy Research, Yujia (Linda) Li
2020-2021 Defense Committee for Thesis, Clinical Pharmaceutical Sciences-PSP, Xiaojiang Guo
2017-2018 Co-Advisor (Thesis), School of Pharmacy, Pharmaceutical Sciences-Meng-Ni (Mandy) Ho
2014-2015 Defense Committee for Essay, School of Public Health-John Cadwalader
2012-2014 Defense Committee for Thesis, School of Medicine- Pam Smithburger

Doctor of Pharmacy Candidates

| | |
|------------|---|
| 2012-2013 | Mentor, Introduction to Research Adrienne Jantzi (P2), John Lyons (P2) |
| 2011- 2012 | Mentor, Writing Skills and Introduction to Research Deanne Rowe (P2) |
| 2010 | Advisor, Clinical Project, UPMC Summer Intern Thomas Wolfel, PharmD Candidate (P3) Kimberly Miller, PharmD Candidate (P3) |
| 2010 | Mentor, Writing Skills and Introduction to Research Catherine Kim, PharmD Candidate (P4) |
| 2009 | Mentor, Short Term Access to Research Training at the University of Pittsburgh Nicholas Wytiaz, PharmD Candidate (P2) An evaluation of weight-based anticoagulant dosing in the intensive care unit. |
| 2009 | Advisor, Clinical Project, UPMC Summer Intern Thomas Wolfel, PharmD Candidate (P2) |
| 2008 | Advisor, Clinical Project, 2 UPMC Summer Interns Joshua Clossin, PharmD Candidate (P3), Robert Kozarian, PharmD Candidate (P3) |
| 2004 | Instructor, Principles of Outcomes Research Rotation International Pharmacy Student (France) |

Fellowship

| | |
|-----------|--|
| 2024-2026 | Medication Safety and Nephrotoxin Stewardship Fellowship Caiden Lukan, PharmD |
| 2023-2025 | Medication Safety and Nephrotoxin Stewardship Fellowship Tiffany Tran, PharmD |
| 2022-2024 | Medication Safety and Nephrotoxin Stewardship Fellowship Nabihah Amatuallah, PharmD |
| 2022-2024 | PharmacoAnalytics/Pharmacovigilance Fellowship of Natural Product Drug Interaction Maryann Chapin, PharmD, MS |
| 2021-2022 | PharmacoAnalytics/Pharmacovigilance Fellowship of Natural Product Drug Interaction Patrick Ndugnu, PharmD, MS |

Pharmacy Practice Residents

| | |
|-----------|--|
| 2021-2022 | Preceptor, Outcomes Research Project, Longitudinal Rotation • Matt Jackson- Natural products resulting on hospital admissions |
|-----------|--|

- Tian Zhang – Apixiban dosing in patients with kidney insufficiency
- 2018-2019 Preceptor, Outcomes Research Project, Longitudinal Rotation
- Bailey Colvin, PGY1- Contrast induced AKI prevention
- 2018-2019 Preceptor, five-week outcomes rotation
- Kaitlin Landolf, PGY1- Pain medications in ECMO
- 2017-2018 Preceptor, Outcomes Research Project, Longitudinal Rotation
- Lindsay Moreland, PGY1- Public reported events of drug-associated QT prolongation from the FDA adverse event reporting system (FAERS)
 - Melissa Bastacky, PGY1- Electrolyte abnormalities in septic patients treated with normal saline compared to plasmalyte
 - Julie Lees, PGY1- Medication related potentially avoidable hospitalizations
- 2016-2017 Preceptor, Outcomes Research Project, Longitudinal Rotation
- Cassius Hudson, PGY1- Withdrawal history a risk factor for acute, resistant alcohol withdrawal.
 - Neil Turco, PGY1, St. Margaret's – Dalbavancin cost and outcomes for skin and soft tissue infections
 - Hanna Welch, PGY1- Public reported events of drug-associated AKI from the FDA adverse event reporting system (FAERS)
- 2015-2016 Preceptor, Outcomes Research Project, Longitudinal Rotation
- Nicole Durie, PGY1 Pharmacogenetic and pharmacokinetics of dexmedetomidine therapeutic failures
- 2014-2015 Preceptor, Outcomes Research Project, Longitudinal Rotation
- Ayesha Athers, PGY1 Deep phenotyping of drug-related hypoglycemia in ED notes
 - Cory Weaver, PGY1 Deep phenotyping of community acquired acute kidney injury in ED notes
- 2014-2015 Preceptor, Outcomes Research Project, five-week outcomes rotation
- Ayesha Athers, PGY1
 - Coody Moore, PGY1
- 2013-2014 Preceptor, Outcomes Research Project, Longitudinal Rotation
- Genevieve Hale, PGY1 Determining the ADRs associated with antipsychotic use in the ICU
 - Adam MacLasco, PGY1 Automating the detection of ADEs in the ICU transfer summary
- 2013-2014 Preceptor, Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation
- Ryan Rivosecchi, PGY1 Assessing non-pharmacologic prevention strategies for delirium in the ICU as an approach to reduce the use of non-evidenced based pharmacologic treatments and related ADEs
- 2011-2012 Preceptor, Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation

- Stephanie Seaton, PGY1 Evaluating the impact of a dose range-checking alert for opioids in elderly patients requiring acute pain management.
- 2011-2012 Preceptor, Outcomes Research Project, Longitudinal Rotation
- Megan Kloet, PGY1 An evaluation of black box warning compliance in general medical units.
- 2010-2011 Preceptor, Outcomes Research Project, Longitudinal Rotation and Four- week Outcomes Research Rotation
- Ibrahim Sales, PGY1 Evaluating the core components of residency teaching programs
- 2010-2011 Preceptor, Outcomes Research Project, Longitudinal Rotation
- Matthew Felbinger, PGY2 Evaluating patient satisfaction with the quality of sedation in the ICU
- 2009-2010 Preceptor, Outcomes Research Project, Longitudinal Rotation
- John Foley, PGY1 A comparison of the frequency and severity of narcotic related ADRs in elderly patients after the implementation of clinical decision support.
 - Michael Armahizer, PGY1 An evaluation QT prolongation resulting from drug-drug interactions in the CCU and CTICU.
- 2008-2009 Preceptor, UPMC ADE Subcommittee, Longitudinal Rotation
- Sarah Yost, PharmD, PGY1, Pharmacy Practice Resident
- 2007-2008 Preceptor, UPMC ADE Subcommittee, Longitudinal Rotation
- Pam Havrilla, PharmD, PGY1, Pharmacy Practice Resident
- 2003-2004 Preceptor, Writing Skills
- Brian Watson, PharmD, PGY1, Pharmacy Practice Resident - Sedation assessment in critically ill adults 2001-2004 update.
- 2001-2002 Preceptor, Pharmacy Practice Resident Outcomes Research Project, Longitudinal Rotation
- Umbreen Idrees (Murtaza), PharmD, PGY1 - Intravenous amiodarone for the treatment of in-hospital cardiac arrest due to pulseless ventricular tachycardia/ventricular fibrillation.

Medication Use Safety Residents

- 2014-2015 Preceptor, Medication Use Safety Resident
Longitudinal outcomes research rotation, longitudinal medication safety topics and a five-week outcomes rotation
John Cadwalader, PharmD, PGY2- Pharmacy service-line redesign to enhance patient safety and efficiency.
- 2012-2013 Preceptor, Medication Use Safety Resident
Longitudinal outcomes research rotation, longitudinal medication safety topics rotation including 2- weeks introduction and every other week meetings and a five-week outcomes rotation
- Tiffany (Chapman) Politz Smith, PGY2, Patient reported outcomes for satisfaction with liposomal bupivacaine and automating the detection of ADEs in the ICU transfer summary

Critical Care Residents

| | |
|-----------|--|
| 2021-2022 | Preceptor, Critical Care Resident Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation <ul style="list-style-type: none">• Marissa Campagna - PGY2- Family Engagement in Adverse Drug Event Reporting in Intensive Care Units |
| 2020-2021 | Preceptor, Critical Care Resident Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation <ul style="list-style-type: none">• Victoria Williams- PGY2- Stress biomarker use in drug associated AKI |
| 2019-2020 | Preceptor, Critical Care Resident Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation <ul style="list-style-type: none">• Abby Meyer- PGY2- Medication Errors during Care Transition out of the ICU |
| 2018-2019 | Preceptor, Critical Care Resident Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation <ul style="list-style-type: none">• Caitlin McHugh (Reardon), PGY2- Delirium ICDSC Assessment |
| 2017-2018 | Preceptor, Critical Care Resident Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation <ul style="list-style-type: none">• Seo Hyun (Claudia) Choi, PGY2- Drug-associated delirium identified in the food and drug administration adverse events reporting system |
| 2016-2017 | Preceptor, Critical Care Resident Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation <ul style="list-style-type: none">• Kyle Strnad, PGY2 – Patient reported outcomes of pain management in the ICU. |
| 2015-2016 | Preceptor, Critical Care Resident Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation <ul style="list-style-type: none">• Cory Weaver, PGY2 – Efficacy of pharmacologic treatment of delirium• Bethany Shoulders, PGY2 – Evidence for off-label drug use |
| 2014-2015 | Preceptor, Critical Care Resident Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation <ul style="list-style-type: none">• Amanda Johnson, PGY2 – Survey of family involvement in delirium prevention• Ryan Rivosecchi, PGY2 Evaluating the time to drug dosing adjustments in response to renal decline and augmentation and resulting outcomes. |
| 2013-2014 | Preceptor, Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation <ul style="list-style-type: none">• Adrian Wong, PGY2 Evaluating treatment strategies and outcomes for patients with benzodiazepine resistant alcohol withdrawal.• Ashleigh Hogue, PGY2 Evaluating patient satisfaction with the quality of sedation in the ICU |
| 2012-2013 | Preceptor, Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation <ul style="list-style-type: none">• Megan Kloet, PGY2 – A validation of risk factors for ADEs in the ICU using ADEs identified in transfer summaries |

- 2011-2012 Preceptor, ICU (SICU, MICU, CCU) Rotation for 5- weeks at UPMC Passavant Hospital for Brian Lohr, PGY2
- Brian Lohr, PGY2 An evaluation of black box warning compliance in intensive care units.
- 2010-2011 Preceptor, Outcomes Research Project, Longitudinal Rotation and Five-week Outcomes Rotation
- Michael Armahizer, PGY2 Clinician assessment of drug-drug interaction severity in the cardiac ICUs
- 2009-2010 Preceptor, Outcomes Research Project, Longitudinal Rotation and Five-week Outcomes Rotation
- Ananth Malurkar Anthes, PGY2- An evaluation of ICU discharge summaries for the identification of ADRs.
 - Lisa Harinstein, PGY2- Evaluation of drug-induced thrombocytopenia in the CCU and MICU.
- 2008-2009 Preceptor, Outcomes Research Project, Longitudinal Rotation
- Pam Smithburger (Havrilla), PharmD, PGY2- Significance of drug interactions in the ICU
- 2008-2009 Preceptor, UPMC ADE Subcommittee, Longitudinal Rotation
Pam Havrilla, PharmD, PGY2, Critical Care Specialty Resident
- 2007-2008 Preceptor, Outcomes Research Project, Longitudinal Rotation and Five-week Outcomes Rotation
- Dan Ford, PharmD, PGY2- The effects of simulation in preventing medication errors in the ICU.
- 2006-2007 Preceptor, Research Project, Longitudinal Rotation and Five-week Outcomes Rotation
- Cassandra Bellamy, PharmD – Determining the sensitivity and specificity of trigger tools for detecting adverse drug reactions in the ICU.
- 2003-2004 Preceptor, Outcomes Research Project, Longitudinal Rotation
- Neal Benedict, PharmD, PGY2 - Effects of a computerized adverse event alerting system on patients at high risk for heparin induced thrombocytopenia (HIT).
- 2002-2003 Preceptor, Outcomes Research Project, Longitudinal Rotation
- Rhonda Rea, PharmD, PGY2 – 1) Intravenous amiodarone for the treatment of in-hospital cardiac arrest due to pulseless ventricular tachycardia/ventricular fibrillation and 2) ADE rates for high cost and frequently used drugs in the ICU: Redirecting pharmacist's time toward ADE prevention efforts.

Cardiology Residents

- 2020-2021 Preceptor, Critical Care Resident Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation
Marisa Levito, PGY2

| | |
|-----------|---|
| 2019-2020 | Preceptor, Critical Care Resident Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation <ul style="list-style-type: none"> • Bailey Colvin, PGY2 -aspirin assay testing in VAD patients |
| 2018-2019 | Preceptor, Critical Care Resident Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation <ul style="list-style-type: none"> • Lindsay Moreland, PGY2 - Pharmacogenetics and Drug Therapy Post PCI |
| 2017-2018 | Preceptor, Outcomes Research Project, Longitudinal Rotation and three-week outcomes rotation <ul style="list-style-type: none"> • Adrienne Szymkowiak, PGY2 |
| 2016-2017 | Preceptor, Outcomes Research Project, Longitudinal Rotation and three-week outcomes rotation <ul style="list-style-type: none"> • Sherry Cheng, PGY2 • Nicole Durie, PGY2 |
| 2015-2016 | Preceptor, Outcomes Research Project, Longitudinal Rotation and three-week outcomes rotation <ul style="list-style-type: none"> • Ashley Modany, PGY2 |
| 2014-2015 | Preceptor, Outcomes Research Project, Longitudinal Rotation and two-week outcomes rotation <ul style="list-style-type: none"> • Nate Verlinden, PGY2, Clinical outcomes in patients treated with ticagrelor or prasugrel, aspirin, and warfarin after percutaneous coronary intervention |
| 2012-2013 | Preceptor, Outcomes Research Project, Longitudinal Rotation and five-week outcomes rotation <ul style="list-style-type: none"> • Taylor Miller, PGY2, Development of an ontology for drug-induced bleeding resulting in hospital care |
| 2010-2011 | Preceptor, Outcomes Research Project, Longitudinal Rotation and Five-week Outcomes Rotation <ul style="list-style-type: none"> • Sandeep Devabhakthuni, PGY2 Assessing the reliability and validity of a performance assessment rubric in human patient simulation |
| 2008-2009 | Preceptor, Outcomes Research Project, Longitudinal Rotation <ul style="list-style-type: none"> • Roman Gokhman, PharmD, PGY2, The incidence of medication errors during medical emergencies in a large, tertiary care, academic medical center. |
| 2007-2008 | Preceptor, Outcomes Research Project, Longitudinal Rotation and Five-week Outcomes Rotation <ul style="list-style-type: none"> • Erik Abel, PharmD, PGY2 – Comparing the clinical and economic outcomes of the direct thrombin inhibitors for the management of heparin-induced thrombocytopenia in a general population and patients receiving hemodialysis. |
| 2003-2004 | Preceptor, Outcomes Research Project, Longitudinal Rotation <ul style="list-style-type: none"> • Kristin Zerumsky, PharmD, PGY2 - An evaluation of the effectiveness of bivalirudin versus unfractionated heparin in percutaneous coronary intervention. |

2002-2003 Preceptor, Outcomes Research Project, Longitudinal Rotation and 4-week Outcomes Research Rotation
• Jim Coons, PharmD, PGY2 - Clinical outcomes and costs of abciximab and eptifibatide for percutaneous coronary intervention.

Pharmacy Administration Residents

2020-2021 Preceptor, Outcomes Research Project, Longitudinal Rotation
• Garrett Day- Inappropriate medication dosing at hospital discharge in patients with unstable kidney function

2019-2020 Preceptor, Outcomes Research Project, Longitudinal Rotation
• Lauren Ray- Drug associated AKI alert
• Keith Hylwa- Drug induced hyperkalemia treatment

2018-2019 Preceptor, Outcomes Research Project, Longitudinal Rotation
• Tyler Hoffman
• Benedicta Asamoah- DOACs for outpatient treatment of patients with DVT/PE at low risk for complications (Part 2)
• Keith Hylwa- Drug induced hyperkalemia treatment
• John Fawzy- Identifying patients at high risk for Vancomycin plus Piperacillin/Tazobactam associated AKI

2017-2018 Preceptor, Outcomes Research Project, Longitudinal Rotation
• Tyler Hoffman
• Benedicta Asamoah- DOACs for outpatient treatment of patients with DVT/PE at low risk for complications

International Residents

2015-2016 Preceptor, Outcomes Research Project, Longitudinal Rotation
• Michelle See- Critical Care Resident from Singapore- Impact of AKI alerts patient care

2014-2015 Preceptor, Outcomes Research Project, Longitudinal Rotation
• Chai Ling- Cardiology Resident from Singapore - impact of introducing simulation-based learning in pharmacy in Singapore

CARNEIGE MELLON UNIVERSITY

2019 Innovation n Information Systems- Healthcare, Course Coordinator- Don Taylor, PhD, MBA, CLP
Project Mentor for Innovative Solutions in Long-term care/nursing homes
Students: Tiffany Chen, Killian Huang, Sarah Wang, Nicole Ang

THE OHIO STATE UNIVERSITY

2001 Pharmacotherapy Case Conference Facilitator

Critical Care and Oncology Section
The Ohio State University

- 1998-2001 SICU Preceptor
Six -Week Rotations for Pharm. D. students
The Ohio State University
- 1998-2000 Monthly Presentations to SICU Team
Pharmacokinetics/Antibiotics/Sedatives/Hypertensive Emergencies & Urgencies
The Ohio State University Medical Center
- 1999-2000 Hemodynamic Support
Pharmacotherapeutics Course Lecture
The Ohio State University

SERVICE

PROFESSIONAL ORGANIZATIONS

American Board of Internal Medicine

- 2024-2027 Critical Care Medicine Specialty Board Member
2022 Critical Care Medicine Specialty Board Representative for SCCM

Advancing American Kidney Health by Optimizing Medication Management (AKHOMM), 2020-present

- 2022- 2023 Review committee for education curriculum
2020- 2023 Practice management standards

American Association of Colleges of Pharmacy, 2020- present

- 2023-24 Chair, Paul R. Dawson for Excellence in Patient Care Award Committee

American College of Clinical Pharmacy, 1997 - present

Society-Wide

- 2024-2027 Member, Board of Regents (elected position)
2023-2024 Chair of the 2024 ACCP Clinical Practice Affairs “A” Committee
Prepare an ACPP Commentary that forecasts the impact of artificial intelligence on future clinical pharmacy practice.
2022-2023 Member, Research Affairs Committee- best practices in pharmacy resident research and quality improvement projects
2020-2021 Member, Clinical Practice Affairs Committee, White Paper on Quality Measures of Clinical Pharmacy Services
2019-2020 Vice Chair, Educational Affairs Committee, White Paper on Telehealth
2018- present Faculty, Research and Scholarship Academy
<https://www.accp.com/academy/researchAndScholarship.aspx>
2015-2016 Member, Research Affairs Committee
2015-2016 Mentor-Mentee Program
Kristin Howard, PharmD (PGY2 CC- UMC of South Nevada)

2014-2015 Mentor-Mentee Program
 Ramzan Judge, PharmD (PGY1 Henry Ford, PGY2 CC Buffalo)
 Prachi Bhatt, PharmD (PGY1 Temple, PGY2-CC Boston Medical Center)

2012-2014 Chair, Program Committee, 2014 Annual Meeting, Austin, Tx
 2011 Member, Task Force on Residencies

2007-2010 Member, Research Fellowship Program Review Committee
 2007 Moderator, Significant Papers in Pharmacotherapy Symposium, Annual Meeting
 2007 Chair, Publication Committee
 2006 Moderator, Critical Care and Pharmacoeconomics Outcome Platform Session, Annual Meeting

2003-2005 Member, Clinical Practice Affairs Committee
 2002 Full Member Approved
 1999-2000 Member, Research Committee

Critical Care PRN

2023-2024 Member, Critical Care Pharmacist Practice Model Opinion Paper
 2010-2011 Member, Program Committee
 2006-2007 Member, Program Committee
 2006 Member, Position Paper Committee
 2003 Member, Travel Award Committee
 2002-2003 Chair, Research Committee

American Society of Health-System Pharmacists, 2013-present

2018-2021 Member, Residency Excellence Award Review Panel
 2023- Sustained Contribution Award Review Committee

IHI/American Society of Professionals in Patient Safety (ASPPS)- previously National Patient Safety Foundation (NPSF), 2015- present

Association of Community Cancer Centers

2020-2021 Advisory Committee, Adoption and Expansion of Telehealth Solutions in the Time of COVID-19 and Beyond <https://www.accc-cancer.org/projects/telehealth-solutions/advisory-committee>
 Telehealth and Blueprint Team

Health Information Management System Society, 2020- present

Jewish Healthcare Foundation (JHF), 2023- present

2023- Regional Autonomous Patient Safety (RAPS) Initiative Advisory Board
<https://www.jhf.org/news-blog-menu/entry/raps-advisory-board-holds-first-meeting-to-discuss-forward-momentum>

Pennsylvania Pharmacists Association, 2015-present

2015- 2018 Pre-Residency Excellence Program (PREP) Steering Committee

Society of Critical Care Medicine, 1997 - present

Society-Wide

2024-2030 Vice-Chair, Chair, Past-Chair of the Audit Committee
 2023- Chair, Biomarker Taskforce

Leader of the Kidney Biomarker Working Group

2023-2025 Member, Critical Care Medicine, and Critical Care Explorations Editor-in-Chief Search Taskforce

2023-2024 **Past-President, Executive Committee, SCCM**

2022-2023 **President, Executive Committee, SCCM**
[SCCM Donor Thank You 2021 - YouTube](#)
[SCCM Member Memories: Celebrating 50 Years - YouTube](#)
[2022 Critical Care Congress - YouTube](#) (presidential address)

2021-2022 **President-elect, Executive Committee, SCCM**

2021 Co-Vice-Chair, Executive Committee, Surviving Sepsis Campaign
[SSC Leadership | SCCM](#)

2021 Member, Nominating Committee

2020 Rapid Cycle Survey Task Force

2019-2021 Treasurer, Executive Committee, SCCM

2019-2022 Member, Data Science Programming Taskforce

2017-2019 *Vice-Chair, Chair, Past-Chair* Strategic Planning Committee

2016-2019 Clinical Pharmacy and Pharmacology (CPP) designated seat, SCCM Council (elected)

2016 Representative, Antibiotic Stewardship in the ICU Workshop

2016 *Co-Chair*, SCCM/ASPEN Research Workshop Taskforce

2016 Moderator, “A NINJA in the ICU: Novel Methods for the Prevention of Drug-Associated AKI”

2015-2016 *Co-Chair*, Physiologic Noise and Alert Fatigue Taskforce

2015 Member, Council Structure Paper Writing Taskforce

2014-2016 At-Large Member, SCCM Council (elected)

2014 Member, Strategic Education Committee

2014-2016 *Vice-chair*, Critical Care Practitioners as Educators Taskforce

2014-2015 Member, Impact of Violent Injuries Taskforce

2014 Moderator, “Don’t be Alarmed” Preventing Distractions, Congress, San Fran

2013 SCCM Steering Committee member for the HHS/CCSC Award Task Force

2013 Moderator, Safe Medication Use Guidelines, Congress, Puerto Rico

2013 Moderator, Controlling Costs of Therapeutics, Congress, Puerto Rico

2013 Moderator, Quality Metrics: Priorities and Applications, Congress, Puerto Rico

2012-2013 Member, Quality and Safety Committee

2011-2013 *Vice Chair and Chair*, Paragon Quality Improvement Committee

2011-2013 *Chair and Past Chair*, Program Committee, Congress 2012

2010-2012 Member, Strategic Education Committee

2011 Moderator, Therapeutics and PK Professor Walk Rounds Poster Session

2010-2011 *Co-Chair*, Pharmacotherapy Post Graduate Course

2010 Moderator, Epidemiology/Outcomes Professor Walk Rounds Poster Session

2009-2011 Member, Paragon Quality Improvement Committee

2009-2012 Paragon Coach

2009-2010 *Chair*, Pharmacotherapy Post Graduate Course 2011, 2012 Congress

2009 Moderator, The terminator: avoiding medication errors in the ICU

2009- 2017 *Chair*, Medication Use Safety Guideline Taskforce

2008-2011 Member, Program Committee

2008-2009 *Co-Chair*, Pharmacotherapy Post Graduate Course

2008 Moderator, Epidemiology/Outcomes Professor Walk Rounds Poster Session

2007-2008 *Co-Chair*, Public Awareness Subcommittee of the Advocacy Committee

2007-2009 Member, Advocacy Committee

2007 Membership Liaison
 2006-2009 Member, Excellence in Quality & Safety in Critical Care Taskforce
 2005-2008 Member, Outcomes Taskforce
 2003-2006 Member, Research Committee

Clinical Pharmacy and Pharmacology (CPP) Section

2018-2019 Mentor for the Mentor-Mentee Program (Angela Slampak-Cindric, PharmD)
 2016- 2020 Strategic Advisory Council
 2016 Mentor – Medication Safety Journal Club and Webinar, Jackie Johnston, PharmD
 2015-2016 Mentor-Mentee Program, Kimberly Brandt, PharmD (Rutgers- EMSOP)
 2014 Reviewer, Research Peer-Review Program (Megan Rech, PharmD)
 2012 Reviewer, Grant Peer-Review Program (Joshua Swan, PharmD)
 2012 Reviewer, Publication Peer-Review Program
 2011-2012 Mentor for the Mentor-Mentee Program (Kimberly Clark, PharmD)
 2010 Senior Investigator Advisor for the Junior CPP Investigators Research Program
 2009-2010 Mentor for the Mentor-Mentee Program (Christopher Paciullo, PharmD)
 2010-2018 Member, Patient Safety Committee
 2008-2009 Mentor for the Mentor-Mentee Program (Marcus Dortch, PharmD)
 2006 *Chair*, Nominations Committee
 2006 Member, Technology Taskforce
 2005-2009 *Chair*, Patient Safety Taskforce (developed the committee)
 2005-2006 Member, Recognition Taskforce
 2004-2006 *Chair-Elect*, Chair (elected position), Past Chair of the CPP Section
 2002-2005 Member, Survey Taskforce
 2002-2004 *Chair*, Research Committee
 2001-2002 *Co-Chair*, Research Committee
 1999-2001 Member, Research Committee

International Society for Pharmacoeconomics and Outcomes Research, 2000-2014

2007 *Co-Chair*, Fellowship Standards Taskforce
 2007 Member, Electronic Patient Reported Outcomes (ePRO) Committee
 2004 Member, Clinical Special Interest Group
 2002-2003 Member, Quality of Life Special Interest Group
 2002-2003 Member, Learning Outcomes Task Force
 2000-2001 Clinical Consultant for the OSU Student Chapter

National Kidney Foundation- American Society of Nephrology

2022-24 NKF-ASN Task Force on Reassessing Inclusion of Race in Diagnosing Kidney Diseases

VA Pittsburgh Healthcare System

2023- Technology Enhancing Cognition and Health - Geriatrics Research Education and Clinical Center (TECH-GRECC) Geriatrics and Gerontology Advisory Committee (GGAC)

World Federation of Intensive and Critical Care

2024-2025 Analgesia Section Lead, Multinational Taskforce on Critical Care Guidelines
 Guidelines are a collaboration between Iberic and Pan-American Federation of Critical Care Societies (FEPIMCTI) and the World Federation of Intensive Care Societies (WFICS).
 2023-24 Mentor, Critical Care Research Academy

Mentee- Oyebola Adekola, MD

United States Pharmacopeia

2006-2010 Member, Therapeutic Decision-Making Expert Committee

Michigan-Ohio Critical Care Pharmacy Symposium

1999-2001 Chairperson of the Annual Meeting

UNIVERSITY OF PITTSBURGH

2024- Member, Women in Medicine & Science Forum Planning Committee
2023- Member, Faculty Retention and Recruitment Working Group
2021-22 Member, School of Pharmacy Dean, Search Committee
2019- present Advisory Committee, Health Services Research Data Center for the Health Sciences
2013 School of Nursing Hub Proposals and the CTSI- Grant Reviewer
2012 The Vascular Medicine Institute (VMI) and the CTSI- Grant Reviewer
2008-2011 Member, Institutional Review Board

UNIVERSITY OF PITTSBURGH, SCHOOL OF PHARMACY

2021-22 Member, Translational Pharmacokinetic and Pharmacodynamics Faculty, Search Committee
2021-2025 *Director*, Medication Safety and Nephrotoxin Stewardship Fellowship
<https://www.pharmacy.pitt.edu/programs/residency/fellowships/clinical-fellowship.php>
2021-2025 *Co-Director*, PharmacoAnalytics of Natural Drug Interactions Fellowship
http://www.pharmacy.pitt.edu/programs/residency/fellowships/pharmacoanalytics_fellowship.php
2020 Phase II of COVID-19 Teaching Taskforce
2018-2019 Facilitator, Resident Research Series (Group 1- Bailey Colvin, PGY1; Keith Hylwa, PGY1; Liam Dadey, PGY1 McKeesport; John Fawzy, PGY1); (Group 2 – Tyler Hoffman, PGY2; Benedicta Asamoah, PGY2; William Kasper, PGY1; Emily Schartner, PGY1)
2018-2024 Member, Graduate Program Council
2018-2024 Member, Appointment, Promotions and Tenure Committee
2018-2019 *Chair*, PharmacoAnalytics and Outcomes Search Committee
2018 Member, Transplant Faculty, Search Committee
2018 Member, Pharmacogenetics and Analytics Faculty, Search Committee
2018-present Lead for the Area of Concentration (ARCO) in PharmacoAnalytics
2017 Ad hoc member of the Graduate Program Council
2017-2018 Facilitator, Resident Research Series (Lindsay Moreland, PGY1; Melissa Bastacky PGY1; Tyler Hoffman, PGY1; Benedicta Asamoah, PGY1)
2017-2020 Member, Postdoctoral Education Taskforce
2017 *Chair*, PharmacoAnalytics Faculty Search Committee
2016-2017 Member, Pharmacometrics and Computational Genomics Faculty Search Committee
2017 Member, Curricular Milestone Taskforce
2017-2019 Member, Curriculum Committee (reappointment)
2016-2017 Facilitator, Resident Research Series (Cassius Hudson, PGY1; Adrienne Szymkowiak PGY2; Hannah Welch, PGY1; Julia Dawson, PGY1)
2015-2016 Facilitator, Resident Research Series (Cory Weaver, PGY2; Nicole Durie PGY1; Bethany Shoulders, PGY2; Michelle See, PGY2)
2015-2019 Member, Academic Performance & Conduct Committee
2015 Member, Resource Standards Subcommittee, ACPE Self-Study

2015-2022 Faculty Mentor for Career Learning and Advising Groups (P1-P3 Students)
 2014-2016 Faculty Member-Mentee Program- Margaret Verrico
 2014-2015 Facilitator, Resident Research Series (Cory Weaver, PGY1; Ayesha Ather, PGY1; Ryan Rivosecchi, PGY2; Amanda Johnson, PGY2; Chai Ling, PGY2)
 2013 International Residency Development Planning Group
 2013-2014 Facilitator, Resident Research Series (Ashleigh Hogue, PGY2; Adrian Wong PGY2; Adam MacLasco, PGY1; Mary Riedy, PGY1)
 2012-2013 Facilitator, Residency Research Series (Megan Kloet, PGY2; Tiffany Chapman, PGY2; Taylor Miller, PGY2; Derek Evans, PGY2)
 2012-2013 Student CV Mentor Program
 2012-2014 Internal Advisory Committee, T32 Fellowship Grant, Post-doctoral training in Obstetric-Fetal Pharmacology
 2012 *Chair*, Cardiology Faculty Search Committee
 2011-2015 Member, Curriculum Committee (reappointment)
 2011-2012 Facilitator, Residency Research Series (Brian Lohr, PGY2; Megan Kloet, PGY1; Stephanie Seaton, PGY1, Emily Polischuk, PGY1)
 2011-2015 Faculty Member-Mentee Program- Pam Smithburger
 2011-2013 Faculty Member-Mentee Program- Shelby Corman
 2011 Member, Comparative Effectiveness Research Faculty Search Committee
 2010-2011 Facilitator, Residency Research Series (Michael Armahizer, PGY2; Sandeep Devabhakthuni, PGY2; Matthew Felbinger, PGY1, Ibrahim Sales, PGY1; Meredith Jernigan, PGY1)
 2009-2010 Facilitator, Residency Research Series (Lisa Harinstein, PGY2; Ananth Anthes PGY2; Michael Armahizer, PGY1; John Foley, PGY1, David Johnson, PGY2)
 2008-2023 Director, Residency Research Series
 2008-2009 Facilitator, Residency Research Series (Roman Gohkman, PharmD, PGY2; Pam Havrilla, PGY2; Avita Johnson, PGY1; Ryan Shields, PGY1)
 2008-2009 Chair, Critical Care Faculty Search Committee
 2007-2008 Facilitator, Residency Research Series (Erik Abel, PharmD, PGY2; Dan Ford, PharmD, PGY1; Ryan Steadman, PharmD, PGY1; Whitney Hung, PharmD, PGY1)
 2007-2020 Member, Resident Research Project Review Committee
 2007-2009 Member, Information Technology Advisory Group
 2006-2008 Member, Curriculum Outcomes Assessment, Public Health Working Group
 2004-2005 *Chair*, Critical Care Faculty Search Committee
 2002-2005 Member, Residency Committee, School of Pharmacy
 2002-2003 Member, Critical Care Faculty Search Committee
 2002-2003 *Chair*, Strategic Planning Subcommittee - Pharm.D. Student Recruitment

UPMC

2019- 2022 Quality Improvement Review Committee (QRC) for the Health System
 2019- 2023 Member, Cardiology Resident Advisory Committee
 2019- 2023 Member, Critical Care Resident Advisory Committee
 2017 Collaborative agreement development for AKI biomarker protocol
 2014- 2018 Quality, Research and Safety Subcommittee of P&T
 2014 Advisor, PGY1 Resident, Cory Weaver
 2013 Resident Research Presentation Taskforce
 2013-2018 Moderator/Evaluator for Resident Seminars
 2013 Automated Sepsis Syndrome Identification Working Group
 2013-2018 Safe Medication Practices Subcommittee of P&T
 2012 Advisor, PGY1 Resident, Vanessa Millisor

| | |
|------------|---|
| 2012-2017 | Member, Center for Assistance in Research Using eRecord (CARE) Advisory Board |
| 2012 | Member, Cerner Drug Interaction Alert Streaming Project |
| 2009 | QI Fair Presentation of Teamwork to Tackle VAP |
| 2009 | Member, Medication Safety Strategic Planning Committee |
| 2009-2023 | Member, Residency Council |
| 2008- 2010 | Member, VAP and Sedation Team |
| 2009 | <i>Co-chair</i> , Adverse Drug Event Subcommittee |
| 2007-2008 | Secretary, Adverse Drug Event Subcommittee |
| 2006 | Member, Adverse Drug Event Subcommittee |
| 2006 | Member, Dexmedetomidine Initiative of Drug Use and Disease Management Program |
| 2002 | Member, Adverse Drug Event Subcommittee |
| 2001-2002 | Member, Anticoagulation Task Force |

INVITED CONFERENCE PARTICIPATION

Acute Disease Quality Initiative Conferences www.adqi.org

| | |
|------|--|
| 2023 | ADQI-ICA: ADQI XXIX and the International Club of Ascites (ICA) - Kidney Dysfunction in Patients with Cirrhosis, San Diego, CA |
| 2022 | ADQI XXVII A process towards developing consensus and guidelines for management of critically ill patients, Vincenzo, Italy |
| 2022 | ADQI XXVI Digital Health Applications for Acute Kidney Injury (DHAKI), San Diego, CA |
| 2019 | ADQI XXIII AKI Biomarkers- Improving Care, Abano Terme, Italy |
| 2018 | ADQI XXI Quality measures and improvement in care of AKI, San Diego, CA |
| 2015 | ADQI XVI Recovery from AKI, San Diego, CA |
| 2015 | ADQI XV Big Data, Banff, Alberta, Canada |

Advancing American Kidney Health through Pharmacy Care Core Planning Committee, 2020

| | |
|--------------|-------------------------------------|
| 2020-present | Member, Practice Standard Workgroup |
|--------------|-------------------------------------|

Kidney Disease: Improving Global Outcomes (KDIGO) Conference

| | |
|------|---|
| 2019 | Steering Committee (co-lead for nephrotoxin working group), Controversies Conference on Acute Kidney Injury, Rome, Italy https://kdigo.org/conferences/aki-conference/ |
|------|---|

EDITORSHIP and REVIEWER

Book, Newsmagazine Editor and Guest Editor

| | |
|-----------|--|
| 2020-21 | Guest editor, themed issue on telehealth in <i>American Journal of Health-System Pharmacy</i> |
| 2018 | Guest editor, themed issue on critical care in <i>Journal of Pharmacy Practice</i> |
| 2017-2018 | Guest editor, themed issue on innovations in improving patient safety in <i>Pharmacotherapy</i> |
| 2015 | Editor of Critical Connections, the critical care industry's only newsmagazine by the Society of Critical Care Medicine. |
| 2011 | Papadopoulos J, Cooper B, <u>Kane-Gill S</u> , Mallow-Corbett S, Barletta JR. Drug induced complications in the critically ill patients: a guide for recognition and treatment. Society of Critical Care Medicine, 2012, pp 1-484. |
| 2011 | <u>Kane-Gill SL</u> , Dasta JF. High-risk IV medications in special patient populations. Springer-Verlag, London, 2011. pp 1-260. |

Journal Editorial Board

2019- Pharmacist's Letter and Physician's Letter, Specialty Consultants Panel
 2015-2019 Pennsylvania Patient Safety Advisory
 2012-2013 International Scholarly Research Network (ISRN) Critical Care
 2012-present Journal of Hospital Administration
 2012-present Annals of Pharmacotherapy-Adverse Reactions and Medication Safety Panel, Editorial Board
 2011- 2020 Advances in Pharmacoepidemiology and Drug Safety (APDS)-open access, Editorial Board
 2009-present Critical Care Medicine, Editorial Board
 2009 Critical Care Medicine, Supplement Editor "Identification and Prevention of Common Adverse Drug Events in the ICU"
 2004- 2019 Hospital Pharmacy, Critical Care Column Editor

Journal Reviewer

2020-present Kidney International
 2016 Nephrology, Dialysis & Transplant
 2011-present British Journal of Clinical Pharmacology
 2011-present Journal of General Internal Medicine
 2010-present American Journal of Pharmaceutical Education
 2010-present Journal of Critical Care
 2009-present Pharmacoepidemiology and Drug Safety
 Best Reviewer Acknowledgement in 2016
 2008-present Annals of Pharmacotherapy
 2006-present Critical Care
 2003-present Annals of Emergency Medicine
 2003-present Pharmacotherapy
 2003-2020 Hospital Pharmacy
 2002-present Critical Care Medicine
 1998-2020 Critical Care Nurse

Meeting Abstracts and Poster Judge

2021-2022 European Society of Intensive Care Medicine, Abstract reviewer
 2016 American College of Clinical Pharmacy, Best Resident and Fellow Poster Judge Annual Meeting, Hollywood, FL
 2014 American College of Clinical Pharmacy, Best Paper Judge 3rd Annual ACCP Virtual Poster Symposium
 2012 American College of Clinical Pharmacy, Best Paper Judge, Annual Meeting, Albuquerque, NM.
 2012 American College of Clinical Pharmacy, Best Poster Judge, 1st Annual ACCP Virtual Poster Symposium
 2012-2014 American College of Clinical Pharmacy, Reviewer, Abstracts Virtual Posters
 2011-present American College of Clinical Pharmacy, Reviewer, Abstracts for Annual Meeting
 2010 American College of Clinical Pharmacy, Student Travel Award Judging Committee, Spring Meeting
 2009-2013 International Society for Pharmacoeconomics and Outcomes Research, Abstracts Review
 European Congress- Cost Studies
 2009 American College of Clinical Pharmacy, Best Resident and Fellow Poster Judging Committee, Annual Meeting, Anaheim, CA.
 2009 American College of Clinical Pharmacy, Student Travel Award Judging Committee, Annual Meeting

| | |
|----------------------|---|
| 2007-2013 | International Society for Pharmacoeconomics and Outcomes Research Abstracts Review International Meeting- Cost Studies |
| 2005-present 2005 | Society of Critical Care Medicine, Reviewer, Abstracts for Annual Congress 2006-2018 International Society for Pharmacoeconomics and Outcomes Research Abstracts Review International Meeting- QoL |
| 2004 | International Society for Pharmacoeconomics and Outcomes Research Abstracts Review International Meeting- Clinical Outcomes |
| 2003 | International Society for Pharmacoeconomics and Outcomes Research Abstracts Review International Meeting- Cost Studies |
| 2002-2010 2002 | American College of Clinical Pharmacy, Reviewer, Abstract (Spring and Annual Meeting) International Society for Pharmacoeconomics and Outcomes Research Abstracts Review International Meeting- Clinical Outcomes |

Medication Name Review

| | |
|-----------|--|
| 2010 | Medical Error Recognition and Revision Strategies, INC. (Med-ERRS) |
| 2015-2016 | Medical Error Recognition and Revision Strategies, INC. (Med-ERRS) |

Agency for Healthcare Research and Quality (AHRQ)

| | |
|------|--|
| 2010 | Special Emphasis Panel/Scientific Review Group- Advancing Patient Safety with Simulation Research |
| 2016 | Ad Hoc Member, Healthcare Safety and Quality Improvement Research (HSQR) Study Section |

American Association of the Colleges of Pharmacy

| | |
|------|------------------------|
| 2017 | New Investigator Award |
|------|------------------------|

MEDIA QUOTES/REPORTS

| | |
|------|--|
| 2024 | Studies with Kratom link to overdoses and seizures https://www.wtae.com/article/kratom/46894629 |
| 2023 | Stewardship can tame drug-related kidney injury in the hospital by Kate Baggaley in Pharmacy Practice News https://www.pharmacypracticenews.com/Clinical/Article/07-23/Stewardship-Can-Tame-Drug-Related-Kidney-Injury-in-the-Hospital/70798 |
| 2023 | UPMC Researchers Hone Alerts for Drug-Associated AKI https://www.pharmacypracticenews.com/PrintArticle/70130 |
| 2022 | When it comes to darker skin, pulse oximeters fall short https://www.npr.org/sections/health-shots/2022/07/11/1110370384/when-it-comes-to-darker-skin-pulse-oximeters-fall-short |
| 2022 | The latest innovations to improve medication adherence https://www.contemporarypediatrics.com/view/the-latest-innovations-to-improve-medication-adherence |
| 2022 | Thanks to COVID-19, drug shortages take center stage https://www.youtube.com/watch?v=elrKr1gNvwA |
| 2022 | Medication Safety 2.0 Advance in Adherence Technology https://www.drugtopics.com/view/medical-device-manufacturers-must-improve-cybersecurity |
| 2022 | How the Omicron surge is taxing hospitals. What Hospitals Are Dealing with During the Omicron Surge (healthline.com) |
| 2021 | Tocilizumab may reduce mortality in certain COVID-19 patients. SCCM Critical Connections Blog |

- https://www.sccm.org/Blog/February-2021/Tocilizumab-May-Reduce-Mortality-in-Certain-COVID?utm_source=2-19-2020%20COVID-19%20Update&utm_medium=Link&utm_campaign=COVID-19%20Emails&_zs=5jwjd1&_zl=etdQ7
- 2021 Dexmedetomidine, propofol similar in ventilated adults with sepsis by Marcia Frellick in Medscape
https://www.medscape.com/viewarticle/945123#vp_2
- 2021 Celebrating 50 Years of Critical Care. Dr. Sandra L. Kane-Gill Shares Her Story.
<https://story.sccm.me/dr-sandra-l-kane-gill-shares-her-story/>
- 2020 A way to cut back on medication alerts. Pharmacy Technology Report by Alison McCook
https://issuu.com/mcmahongroup/docs/ptr0920_de
- 2020 “Shortages of drugs used with coronavirus patients on ventilators feared.” WCVB by Kathy Curran
<https://www.wcvb.com/article/shortages-of-drugs-used-with-coronavirus-patients-on-ventilators-feared/32099145>
- 2020 “Evidence mounts supporting inhaled nitric oxide as COVID-19 treatment”
<https://www.healio.com/primary-care/infectious-diseases/news/online/%7Bfbc4d7b3-40e5-4363-8808-a464f4b53f4f%7D/evidence-mounts-supporting-inhaled-nitric-oxide-as-covid-19-treatment>
- 2020 “Amid rush to secure ventilators, doctors warn of shortage of crucial drugs” CBS News by Melissa Quinn
<https://www.cbsnews.com/news/coronavirus-covid-19-ventilators-shortage-drugs-propofol-morphine-lorazepam-fentanyl/>
- 2020 COVID-19 by David Wild in Pharmacy Practice News.
<https://www.pharmacypracticenews.com/Covid-19/Article/03-20/New-Guidelines-Released-for-Managing-COVID-19-Patients/57723>
- 2020 Sedation in the ICU debated by I. Hein in Medscape.
<https://www.medscape.com/viewarticle/925446>
- 2019 Nuts & Bolts of SCCM podcast.
<http://connect.sccm.org/library.htm?mode=view&did=229847&lid=157544&wf=182105>
- 2018 Perspective on Innovations in Medication Safety. American College of Clinical Pharmacy Episode 27 Podcast. <https://www.stitcher.com/podcast/accp-podcast/e/55900974>
- 2018 THRIVE: Reaching out to patients and families after the ICU. Society of Critical Care Medicine, 47th Congress, San Antonio, Tx. <https://www.youtube.com/watch?v=0JysKog1L3I>
- 2018 Report on Kane-Gill’s presentation at SCCM on Safe Medication Use Clinical Practice Guidelines by Bruce Buckley in Pharmacy Practice News. Some Yeses, Some Nos in New ICU Guidelines. Pharmacy Practice News, June 2018;45(6):20-21.
- 2018 Report on Kane-Gill’s presentation at ASHP on Safe Medication Use Clinical Practice Guidelines by Madison Brunner in Pharmacy Practice News.
- 2017 Cited Kane-Gill in a report on “how a baking soda shortage became a health care crisis” in USA Today by Nathan Bomey.
<https://www.usatoday.com/story/money/2017/05/31/how-baking-soda-shortage-became-health-care-crisis/102320494/>
- 2017 Report on Melissa Thompson Bastin presentation on “ICU-based pharmacy technicians may significantly improve medication distribution process” at SCCM in Pharmacy Practice News by Colleen Owens
- 2017 Report on Kane-Gill’s SCCM webinar presentation “Alert fatigue: management approaches and appropriate metrics” in Pharmacy Practice News by Robert Carlson.
- 2016 Radio interview for 88.9FM Boston “Making ICUs less frightening and more comfortable for patients” (Kane-Gill 8:30-11minutes with news reporter Chloe Goldstein)
<https://soundcloud.com/889-wers/the-key-to-making-ic-us-less-frightening-and-more-comfortable-for-patients?in=889-wers/sets/you-are-here-taking-care-1>
- 2015 Reducing errors in the ICU. Pharmacy Practice News.
http://www.pharmacypracticenews.com/ViewArticle.aspx?d=Videos&d_id=550&i=December+2015&i_id=1273&a_id=34511

- 2014 Report on Kane-Gill’s presentation at ACCP about a pharmacist led acid suppression program by C. Huff in Pharmacy Practice News
- 2014 Report “Impact of BMI on drug dosing” in Healthday by Beth Gilbert
- 2013 Report “Three algorithms are effective in assessing medications likely to have caused ADRs in ICUs.” in AHRQ’s Research Activities
- 2013 Report on Kane-Gill’s presentation at SCCM on “are \$100,00 drugs worth the cost?” by Neil Osterweil in Hospitalist News
- 2012 Report on Kane-Gill’s presentation at SCCM on culture and patient safety by Steve Frandzel in Pharmacy Practice News.
- 2012 Report on Kane-Gill’s Analysis of risk factors for ADEs in critically ill patients. Pharmacy Practice News
- 2011 Cite Kane-Gill about de-escalation of antibiotics in the ICU by F. Lowry in Infectious Disease Special Edition of Pharmacy Practice News
- 2011 Cite Kane-Gill about elderly ICU survivors are discharged on inappropriate medications by F. Lowry in Pharmacy Practice News
- 2010 Cited Kane-Gill about medication errors during medical emergencies by C. Huff in Pharmacy Practice News
- 2010 Cited Kane-Gill about pharmacist’s enhancement in patient outcomes by D. Moulton in Pharmacy Business Magazine
- 2009 Cited Kane-Gill about cost and ADEs associated with sedation. Pharmacy Practice News
- 2008 Report on Kane-Gill to present at ASHP about simulation by B. Buckley in Pharmacy Practice News
- 2008 Report on Kane-Gill as co-recipient of the innovation in education award for simulation-based education in University of Pittsburgh Teaching Times
- 2007 Cited Kane-Gill quote about medication errors by C. Huff in Pharmacy Practice News
- 2006 Cited Kane-Gill quote about quality of life in the ICU by F. Gebhart in American Academy of Medical Administrators
- 2005 Cited Kane-Gill quote about sedation management in the critically ill by R. Frei in Pharmacy Practice News

PRESENTATIONS

ABSTRACTS: POSTERS AND ORAL SCIENTIFIC PRESENTATIONS

Selected abstracts from the past 5 years and award winning/ top ranking abstracts from a total of 202 presentations

Students/residents* under my direction are indicated by an asterisk.

1. Abebe KZ, Kane-Gill SL, Fried LF, Liu K, Parikh C, Poggio E, Siew E, Horwitz E, Neyra J, Weir M, Wilson F, Beach S, Demirjian S, Fissel W, Huml A, Menez S, Moledina D, Switzer G, Yabes J, Schulman I, Palevsky P on behalf of the COPE-AKI Consortium. Design and rationale of a patient-centered, randomized trial of a process-of-care intervention in hospitalized AKI patients: the COPE-AKI Trial. Am Society of Nephrology Kidney Week 2024, Sand Diego, CA.
2. Ren Y, Adiyeeke E, Vedala A, Tripathi C, Kane-Gill SL, Shickel B, Bihorac A, Ozrazgat-Baslanti T. AI/ML ready data Enriched with social determinants of health and unstructured text data for acute kidney injury risk prediction. International Society for Computational Biology 2024, Montreal, CA.

3. Albert SM, Li X*, Kane-Gill SL, Lombardi J*, Boyce R. Incidence of potentially inappropriate prescribing among older adults: A large-scale, longitudinal investigation of outpatient prescriptions. Presented at the ACCP virtual meeting, 2024.
4. Amatullah M*, Lombardi JP*, Culley CM, Kane-Gill SL. Altering alert logic configuration to improve performance of D-AKI prediction. Presented at the ACCP virtual meeting, 2024.
5. Spencer Krichevsky, Yun Jae Yoo, Kenneth J. Wilkins, Fadhl Alakwaa, Feifan Liu, Ankit Sakhuja, Joel H. Saltz, Yun Han, Rajiv Saran, Richard L. Zhu, Soko Setoguchi, Sandra L. Kane-Gill, Sandeep K. Mallipattu, Yongqun He, David H. Ellison, James Brian Byrd, Chirag R. Parikh, Richard A. Moffitt and Farrukh M. Koraihy* on behalf of the N3C and RECOVER consortia. Risk Factors of Post-COVID Incident Chronic Kidney Disease in the National COVID Cohort Collaborative. AM Soc Nephrology 2023, Philadelphia, PA
6. Yang L*, Gabriel N, Guo J, Empey K, Suh K, Kane-Gill SL, Kirisci L, Hernandez I. Cardiovascular Risk and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors: A Nationwide Comparative Effectiveness Research Study. Abstract presented at the ICPE 2023 Conference, Halifax, Nova Scotia, Canada
7. Li X*, Kane-Gill SL, Boyce R. Interaction between cannabis and cytochromes P450 substrates: Potential safety signals from a disproportionality analysis using the US Food and Drug Administration adverse event reporting system database. Abstract presented at the ICPE 2023 Conference, Halifax, Nova Scotia, Canada
8. Chapin M*, Li X*, Taneja S, Kane-Gill SL, Boyce RD. Review of Case Reports and Analysis of VigiBase Data to Identify Potential Cannabis Natural Product Drug Interactions. *Poster presentation, International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23-27, 2023*. Abstract presented at the ICPE 2023 Conference, Halifax, Nova Scotia, Canada
9. Taneja SB, Chapin MR, Li X, Kane-Gill SL, Boyce RD. Generating mechanistic hypotheses for pharmacovigilance signals using a natural products knowledge graph. Advances in Pharmacovigilance for Herbal Medicines conference 2023, London, UK
10. Newman TV, Yang J, Suh K, Jonassaint C, Kane-Gill SL, Novelli EM. Trends of Disease Modifying Treatment Use in Sickle Cell Disease: Retrospective Analysis of Claims Data, 2014-2021. 64th American Society of Hematology Annual Meeting 2022, New Orleans. LA. **Invited oral presentation.
11. Kazarov C, Novelli E, Kane-Gill S, Jonassaint C, Jalowsky M, Lewis C, Newman TV. Barriers to the Use of Disease-Modifying Treatments in Sickle Cell Disease: A Survey of Patients and Caregivers. Poster Presentation at the 64th Annual American Society of Hematology Annual Meeting. New Orleans, LA. December 10th, 2022
12. Kazarov C, Grubic M, Kane-Gill SL, Boyce RD. Differences in Adverse Events Reporting Between Natural Products Versus Prescription Products in the United States and Canada. ISPOR Europe 2022, Vienna, Austria
13. Taneja SB, Paine MF, Kane-Gill SL, Boyce RD. Extending the OMOP Standard Vocabulary to Include Botanical Natural Products. Presented at the Observational Health Data Sciences and Informatics (OHDSI) Symposium; October 14-16, 2022.
14. Stottlemeyer BA*, Abebe K, Fried L, Palevsky P, Kane-Gill SL. Expert consensus on the nephrotoxic potential of 195 medications in the non-intensive care setting: a modified-Delphi method. Presented at the ACCP Spring Meeting 2022.

15. Chen N, Kane-Gill SL, Suh K. Real-world evidence of adverse kidney outcomes for intravitreal use of vascular endothelial growth factor (VEGF) inhibitors among patients with diabetic retinopathy. Presented at ISPOR 2022, National Harbor, MD.
16. Zerfas I*, Stevens C*, Tkuchuk S*, Kane-Gill S. A Scoping Review of Drug-Associated Acute Kidney Injury Definitions in the Literature: A Call for Consistency. 2022 Mid-year Meeting, Harrisburg, PA.
17. Morin C, Padki A, Miano T, Kane-Gill SL, Deveau R, Cozzi G, Wong A. Comparison of COVID-19 Pre-print and Published Versions of Studies Evaluating NIH-recommended Therapies for Critically Ill Patients. Presented at the 51st SCCM Critical Care Congress 2022, San Juan, Puerto Rico.
18. Zerfas I, Hume E, Wong A, Klein-Fedyshin M, Smithburger PL, Buckley MS, Devlin JW, Kane-Gill SL. Strategies for Implementation of PAD/PADIS Guideline Recommendations in ICU Practice. Presented at the 51st SCCM Critical Care Congress 2022, San Juan, Puerto Rico.
19. Taneja SB, Ndungu PW*, Paine MG, Kane-Gill SL, Boyce RD. Relational extraction from biomedical literature on natural product-drug interactions. Presented at the AMIA Informatics Summit 2022, Chicago, IL
20. Le T, Li Y, Mast M, Beisel C, Tsuchihashi K, Gibbon L, Yagnala N, Ray L, Kane-Gill SL. Evaluating a rule-based clinical decision support alert for drug induced AKI. Presented at the 57th ASHP 2019 Midyear Clinical Meeting (virtual)
21. Rust T, Miller T, Verrico M, Kane-Gill SL. Evaluation of a fixed weight-based heparin dosing protocol in patients with prior direct oral anticoagulant use. Presented at the 57th ASHP 2019 Midyear Clinical Meeting (virtual)
22. White E*, Kane-Gill SL, Jain S, Medico C, Coons J. Barrier assessment and intervention design using implementation science to enhance atrial fibrillation care. Presented at the ACCP 2021 Annual Meeting, Phoenix, Az.
23. Kim H*, Yu D*, Kane-Gill SL, Suh K. Trends in healthcare expenditure in United States Adults with chronic kidney disease: 2014-18. Presented at the ACCP 2021 Annual Meeting, Phoenix, Az.
24. Buckley MS, Komerdelj IA, D'Alessio PA, Rangan P, Agarwal SK, Tinta NC, Martinez BK, Ziadat DS, Yerondopoulos MJ, Kobic E, Kane-Gill SL. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associate acute kidney injury in general ward patients: A multicenter propensity-matched study. Presented at the ACCP 2021 Annual Meeting, Phoenix, Az.
25. Taneja SB, Callahan TJ, Brochhausen M, Zayas C, Paine MG, Kane-Gill SL, Boyce RD. Designing potential extension from G-SRS to ChEBI to help identify potential natural product-drug interaction. Invited as *Oral presentation* at the Intelligent Systems for Molecular Biology/European Conference on Computational Biology 2021 Virtual Meeting.
26. Rong G*, Chang J*, Kane-Gill SL, Gray MP, Boyce RD, Novelli EM, Newman T. Adverse drug reactions for disease modifying treatments in sickle cell disease: A descriptive analysis of the food and drug administration adverse events reporting system (FAERS) database. Presented at the ACCP 2021 spring virtual meeting.

27. Delapaz N*, Snader LA*, Gray MP*, Boyce RD, Suh K, Kane-Gill SL. Adverse drug reactions for COVID-19 treatments: A pharmacovigilance study using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Presented at the ACCP 2021 spring virtual meeting.
28. Snader L*, Soh Y*, Berenbrok L, Wong A, Kane-Gill SL. Identification of facilitators and barriers to clinicians' response to receiving clinical decision support alerts in the Intensive Care Unit (ICU). Presented at the ACCP 2021 spring virtual meeting.
29. Gray MP*, Priyanka P, Kane-Gill SL, Kellum JA. The association of ondansetron use and subsequent acute kidney injury in critical care. Presented at the International Conference for Pharmacoepidemiology, 2021 (virtual) AND 12th Annual Pharmaceutical Sciences Research Symposium (awarded second place for outcomes research category) AND 10th Annual Mitchell P. Fink Scholar Day, UPMC.
30. Desai R*, Kazarov C*, Kane-Gill SL. Comparing serum creatine to stress/damage biomarkers for early detection of drug-associated acute kidney injury: a systematic review. Presented at the Virtual ISPOR 2021 AND 12th Annual Pharmaceutical Sciences Research Symposium (Virtual <https://www.12psrs.com>)
31. Callaway K, Tadrous M, Kane-Gill SL, Barbash I, Suda K. Changes in purchases of intensive care medicines during COVID-19 in developed vs. developing countries. Presented at the 37th International Society for Pharmacoepidemiology Conference, 2021 (virtual).
32. Callaway K, Tadrous M, Kane-Gill SL, Barbash I, Suda K. Global changes in purchases of intensive care medicines during COVID-19. Presented at the Academy Health 2021 Annual Research Meeting (virtual).
33. Li Y, Guo J, Gabriel N, Kane-Gill SL, Essien UR, Toledo FGS, Hernandez I. Racial/ethnic and geographic variation in the initiation of antidiabetic therapies in Medicare enrollees with newly diagnosed type 2 diabetes (T2D). Presented at the American Diabetes Association, 81st scientific meeting (virtual)- Invited as an oral presentation. Presented at the 12th Annual Pharmaceutical Sciences Research Symposium (awarded first place for outcomes research category).
34. Li Y, Hernandez I, Gabriel N, Kane-Gill SL, Essien UR, Toledo FGS, Guo J. Trends of first-time antidiabetic treatment among 2007-2017 Medicare beneficiaries newly diagnosed with type 2 diabetes and their determinants. Presented at the American Diabetes Association, 81st scientific meeting (virtual).
35. Kleinpell R, Ferraro DM, Maves RC, Kane-Gill SL, Branson R, Greenberg S, Doersam JK, Raman R, Kaplan LJ. COVID-19 from the Frontlines: Reports from over 14,000 ICU Clinicians. Presented at the 50th SCCM Critical Care Congress 2021(virtual).
36. Buckley MS, Komerdelj IA, D'Alessio PA, Rangan P, Agarwal SK, Tinta NC, Martinez BK, Ziadat DS, Yerondopoulos MJ, Kobic E, Kane-Gill SL. Nephrotoxicity with vancomycin in combination with piperacillin-tazobactam or cefepime/meropenem. Crit Care Med 2021;49(1):441. Presented at the 50th SCCM Critical Care Congress 2021(virtual).
37. Chiappeli, AL*, Kane-Gill SL, Smithburger PL. Pharmacist impact on transitions of care from the intensive care unit: readmission rates. Presented at the 50th SCCM Critical Care Congress 2021(virtual).
38. Le T*, Yagnala N*, Ray L*, Kane-Gill SL. Evaluating the performance characteristics of a drug-associated acute kidney injury (D-AKI) clinical decision support alert in ICU patients. Presented the ASHP 2020 Virtual Midyear Meeting.

39. Zerfas I*, Hume E*, Devlin J, Fedyshin M, Kane-Gill SL. Implement strategies for uptake of the PAD and PADIS guidelines in clinical practice. Presented at the ASHP 2020 Virtual Annual Meeting and at the 12th Annual Pharmaceutical Research Symposium, Pittsburgh, PA (awarded second place for best PharmD student poster)
40. Yagnala N*, Le T*, Ray L*, Kane-Gill SL. Evaluating the performance characteristics of a drug-associated AKI (D-AKI) clinical decision support alert in non-ICU patients. Presented at the ACCP 2020 Virtual Annual Meeting. <https://accp.confex.com/accp/2020am/meetingapp.cgi/Paper/56321>
41. Patel N*, Stottlemeyer B, Gray M, Boyce R, Kane-Gill SL. A pharmacovigilance study of adverse drug reactions reported for new pulmonary hypertension medications in the US Food & Drug Administration Adverse Event Reporting System (FAERS) database. Presented at the ACCP 2020 Virtual Annual Meeting.
42. Colvin BM*, Rivosecchi RM, Kane-Gill SL, Horn E. Assessment of bleeding and thrombosis outcomes after VerifyNow aspirin responsiveness testing in patients with left ventricular assist devices. Submitted to the American College of Cardiology and World Congress of Cardiology Virtual Annual Conference, 2020.
43. Reardon C*, Kane-Gill SL, Smithburger PL. Characterizing ICU delirium in older patients with ICDSC domains. Presented at the 49th SCCM Critical Care Congress 2020, Orlando, FL.
44. Buckley MS, Smithburger PL, Wong A, Fraser G, Reade MC, Saggar R, Hodges T, Ardiles T, Kane-Gill SL. Dexmedetomidine for facilitating extubation to weaning ICU patients: A systematic review and meta-analysis. Presented at the 49th SCCM Critical Care Congress 2020, Orlando, FL.
45. Colvin B*, Kane-Gill S. Evaluation of prevention strategies for contrast-induced nephropathy. Presented at the 54th ASHP 2019 Midyear Clinical Meeting, Las Vegas, NV.
46. Brock L*, Hwang E*, Kane-Gill SL. Integration of real-world patient reported outcome experiences in schools of pharmacy curriculum: Implementation strategies at the University of Pittsburgh. Presented at the 54th ASHP 2019 Midyear Clinical Meeting, Las Vegas, NV.
47. Lear A, Rice, LaFratte C, Groetzinger L, Pelts M, McGinnis C, Rivosecchi R, Mayer A, Moore C, Nguyen V, Kane-Gill S, Smithburger P. Appropriate continuation of home medications during transitions of care from the medical intensive care unit. Presented at the 54th ASHP 2019 Midyear Clinical Meeting, Las Vegas, NV.
48. Mirabile M*, Novak E*, Sampathkumar S*, Andreaggi C*, Kane-Gill SL. Evaluation of 15 years of adverse event reports reveals changes in most commonly reported opioid-related adverse drug reactions among a steady increase in adverse event reporting. Presented at the 54th ASHP 2019 Midyear Clinical Meeting, Las Vegas, NV.
49. Yagnala N*, Asamoah B*, Rivosecchi R, L'Altrelli A, Baumgartner M, Kane-Gill SL. Medical charges for the treatment of low risk VTE patients discharged versus hospitalized from the emergency department. Presented at the ACCP 2019 Annual Meeting, New York, NY.
50. Patel J, Toscani M, Volino L, Barone J, Kane-Gill SL, Hilas O. Opioid abuse risk among pharmacy students. Presented at the International Conference on Opioids, 2019. Boston, MA.

51. Avramovska S, Lamberty PE, Kane-Gill SL, Smithburger PL. Medication use and adverse drug reaction evaluation in the peri-emergency endotracheal intubation period. University of Pittsburgh, Department of Medicine Annual Research Day, 2019. Pittsburgh, PA.
52. Prakasam D*, Wong A, Kane-Gill SL. Benefit of patient/caregiver reporting compared to other sources of reporting in the inpatient setting: a systematic review. Presented at the APhA Meeting & Exposition 2019, Seattle, WA. (Semifinalist best poster- only 3 selected)
53. Schrier D, Kianoush K, Rule RD, Lieske JC, Kane-Gill SL, Chamberlain A, Mara CK, Barreto EF. Nephrotoxin exposure after hospital discharge predicts development of CKD among AKI survivors. American Society of Nephrology, 2019. SA-P0871. <https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3224803>
54. Reynolds M, Kane-Gill SL, Culley CM, Boyce RD, Perera S, Wong A, Aspinall M. Transforming the Medication Regimen Review Process of High-Risk Drugs Using a Patient-Centered Telemedicine-Based Approach to Prevent Adverse Drug Events in the Nursing Home. Society for Prevention Research 27th Annual Meeting, San Francisco, CA.
55. Rivosecchi, RM, Kane-Gill SL, Seybert AL, Then J. Clinical pharmacist burnout across a multi-hospital health system. Presented at the 48th SCCM Critical Care Congress 2019, San Diego, CA.
56. Prakasam D*, Berenbrok LA, Achanta A*, Smithburger PL, Sharer A*, Ching K*, Donihi A, Seybert AL, Kane-Gill SL. Identifying themes for residents with published and unpublished resident research projects: a qualitative study. Presented at the 53rd ASHP 2018 Midyear Clinical Meeting. Anaheim, CA.
57. Li A, Choi SH, Smithburger PL, Kane-Gill SL. Drug associated indemnified in the Food and Drug Administration Adverse Events Reporting. Presented at the 53rd ASHP 2018 Midyear Clinical Meeting. Anaheim, CA.
58. Albert L, Calleja L, Jan C, Zhang R, Chen W, Smithburger PL, Kane-Gill SL. Medication management after acute kidney stress identified by a TIMP2-IGFBP7 value. Presented at the 53rd ASHP 2018 Midyear Clinical Meeting. Anaheim, CA.
59. Akerberg HA, Wong A, Reynolds MD, Aspinall M, Pellett M, Boyce RD, Culley CM, Dziuba G, Handler SM, Kellum JA, Perrera S, Kane-Gill SL. Resident perceptions of using telemedicine for resident-pharmacist communications in the nursing home. Presented at the ACCP 2018 Annual Meeting, Seattle, WA. (Student poster).
60. Dziuba G, Boyce R, Kane-Gill SL. Understanding medication related fall risk pathways involving antidepressant, psychotropic and CNS exposure. Presented at the 2018 PQA Annual Meeting, Baltimore, MD. (Gabrielle Dziuba received Best Scholar Award)
61. Buckley MS, Rasmussen JR, Bikin DS, Richards EC, Berry AJ, Culver MA, Rivosecchi RM, Kane-Gill SL. Evaluation of trigger alerts associate with laboratory abnormalities on preventing adverse drug events in the intensive care unit and general ward. Presented at the 47th SCCM Critical Care Congress 2018, San Antonio, Tx.
62. Rivosecchi RM*, Kane-Gill SL, Svec S, Campbell S, Smithburger PL. Giving your patients M.O.R.E.: the impact of a non-pharmacologic protocol to prevent intensive care delirium. Oral presentation at the 44th SCCM Critical Care Congress, Phoenix, Az. Crit Care Med 2014;42;12 (suppl): 32. (*First place (top score)*)

in the Patient Family and Support Specialty; also, in the top 64 scores out of 1400 abstracts to be invited as an oral presentation)

63. Farina NM, Csovelak ML, Filiagi RA, Ordons KJ, Shook MR, Rivosecchi RM, Kane-Gill SL, Smithburger PL. Characterization of delirium in a medical ICU that emphasizes frequent delirium screening at a tertiary, academic medical center. (Student poster). Presented at the ACCP 2014 Annual Meeting, Austin, Tx. (*Selected as top 6 student posters in the meeting- Finalist in the Best Student Poster- then selected at the meeting as the first-place student poster award following oral presentation*) *Pharmacotherapy* 2014;34:e267. http://www.accp.com/docs/meetings/abstracts/2014_annual.pdf
64. Buckley MS, Park AS, Anderson CS, Barletta JF, Wicks LM, O'Malley C, Gerkin R, Kane-Gill SL. The impact of a clinical pharmacist managed acid suppression program on inappropriate therapy in general ward patients. Presented at the ACCP 2014 Annual Meeting, Austin, Tx. (*Selected as top 8 posters in the meeting- Finalist in the Great Eight Platform Presentation for Best Paper Competition*) *Pharmacotherapy* 2014;34:e202.
65. Williams E*, Kane-Gill SL. Has the quality of reporting improved for published case reports of adverse drug events? Presented at the ACCP 2014 Virtual Poster Symposium. *Pharmacotherapy* 2014;34 (6): e85. *Ranked top 5% of posters.*
66. Kane-Gill SL, Leblanc JL, Dasta JF and the CPP Hypotension Research Group. Severity and preventability of drug induced hypotension. Presented at the 40th SCCM Critical Care Congress, San Diego, CA. *Crit Care Med* 2010;38 (suppl): 580. Presented as an encore at ACCP 2011 Annual Meeting, Pittsburgh, PA- *ranked in the top 5% of 588 posters*
http://www.pharmacotherapy.org/pdf/free/Pharm3110e_ACCP_Abstracts.pdf (pg 324e)
67. Armahizer M*, Seybert AL, Smithburger PL, Kane-Gill SL. Evaluating the occurrence of QT prolongation resulting from drug-drug interactions. Presented at the 40th SCCM Critical Care Congress, San Diego, CA. (*Top 5% of abstracts- research citation finalist*) *Crit Care Med* 2010;38 (suppl): 89. (Presented as an encore at ACCP 2011 Annual Meeting, Pittsburgh, PA
http://www.pharmacotherapy.org/pdf/free/Pharm3110e_ACCP_Abstracts.pdf (pg 312e))
68. Dasta J, Bokesch P, Kane-Gill S, Pencina M, Riker R. Economic impact of dexmedetomidine vs. midazolam in adult ICU patients with prolonged mechanical ventilation: an economic model. Poster presentation at the 2009 International Anesthesia Research Society (IARS) meeting, San Diego, CA. Selected as a Best of the Meeting Abstract (one of top eight scores out of 415 submitted) *Anesth Analg* 2009;108:S5. – Encore poster presentation at the ACCP 2009 Annual Meeting, Anaheim, CA.
69. Kane-Gill SL, Kowiatek JG, Weber RJ. A comparison of medication errors reported in ICU and non-ICU patients. Poster discussion presentation at the 36th SCCM Critical Care Congress, Orlando, FL. February 2007. (*Top 25% of posters based on scoring*) *Crit Care Med* 2007;34:A22.

INVITED PRESENTATIONS (n=221)

- | | |
|-------------------|--|
| February 22, 2025 | Critical Care and Beyond: How Critical Care Pharmacy Prepared Me for My Current Role CCM CPP Pre-Congress Forum, 54th Annual Congress SCCM, Orlando, FL |
| December 8, 2024 | Evolution of Excellence: Implementation of ICU Sedation Best Practices ASHP 2024 Midyear Clinical Meeting & Exhibition in New Orleans, LA |

| | |
|----------------------|--|
| November 29, 2024 | This is Your Patient's Kidneys on Drugs: Ensuring Recovery and Kidney Health 2 nd Multidisciplinary Critical Care Rehabilitation Conference at Tallaght University Hospital, Dublin |
| November 8, 2024 | Artificial Intelligence in Guideline Development and Clinical Practice Best of SCCM, Abu Dhabi UAE |
| October 12, 2024 | Digging for Gold: Using real-time data to accelerate guideline updates (AI)ming Higher: Artificial Intelligence in Frontline Clinical Practice and Technology in Guideline Development American College of Clinical Pharmacy, Phoenix, Az |
| September 20,2024 | 1. Contrast Associated AKI 2. Implementation Science: Considerations for the Critically Ill 4th Annual International Anesthesia and Acute Care Conference Abu Dhabi, UAE |
| September 27, 2024 | Rethinking our Current Thinking for Drug Related Kidney Diseases and Disorders 21st Annual New England Critical Care Pharmacotherapy Symposium, Boston, MA |
| June 13-16, 2024 | Nephrotoxin Stewardship and AKI Prevention Asia Pacific Congress of Nephrology (APCN) & Korea Society of Nephrology (KSN) Seoul, South Korea |
| April 18, 2024 | This is your Kidney on Drugs Meet the Professor American College of Physicians, Boston, MA |
| February 2024 | D-AKI and Nephrotoxin Stewardship Programs Geisinger Pharmacy Grand Rounds https://cce.geisinger.edu/pharmacygrandrounds24/content/drug-related-kidney-diseases-and-nephrotoxin-stewardship-february-9-2024 |
| January 19, 2024 | 1. Searching for Sasquatch! Busting kidney myths in the ICU Contrast Associated AKI 2. ESICM/SCCM Joint Session: Surviving Sepsis Campaign Research Priorities and Norepinephrine Challenges 53rd Annual Congress SCCM, Phoenix, AZ |
| January 16, 2024 | Drugs and Kidney Interaction King's College, London, UK (Virtual) |
| January 8,9,10, 2024 | 1. Survey Research: Instrument Design, Method Evaluation- Research Primer 2. Survey Research: Instrument Design, Method Evaluation- Research Basics ACCP Research and Scholarship Certification Program (virtual) |
| December 2023 | Critical Care Nephrology- KDIGO Latest Update Egyptian College of Critical Care Medicine (virtual) |

- November 2023
1. Expanding our Understanding and Stewardship of Drug Related Kidney Diseases (DRKD) - **Therapeutics Frontier Lecture**
 2. Survey Research: Instrument Design, Method Evaluation- Research Primer
 3. Survey Research: Instrument Design, Method Evaluation- Research Basics
- ACCP Research and Scholarship Certification Program
American College of Clinical Pharmacy, Dallas, Tx
- November 2023
- Detecting New Nephrotoxins in an Era of Big Data
American Society of Nephrology, Philadelphia, PA
- October 12, 2023
- Multicenter Implementation of an Electronic Decision Support System for Drug-Associated AKI (MEnD-AKI)**
13th AKI Symposium, University of Pittsburgh, Pittsburgh, PA
- October 5, 2023
1. Clinical Decision Support and Machine Learning for Detecting AKI
 2. Telehealth and Virtual Care for Critically Ill Patients
- 3rd Annual International Anesthesia and Acute Care Conference
Abu Dhabi, UAE
- September 15, 2023
1. Better Together: Building a Multiprofessional Organization and Providing Outreach (Pekanbaru)
 2. Sepsis Associated AKI; What's new? (Jakarta)
 3. Implementation Science (Jakarta)
 4. Drug Associated AKI (Jakarta)
 5. Sepsis associated AKI; What's new? (Bandu)
 6. Adverse Drug Event, Pharmacovigilance in The ICU (Bangdu)
 7. Clinical Decision Support System Use in the ICU (Bangdu)
- Indonesia Society of Intensive Care Medicine, Pekanbaru, Indonesia
- August 26, 2023
1. Sepsis and AKI: What's New?
 2. Bundles and ICU Liberation
- 16th World Federation of Intensive and Critical Care, Istanbul, Turkey
<https://www.tuyud.org.tr/wp-content/uploads/2023/11/dergi-wicc-10112023-FINAL.pdf>
- August 18, 2023
1. Implementation Science: Considerations for the Critically Ill
 2. All in the Family: Incorporating Patients and Family Members into Pharmacotherapy
- Pennsylvania Chapter of SCCM, Hershey, PA
- June 12-14, 2023
- Contemporary Classification of Drug- induced Kidney Disease
AKI & CRRT Vincenza Course, Vincenza, Italy
- June 9, 2023
- Systematic approach to detecting drug related kidney diseases and disorders in database research.
Ohio Chapter of SCCM, Columbus, OH (virtual)
- April 17-21, 2023
- Data and Information - Securing and streamlining health information to improve care delivery: Prevention and Detection of Acute Kidney Injury with Clinical Surveillance
Health Information and Systems Society, Chicago, IL

- March 29, 2023 1. Changing Paradigms in AKI: From Mechanisms to Management- Nephrotoxin Stewardship
https://www.crrtonline.com/conference/CRRT23_PresPDFs/Gill_sg2537_20230324_AKI_CRRT2023_Nephrotoxin%20Stewardship%20submitted.pdf
- April 1, 2023 2. Health System Perspectives in AKI: Commitment to Kidney Health
 Changing Paradigms in Acute Kidney Injury: From Mechanisms to Management
 3. OncoNephrology: Assessing Causality
 AKI & CRRT Pre-Symposium, San Diego, CA
 28th International Conference on Advances in Critical Care Nephrology
- January 21, 2023 1. Opening Session- President
https://www.google.com/search?client=safari&rls=en&q=Sandra+Kane-Gill+SCCM+video&ie=UTF-8&oe=UTF-8#fpstate=ive&vld=cid:db7e7d4c,vid:aB6jhQqZ_lw
 2. What's in a Name? Standardizing Nomenclature for Nephrotoxicity
 Session: Everyday Villains: Drugs as Kidney Toxins
 3. Yes Mission... Yes Money: Paying it Forward (and Backward) by ICU Response to Global Crises
 52nd Annual Congress SCCM, San Francisco, CA
- January 12, 2023 The Future of Critical Care Medicine
 Menoufia Anaesthesia, Pain, and Intensive Care Club (MAPIC)
 Egypt Virtual Meeting for Intensivist and Anesthesiologists
- January 7,8,10, 2023 1. Survey Research: Instrument Design, Method Evaluation
 2. Mixed Methods and Qualitative Analysis
 3. Building a Research Team
 ACCP Research and Scholarship Certification Program (virtual)
- November 30, 2022 1. Acute Kidney Injury Diagnosis and Management
 Multiprofessional Critical Care Review Course (MCCRC)
 2. The Future of Antimicrobial Use in the ICU: Considerations in Sepsis Management
 3. Strategies for Improving Critical Care: Does the ICU really need a specialized pharmacist?
 10th International Conference of the Egyptian Society of Intensive Care and Trauma (ESCIT), Cairo, Egypt
- November 21, 2022 Best Practices in Nutrition, Drug Management, and Multi-Organ Support in Patients with AKI - KDIGO Conversations in Nephrology Podcast (Episode 9)
<https://open.spotify.com/episode/49EWQXSQ7ykvYk0nzWEjch>
<https://kdigo.org/podcast/>
- November 18, 2022 Nephrotoxin Stewardship - Plenary
 West-China Mayo International Forum of Critical Care Medicine, Chengdu City, Sichuan Province, P.R. China (virtual > 1000 participants)
- November 10th, 2022 1. Pharmacy Services: Indicators for Results- How do I do it?
 2. Pain: Patient Experience and Satisfaction: How to measure it?
 3. Artificial Intelligence in Intensive Care

| | |
|------------------|---|
| | 27th CBMI Brazilian Congress of Intensive Care Medicine, Brasilia, Brazil (2700 participants) |
| November 3, 2022 | <ol style="list-style-type: none"> 1. The Future of Critical Care Medicine 2. The Future of Antimicrobial Use in the ICU Chinese Society of Critical Care Medicine (CSCCM), Tianjin, China (virtual >100,000 participants) |
| November 2, 2022 | <ol style="list-style-type: none"> 1. ICU-Liberation: Implementation strategies for the A-F bundle 2. Implementation Science: Considerations for the Critically Ill Iberic and Pan-American Federation of Critical Care Societies (FEPIMCTI) XIV Iberian Pan American Congress, Lima, Peru |
| October 24, 2022 | Global Guidelines: from research to bedside practice European Society of Intensive Care Medicine 35th th Annual Congress, Paris, France |
| October 11, 2022 | Overcoming Barriers to Guideline Implementation in the ICU- Plenary Colegio Mexicano de Medicina Critical (COMMEC), Guadalajara, Mexico |
| October 4, 2022 | <ol style="list-style-type: none"> 1. The Future of Critical Care Medicine 2. The Future of Antimicrobial Use in the ICU 3. Perioperative Use of Novel Biomarkers for Acute Kidney Injury 2 nd Annual International Anesthesia and Acute Care Conference, Abu Dhabi, UAE |
| August 30, 2022 | Promoting Best Practices in the ICU with Safe Medication Use Guidelines Southeast Chapter of Society of Critical Care Medicine (Virtual) |
| August 19, 2022 | <ol style="list-style-type: none"> 1. Critical Care Nephrology symposium talk: Nephrotoxin stewardship 2. Global health care of critically ill patients - symposium talk: Intensive Care Unit Quality Improvement 3. ICU of the Future symposium talk: The future of antimicrobial use in ICU using advanced technology and data science Asian Pacific Intensive Care Symposium (APICS), Singapore |
| June 2022 | Implementation Science: Changing Practice in Critical Care Carolinas-Virginias Chapter SCCM Symposium, Roanoke, VA |
| May 2022 | Developing a Nephrotoxin Stewardship Program 42 nd Korean Society of Critical Care Medicine Annual Congress- Acute and Critical Care Conference (ACCC), Kyungju, Korea 2022 (hybrid) |
| April 2022 | Drug Induced Kidney Injury in the ICU: Mechanisms, Susceptibility, Diagnosis and Management Strategies Virtual Journal Club Egyptian College of Critical Care Physicians, Cairo, Egypt https://www.ecccp.org/tag/critical-care/ |
| April 2022 | <ol style="list-style-type: none"> 1. Presidential Address 2. ESICM/SCCM Joint Session: How data science will affect your and your patients. 3. Diversity, Equity and Inclusion in Critical Care Medicine 51 st Annual Congress SCCM (virtual) |

| | |
|------------------|--|
| March 2022 | Max Harry Weil Lecture: Drug Induced Kidney Injury in the ICU: Mechanisms, Susceptibility, Diagnosis and Management Strategies 40 th Critical Care Summit of the Egyptian College of Critical Care Physicians, Cairo, Egypt https://www.ecccp.org/tag/critical-care/ |
| March 2022 | Using Novel Kidney Biomarkers to Guide Drug Therapy Clinical Pharmacy Department of Cairo University, Cairo, Egypt https://www.ecccp.org/tag/conference/ |
| March 2022 | Preventing Drug Associated Acute Kidney Injury in the ICU 49 th Japanese Society of Intensive Care Medicine Sendai International Center, Sendai, Miyagi, Japan (virtual) Guest Speakers The 49th Annual Meeting of the Japanese Society of Intensive Care Medicine (jsicm.org) |
| March 2022 | Improving Nephrotoxic Stewardship by Utilization of Clinical Surveillance Premier-wide Pharmacy Practice Forum (virtual) |
| March 2022 | Sharing my Leadership Path Celebrating Women' History Month, New York Presbyterian Hospital, NY, NY |
| March 2022 | 1. Acute Kidney Injury Diagnosis and Management 2. Cutting Edge Delirium Multiprofessional Critical Care Review Course (MCCRC), Dubai, UAE |
| December 2021 | 1. Alarmed and Dangerous: Strategies to improve clinical decision support medication alerts in the ICU. Drug-drug interaction alerts: promoting clinical significance over trivial warnings 2. More than just a hill of beans: clinical controversies related to AKI in the ICU The diuretic and acute kidney injury relationship: Well... its complicated. 56 th ASHP Midyear Clinical Meeting, Orlando, FL. |
| November 2021 | Current Trends in the Use of Biomarkers to Predict and Diagnose AKI American Society of Nephrology, San Diego, CA |
| November 2021 | Using Clinical Decision Support Systems for Drug Associated AKI Research Colloquium, Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA |
| November 2021 | The Spectrum of Critical Illness: from Community to Hospital, Transitions of Care to Recovery: Challenges and future directions- Pharmacist involvement. SCCM Discovery Fall Investigator Meeting (webcast) |
| November 2021 | 1. Survey Research: Instrument Design, Method Evaluation 2. Mixed Methods and Qualitative Analysis ACCP Research and Scholarship Certification Program (moved to virtual) |
| October 21, 2021 | Clinical Decision Support for Drug Associated AKI |

11th AKI Symposium, University of Pittsburgh, Pittsburgh, PA

- October 3, 2021
1. What will not exist anymore in 2050 ICU- Panel Discussion
2. Drug-induced AKI
European Society of Intensive Care Medicine (ESICM)
- September 2021
Team Approach to Providing Patient Care - Addressing Arising Patient Care Needs
Post Pandemic Reflection and Planning
Joint Commission of Pharmacy Practitioners, Alexandria, VA
- September 2021
Developing a Nephrotoxin Stewardship Program
Clinical Pharmacy and Pharmacology Section, SCCM Podcast
- August 2021
Clinical Decision Support: Is AI the Way?
Chinese Society of Critical Care Medicine (virtual)
- July 2021
Using Clinical Surveillance to Improve Nephrotoxin Stewardship
Capstone Health Alliance, Asheville, NC representing 300 hospitals in 50 states
- July 2021
Surviving Sepsis Campaign COVID-19 and Critical Care Nutrition Webinar
Society of Critical Care Medicine (China)-6000 virtual attendees
- July 2021
Perioperative Quality Initiative (POQI) Session: Perioperative Renal Injury
Health System Perspectives in AKI
World Congress Evidence Based Perioperative Medicine (EBPOM) 2021
London, England (Hybrid Meeting-Virtual and In-person with about 2,500 attendees)
<https://ebpom.org/faculty>
[Part 3 Know AKI and say no to acute kidney injury for patients | Health systems perspectives in AKI – TopMedTalk](#)
- July 2021
Intensive Care Medicine Masterclass: Diagnosis and Therapy of AKI
Nephrotoxic Agents & Drugs that Affect Kidney Function Lecture and Breakouts
European Society of Anaesthesiology and Intensive Care (ESAIC)
<https://www.esaic.org/event/icm-masterclass-2>
- June 2021
Using Clinical Surveillance to Improve Nephrotoxin Stewardship
Premier's Annual Breakthrough Conference and Exhibition
National Harbor, MD (moved to virtual)
- May 2021
Pharmacy Executive Leadership Alliance Virtual Summit on Opportunities for Telehealth,
American Society of Health System Pharmacists
- April 2021
1. Promoting Best Practice in the ICU with Safe Medication Use Guidelines
2. Training System of Critical Care Pharmacists in the USA
41st Korean Society of Critical Care Medicine Annual Congress- Acute and Critical Care
Conference (ACCC), Seoul, Korea 2021(virtual)
- April 2021
1. Survey Research: Instrument Design, Method Evaluation
2. Mixed Methods and Qualitative Analysis
ACCP Research and Scholarship Certification Program (virtual)

| | |
|----------------|---|
| February 2021 | Moving Towards Nephrotoxin Stewardship 4 th Annual Tri-State Critical Care Symposium, New Brunswick, NJ (Virtual) |
| December 2020 | Cases in Acute Kidney Injury: Applications for Clinical Practice CME on ReachMD https://provaeducation.com/programs/cme/cases-acute-kidney-injury-applications-clinical-practice/12072/?quiz_step=pretest&activity=23391 |
| November 2020 | On Your Mark, Ready, Set...Should We Go? An Update on Acute Kidney Injury Biomarkers ASHP Midyear Meeting, New Orleans, LA (moved to virtual) |
| October 2020 | All in the Family: Incorporating Patients and Family Members into Pharmacotherapy Decisions Across the Continuum of Care Caregiver pharmacotherapy discussions are critical in critical settings ACCP Annual Meeting 2020, Dallas, Tx (moved to virtual) |
| September 2020 | COVID-19: What's Next- Preparing for the Second Wave (virtual event) Questions and answers to drug-related controversies, Society of Critical Care Medicine |
| June 2020 | Clinical Decision Support Embedded in a Surveillance System to Facilitate Quality Improvement and Research Premier's Annual Breakthrough Conference and Exhibition Nashville, TN (moved to virtual) |
| April 2020 | COVID-19: What do we not yet know that we need to understand. American College of Emergency Physicians and Society of Critical Care Medicine- Webinar |
| March 2020 | Nephrotoxin Stewardship National Kidney Foundation 2020 Spring Clinical Meeting, New Orleans, LA. (virtual) |
| February 2020 | 1. More Than the Monitor: How Many Alarms Do We Face in a Day in the ICU? 2. Use Biomarkers for Acute Kidney Injury: Applications for Prevention 49th SCCM Critical Care Congress, Orlando, FL |
| February 2020 | Early Recognition of Acute Kidney Injury: What's the role of biomarkers? CME on ReachMD https://reachmd.com/programs/cme/early-recognition-of-acute-kidney-injury-whats-the-role-of-biomarkers/11222/ |
| October 2019 | Survey Research: Instrument Design, Method Evaluation and Publishing Your Work Research and Scholarship Certification Program ACCP Annual Meeting 2019, New York, NY |
| October 2019 | Early Warning Biomarkers for Acute Kidney Injury: Drug Management Considerations 9 th AKI Symposium, University of Pittsburgh, Pittsburgh, PA |

| | |
|---------------|---|
| October 2019 | Panelist, Approaches to the Effective Presentation of Comprehensive Drug Interaction Information in Labeling Duke-Margolis & FDA Section 7 Labeling Stakeholder Workshop, Washington, DC |
| June 2019 | Keynote Speaker, WVU Residency Banquet West Virginia University Hospitals, Morgantown, WV |
| April 2019 | Early Warning Biomarkers for Acute Kidney Injury: Using Tissue Inhibitor of Metalloproteinase 2 and Insulin-like Growth Factor-Binding Protein 7 [TIMP-2]•[IGFBP7] and Drug Management Biomarker Webinar Series, American Society of Health System Pharmacists http://elearning.ashp.org/products/8247/biomarkers-primer-recorded-pharmacist-series-no-ce |
| April 2019 | BCCCP Prep Course: Pharmacoeconomics and Safe Medication Use ACCP Updates in Therapeutics Webinar |
| March 2019 | Impact of Pharmacy Services using Telemedicine and Clinical Decision Support in Nursing Homes Research Colloquium, Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA. |
| February 2019 | Non-Traditional Learning Platforms A Precepting Primer: A Focus on Resident and Student Precepting SCCM CPP Pre-Congress Forum 48th SCCM Critical Care Congress, San Diego, CA |
| February 2019 | Considerations for Medication Management in Kidney Disease Baptist Temple Church, Pittsburgh, PA http://baptisttemple.church |
| February 2019 | Impact of Pharmacy Services using Telemedicine and Clinical Decision Support in Nursing Homes Geriatric Conference, Division of Geriatrics, School of Medicine, University of Pittsburgh, Pittsburgh, PA. |
| November 2018 | Expanding Pharmacist Services Using Telemedicine Telehealth Panel, American Society of Consultant Pharmacists Annual Meeting, Washington D.C. |
| October 2018 | Preventing Drug Associated AKI: Real World Medication Management Experience Cardio Renal Society of America at the American Society of Nephrology Kidney Week, San Diego, CA https://vimeo.com/510482917 |
| October 2018 | 1. Survey Research: Instrument Design, Method Evaluation and Publishing Your Work Research and Scholarship Certification Program 2. Chair, Clinical Reasoning Series on PAD-IS Guidelines 3. Population Health and Telemedicine Approaches to Commonly Encountered Conditions: Telemedicine Approaches in the Ambulatory Care Setting |

ACCP Annual Meeting 2018, Seattle, WA.

- October 2018 Patient Education Following an Episode of AKI
8th AKI Symposium, University of Pittsburgh, Pittsburgh, PA.
- August 2018 Advanced Approaches to Preventing Drug Associated AKI and Optimizing Drug Dosing
Cardio Renal Society of America Webinar
https://event.webcasts.com/starthere.jsp?ei=1178045&tp_key=3a0fe8ec8a
- April 2018 Acute Kidney Injury: Treatment and Management
Preventing AKI Induced Adverse Drug Events
Webinar, VuMedi (200,000 registered physicians)
www.vumedi.com
- March 2018 1. Using Kidney Biomarkers for Guiding Drug Therapy
2. Drug Induced Kidney Injury in the ICU: Mechanisms, Susceptibility, Diagnosis, Management Strategies
3. Emerging Strategies for Monitoring Changes in Renal Structure and Function (symposium facilitator)
AKI&CRRT 2018, San Diego, CA.
- February 2018 1. Clinical Practice Guideline: Safe Medication Use in the ICU
2. ACCP/SCCM BCCCP Prep Course: Pharmacoeconomics and Safe Medication Use
47th SCCM Critical Care Congress, San Antonio, Tx.
- January 2018 1. Nephrotoxins
2. Drug Dosing and Drug Selection in AKI
3. AKI Prevention Workshop
Advanced Practice in Acute Kidney Injury (APAKI) Workshop
Los Angeles, CA.
- December 2017 1. Promoting Best Practices in the ICU with Safe Medication Use Guidelines
Keeping a Watchful Eye: Recommended Safety Surveillance Systems
2. Marrying Structure with Function: The Impact of Novel Renal Biomarkers on Drug Therapy Use
52nd ASHP Midyear Clinical Meeting, Orlando, FL.
- November 2017 1. Drug Dosing and Drug Selection in AKI
2. AKI Prevention Workshop
Advanced Practice in Acute Kidney Injury (APAKI) Workshop
Pittsburgh, PA.
- October 2017 Survey Research: Instrument Design, Method Evaluation and Publishing Your Work
Research and Scholarship Certification Program
ACCP Annual Meeting, Phoenix, AZ.
- October 2017 1. Patient Education Following an Episode of AKI
2. Post-hospitalization Medication Management
7th AKI Symposium, University of Pittsburgh, Pittsburgh, PA.

| | |
|---------------|--|
| August 2017 | Enhancing Residents' Training with Simulation: Knowledge, Assessment and Research ASHP National Pharmacy Preceptors Conference, Washington, D.C. |
| July 2017 | Improving Medication Safety with Telemedicine and Clinical Decision Support in Nursing Homes Geriatric Conference, Division of Geriatrics, School of Medicine, University of Pittsburgh, Pittsburgh, PA. |
| May 2017 | Simulation Workshop Debriefing; Integrating Scholarship and Developing a Research Network School of Pharmacy, University of Pittsburgh, Pittsburgh, PA |
| April 2017 | Approaches to Manage Alert Fatigue and Suggestions for Appropriate Metrics SCCM Webinar https://www.youtube.com/watch?v=dEAeB_LtrKI |
| March 2017 | Developing 'state of the art' medication safety surveillance in your ICU 14 th Annual New England Critical Care Pharmacy Symposium, Boston, MA |
| March 2017 | 10 Solutions to Publishing Your Way Forward ASHP Webinar http://elearning.ashp.org/products/5918/on-demand-10-solutions-to-publishing-your-way-forward-march-8-2017 |
| February 2017 | BCCCP Prep Course: Pharmacoeconomics and Safe Medication Use ACCP Updates in Therapeutics Meeting, Jacksonville, FL |
| January 2017 | 1. Technological Distractions: Alert and Alarm Fatigue Return on Investment for Alert and Alarm Systems 2. ACCP/SCCM BCCCP Prep Course: Pharmacoeconomics and Safe Medication Use 46 th SCCM Critical Care Congress, Honolulu, HI. |
| November 2016 | Pharmacologic Considerations for Patients with Severe Alcohol Withdrawal Grand Rounds, Department of Plastic Surgery, UPMC, Pittsburgh, PA |
| February 2016 | Striving for Early Detection of Drug-Associated AKI 45 th SCCM Critical Care Congress, Orlando, FL. |
| October 2015 | Decision Support- Preventing Drug Errors Critical Care Canada Forum (CCCF), Toronto, ON |
| October 2015 | GRADE-ing Drug Combinations Associated with AKI. 5 th AKI Symposium, University of Pittsburgh, Pittsburgh, PA |
| June 2015 | Publishing Your Way Forward: Overcoming the Obstacles UPMC/University of Pittsburgh Resident Research Day, Pittsburgh, PA |

| | |
|--|---|
| February 2015 | Advancing the role of clinical decision support and telemedicine to prevent drug-associated AKI. AKI as a Quality Paradigm Roundtable, San Diego, CA |
| January 2015 | Improving Medication Safety Strategies in the ICU: Maximizing Adverse Drug Event Surveillance with Automation 44th SCCM Critical Care Congress, Phoenix, AZ |
| October 2014 | What do we know about patients at risk for drug associated AKI? 4 th AKI Symposium, University of Pittsburgh, Pittsburgh, PA |
| May 2014 May 2015 May 2016 May 2017 | Pre-Residency Excellence Program (PREP) – Resident Research: Frequently Asked Questions and Tips for Success Webinar for Registrants in the PREP Program for Pennsylvania Pharmacists Association |
| January 2014 | Managing alert overload: Clinical decision support 43rd SCCM Critical Care Congress, San Francisco, CA |
| December 2013 | “Med Wreck or Med Safety”: The impact of medication reconciliation on medication errors and adverse drug events. 46 th ASHP Midyear Clinical Meeting, Orlando, FL |
| October 2013 | Acute kidney injury in the critically ill, elderly patient 3 rd AKI Symposium, University of Pittsburgh, Pittsburgh, PA |
| October 2013 | Pulling the Trigger on ADE Surveillance in the ICU Greater New York Hospital Association- webinar for 180 acute care hospitals and health systems in New York, New Jersey, Connecticut, Massachusetts. |
| June 2013 | Assessing and Managing Sedation Virginia Region 5 Society of Health System Pharmacists Meeting, Virginia Beach, VA |
| May 2013 | 1. Guidelines for Resident Teaching Experiences 2. Bridge to the Future: The Importance of Pharmacists’ Contributions to Scholarship- Publishing your way Forward Eastern State Conference for Residents and Preceptors (ESCRP) 32 nd Annual Conference, Hershey, PA |
| April 2013 | Safe Medication Use in the ICU: Optimizing Surveillance and Applying ADE Prevention Strategies Department of Pharmacy Practice Seminar Series, Purdue University, Indianapolis, IN |
| January 2013 | 1. Controlling Costs in an Era Of \$100,000 Therapeutics 2. Safe Medication Use Guidelines: Developing a Medication Safety Surveillance Program for your ICU based on Evidence 42nd SCCM Critical Care Congress, San Juan, Puerto Rico |
| December 2012 | Assessing and Managing Sedation – Incorporating the PAD Guidelines into Practice Las Palmas Medical Center, El Paso, Tx. |

| | |
|----------------|--|
| December 2012 | Evaluating New Pharmaceutical Products at Your Health System - Efficacy, Safety and Economic Considerations in Developing Medication-use Evaluations 45 th ASHP Midyear Clinical Meeting, Las Vegas, NV |
| September 2012 | Assessing and Managing Sedation Presented at the Downstate New York Society of Health System Pharmacists, New York, NY. |
| May 2012 | Assessing and Managing Sedation Austin Area Society of Health System Pharmacists, Austin, Tx. |
| February 2012 | Establishing a Safety Culture in the ICU: Making Systematic Changes Using ADE Data 41st SCCM Critical Care Congress, Houston, Tx. |
| December 2011 | 1. Strategies for Improving the Safe Use of IV Medications in the Critical Care Setting. 2. Economic Implications of Postoperative Pain Management 44 th ASHP Midyear Clinical Meeting, New Orleans, LA |
| October 2011 | 1. The Great Masquerader: Recognizing ADRs in the ICU Learning Using Simulation 2. Severity and Preventability of Drug-Induced Hypotension ACCP 2011 Annual Meeting, Pittsburgh, PA. |
| January 2011 | 1. Prevention without Perfection: CPOE and Clinical Decision Support Knowing the Limits 2. Answers to Challenging Pharmcotherapeutic Questions: Which drug for routine sedation? 40 th SCCM Critical Care Congress, San Diego, CA |
| July 2010 | SEDATION: Sedation Education Demonstrating Advances in the Intensive Care and Peri-operative Settings. Florida ASHP Annual Meeting, Buena Vista, FL. |
| January 2010 | 1. Using Simulation to Improve Patient Safety 2. Establishing Effective Systems to Prevent Adverse Drug Events 39 th SCCM Critical Care Congress, Miami, FL. |
| January 2010 | Scanning for Medication Error Solutions: Barcode Technology- Show me the Money! 39 th SCCM Critical Care Congress, Miami, FL. |
| December 2009 | IV sedation in the ICU- applying pharmacoeconomic principles: An overview of pharmacoeconomic considerations 44 th ASHP Midyear Clinical Meeting, Las Vegas, NV. |
| November 2009 | Cardiovascular Pharmacotherapy Update: Ready, Set... Practice! Anticoagulation and Acute Hypertension: Interactive cases with simulation and audience response system. University of Pittsburgh, School of Pharmacy Alumni Association |
| August 2009 | Data Collection Strategies- Quantitative Approaches |

Presented for the Community Resident Research Online Lecture Series to Community Pharmacy Practice Residents at Wilkes University, Temple University and University of Pittsburgh

- February 2009
1. Developing Adverse Drug Event Surveillance Systems for the ICU
 2. A Little Less Talk and A Lot More Action Results in Fewer Adverse Drug Reactions
38th SCCM Critical Care Congress, Memphis, TN.
- December 2008
- Introducing Patient Simulation to Pharmacy: Impact of Human Patient Simulation on Patient Care and Medication Safety
43rd ASHP Midyear Clinical Meeting, Orlando, FL
- May 2008
- Strategies to Prevent Medication Errors and Adverse Drug Events
National Teaching Institute (NTI) and Critical Care Exposition in Chicago, IL
- September 2007
- Practical and Regulatory Perspectives of Bioequivalence
Moderator and Presenter- continuing education web telecast.
<http://www.cmediscovery.com/7155/>
- June/July 2007
- Future Strategies for Improving Critical Care: Does the ICU really need a specialized pharmacist?
Presented as a series of 6 web conferences by MedPoint Communications
- May 2007
- Pharmacoeconomic Fellowship Guidelines
ISPOR 12th Annual International Meeting, Arlington, VA.
- September 2006
- Patient Safety Surveillance Systems in the ICU
Excellence in Quality and Safety in Critical Care Conference sponsored by the Society of Critical Care Medicine presented in Baltimore, MD
- September 2006
- Utilizing Patient Safety Data to Initiate Quality Improvements
Excellence in Quality and Safety in Critical Care Conference sponsored by the Society of Critical Care Medicine presented in Baltimore, MD
- July 2006
- Common Misconceptions with Bioequivalence and Product Interchangeability
Moderator and Presenter- continuing education web telecast.
<http://www.cmediscovery.com/CMBI/faculty.html#pultz>
- July 2006
- Real World Best Practices for DVT Prophylaxis
Moderator- continuing education web telecast.
<http://www.cmediscovery.com/dvt/>
- January 2006
1. Year in Review: Pharmacology
Use of Technology to Enhance Patient Safety
 2. It's not just the drug costs! Clinical Application of Pharmacoeconomics in the Critical Care Setting - Quality of Life Studies in Critical Care
35th SCCM Critical Care Congress, San Francisco, CA.
- October 2005
- Challenges in Dosing Low Molecular Weight Heparin
Presenter- continuing education web telecast.

<http://www.arcmesa.org/lmwh/default.aspx>

- March 2005 Current Issues in Patient Safety
Jefferson County Academy of Pharmacy Annual Meeting, St. Clairsville, OH
- October 2004 Evaluating Medication Reactions: Naranjo and Beyond.
American College of Clinical Pharmacy Annual Meeting, Dallas, TX.
- October 2003 An Update on Sedation and Neuromuscular Blockade for Adult Critically Ill Patients.
Virginia Society of Health System Pharmacists, Norfolk, VA.
- October 2003 Sedation and Neuromuscular Blockade for Adult Critically Ill Patients.
Presented to the Northeastern Pennsylvania Society of Health System Pharmacists, Wilkes-Barre, PA.
- March 2003 Pharmacoeconomic Issues in the Critical Care Environment: Balancing costs with optimal delivery of patient care.
Continuing education on CD-ROM.
- March 2002 Sedation in the Critical Care Setting: an update on the standards and guidelines
VHA satellite broadcast from Dallas, TX.
- February 2002 Year in Review: Pharmacoeconomics & Humanistic Outcomes
31st SCCM Educational and Scientific Symposium, San Diego, CA.
- April 2001 An Analysis of Adverse Events in the ICU
Third Annual Michigan-Ohio Critical Care Pharmacy Symposium, Toledo, OH.
- May 2000 Gram Positive Resistance
Vencare Pharmacy Services
Columbus, OH.
- April 2000 Continuous Infusion of Enoxaparin in Hospitalized Patients
Second Annual Michigan-Ohio Critical Care Pharmacy Symposium, Toledo, OH.
- October 1999 Economic Impact of Gram-Positive Resistance
West Virginia Society of Health-System Pharmacists,
Canaan Valley, WV.
- June 1999 Impact of trovafloxacin use on gram-negative drug resistance in the surgical intensive care unit (SICU)
First Annual Michigan-Ohio Critical Care Pharmacy Symposium
Toledo, OH.